Spring ’08 Clinical Meetings
April 2–6, 2008 Gaylord Texan, Dallas, Texas
JC A[[fkfm_j^A;;F <_dZekj^emj^[DWj_edWbA_Zd[o @::E^hi]ZaVg\ZhiYZiZXi^dcegd\gVb^ci]Z Jc^iZYHiViZh[dg`^YcZnY^hZVhZ# BdgZi]Vc&%%!%%%eVgi^X^eVcih @::E^h[daadl^c\"jel^i]eVgi^X^eVcihdkZg VcZmiZcYZYeZg^dYd[i^bZ# B[Whdceh[WXekjA;;F m^_b[oekWh[Wjj^[Yed\[h[dY[$ &# K^hijhVii]ZC@;Wddi],&.[dgi]ZaViZhi^c[dgbVi^dc# '#?d^cjh[dgV[gZZ8B:7gZV`[VhiHnbedh^jb^c (# K^Zli]ZaViZhi@::EYViVWZ^c\egZhZciZY^c&&edhiZgh Yjg^c\i]ZedhiZghZhh^dc#Add`[dgedhiZgcjbWZgh/)*!*(! +)!,*!,,!,-!'%*!',%!'-'!'-(VcY'-.# NdjXVcVahdk^h^ia[[fedb_d[$eh][dgi]ZaViZhi@::E^c[dgbVi^dcVcYVhX]ZYjaZd[ hXgZZc^c\hVXgdhhi]ZJ#H# www.keeponline.org '%%-CVi^dcVa@^YcZn;djcYVi^dc!>cX#6aag^\]ihgZhZgkZY#%'"(*"),(6 Prints: 4C — 4C Prints: 11"h x 8"w Size: Live 12"h x 9"w TrimSize: 12.25"h x 9.25"w Size: Bleed TransplantaionJournalof Abstracts/American AST PGF-0288Ad Mechanical resized from PGF-0163 by CF PGF-0163 by from resized Mechanical •C •C •M •M •Y •K Your Partner in Transplantation At Astellas, we are committed to uncovering new possibilities in immunology through broad scale research aimed at new product development. Through the transference and sharing of scientifi c knowledge, we work in partnership with healthcare professionals like you to positively impact patient care. Our goal remains clear: Enhance the practice of transplantation. It is our passion and our priority. © 2007 Astellas Pharma US, Inc. PRG00266-MK-R0-12/06 2.22.2008 08020023kafA04_280.indd NKF_AD_Full_Page rev 2.pdf 3/3/08 3:39:36 PM Quality Dialysis Experience dialysis in the comfort of your home! QUALITY DIALYSIS has been providing Staff-Assisted Home Dialysis services to Texas for over thirteen years. Founded in 1993, the founder’s goal and mission has always been to educate patients and their families about chronic kidney disease, and provide professional, quality services to clients in the home. Our wellness team consist of experienced social workers, renal dietitians, registered nurses, and bio-medical technicians under the direct supervision of Nephrologist. Quality Dialysis offers home dialysis services in the Central, Southwestern and Northeastern regions of Texas. We consider it our privilege and your choice to provide home C dialysis services to you. M Y CM 890 East Travis 4007 Greenbriar Drive, Suite E 1034 Shady Trail, Suite 112 MY La Grange, TX 78945 Stafford, TX 77477 Dallas, TX 75229 CY 979-968-3800 281-491-4009 214-295-7344 CMY K www.gethomedialysis.com By Author Cindy Barclay That Damn Dialysis A Must Read !!! This book answers a myriad of questions about chronic kidney disease and dialysis. The answers are expertly woven into the humerous heartfelt journey of 50 year old Cledus B. Washington. If you have questions, this book has answers ! Visit Booth #636 www.claybarpublishing.comwww.gethomedialysis.com 1-888-491-9533 545-074-01-08-SC-Program-Ad-v5:NKF-1 Advertisement 2/27/08 4:11 PM Page 1 Association of Mineral Metabolism, Vitamin D Therapy, and Calcimimetics on Chronic Kidney Disease Patient Survival A CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings Wednesday, April 2, 2008 Gaylord Texan Dallas, Texas 7:30 PM – 9:30 PM Grapevine Ballroom D PROGRAM OVERVIEW FACULTY This symposium will provide an overview of recent evidence on altered mineral Myles Wolf, MD, MMSc Daniel Coyne, MD metabolism occurring in chronic kidney disease and therapeutic regimens that Assistant Professor of Medicine Professor of Medicine restore mineral homeostasis in chronic kidney disease patients. The session will Harvard Medical School; Renal Unit Division of Renal Diseases also discuss the impact of altered mineral metabolism on cardiovascular risk Massachusetts General Hospital Director, Hemodialysis factors and maximizing therapy to improve survival. Current information will Boston, Massachusetts Chromalloy American Kidney Center focus on important differences between nonselective and selective vitamin D Director, Outpatient Renal Clinics receptor activator therapy, that not only include suppression of parathyroid Stuart Sprague, DO Co-Director, Renal Fellowship hormone and regulation of calcium balance, but also examine nonclassical Chief, Division of Nephrology and Training Program actions of vitamin D receptor activators and how they impact cardiovascular and Hypertension, Evanston Washington University bone health. In addition, the session will provide an understanding of Northwestern Healthcare School of Medicine calcimimetic use in treating secondary hyperparathyroidism in chronic kidney Professor of Medicine Division of Renal Diseases disease patients, and the impact of calcimimetics on risk factors and survival. Northwestern University St. Louis, Missouri Feinberg School of Medicine LEARNING OBJECTIVES Chicago, Illinois • Understand the impact of disordered mineral metabolism on risk factors and survival in chronic kidney disease patients. • Discuss the differences between nonselective and selective vitamin D receptor activators and how their use impact survival in chronic kidney disease patients. AGENDA • Review the mechanism of action of calcimimetic therapy, its role in therapy of secondary hyperparathyroidism, and long-term benefits on risk factors and Wednesday, April 2, 2008 survival in chronic kidney disease. 7:30 PM Registration TARGET AUDIENCE: This CME-certified symposium is directed towards 8:00 PM Welcome and Introduction nephrologists and clinicians who treat patients with chronic kidney disease. Myles Wolf, MD, MMSc HOW YOU WILL LEARN: This CME activity will be a live symposium consisting 8:05 PM “Associations of Mineral Metabolism with Patient Survival” of lectures with panel audience participation Daniel Coyne, MD ACCREDITATION STATEMENT: The National Kidney Foundation is accredited 8:30 PM “Impact of Vitamin D therapy on Patient Survival” by the Accreditation Council for Continuing Medical Education to provide Myles Wolf, MD, MMSc continuing medical education for physicians. 8:55 PM “Does Direct Modulation of the Calcium Sensor Affect DESIGNATION STATEMENT: The National Kidney Foundation designates this Patient Survival?” educational activity for a maximum of 1.5 AMA PRA Category 1 Credit TM. Stuart Sprague, DO Physicians should only claim credit commensurate with the extent of their participation in the activity. 9:20 PM Q&A/Discussion The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program is pending approval with the American Academy of Nurse Practitioners. REGISTRATION: You must be registered for the NKF 2008 Spring Clinical DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Meetings to attend this symposia and receive credit. Foundation to ensure balance, independence, objectivity, and scientific rigor in all CME activities. Faculty participating in this activity are required to disclose DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do not to the audience any relationship they may have with the commercial supporters recommend the use of any pharmaceutical, diagnostic test, or device outside of the of this activity or with any other commercial organizations whose products or labeled indications as approved by the FDA. Please refer to the official prescribing devices may be mentioned in their presentations. information for each product for approved indications, contraindications, and warnings. UNLABELED / INVESTIGATIONAL USE DECLARATION: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to Supported by an unrestricted Sponsored by the disclose this information to the audience when referring to an unlabeled or medical educational National Kidney investigational use. grant from Abbott. Foundation 08-11 Novo Ad 2/22/08 1:10 PM Page 1 A Symposium and Breakfast during the National Kidney Foundation 2008 Spring Clinical Meetings The Impact of Glycemic Control in Patients with Diabetes and Chronic Kidney Disease Thursday, April 3, 2008 | 6:00 AM – 8:00 AM | The Gaylord Texan | Grapevine Ballroom B | Grapevine, Texas Program Purpose Program Objectives Diabetes is currently the fifth leading cause of death in the United States At the conclusion of this program participants should: and is associated with significant morbidity due to associated • Describe optimal glycemic targets and the impact of glycemic control macrovascular and microvascular complications, particularly chronic on outcomes in different stages of CKD kidney disease (CKD). In both diabetes and CKD there is evidence that • Develop an optimal clinical management plan of diabetes in patients identifying individuals early in the disease continuum can reduce with different stages of CKD morbidity and mortality. Yet experts estimate that fewer than 1 in 4 patients with diabetes receive the minimum annual testing in preventive • Simplify the complex medication regimens in patients with CKD and care for blood glucose and lipid levels. Management of diabetes in diabetes in order to improve compliance patients with CKD may be complicated as many medications may require Symposium Registration dosage adjustment or may be contraindicated, thus it is essential to have • Pre-registration for this symposium is not required. understanding of the most effective treatment approaches for achieving We recommend arriving at the symposium early. Seating is limited and tight glycemic control in these patients. Patient compliance is essential will be available on a first come, first serve basis. for an impact on patient outcome to be realized. This symposium will • You must be registered for the NKF 2008 Spring Clinical Meetings to address considerations in managing patients with CKD and diabetes. attend this symposium and Specifically the impact of strict glycemic control on outcome and receive credit. strategies for enhancing patient compliance with these complicated medical regimens will be discussed. Target Audience Nephrology professionals Agenda Educational Method This CME activity will be a live symposium consisting of lectures and panel 6:00 AM Registration and Breakfast discussion with audience participation. Accreditation 6:30 AM Welcome and Introduction The National Kidney Foundation is accredited by the Accreditation Council for Martin J. Abrahamson, MD Continuing Medical Education to provide continuing medical education for Medical Director and Senior Vice President physicians. Joslin Diabetes Center Designation Associate Professor of Medicine The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only Harvard Medical School claim credit commensurate with the extent of their participation in the activity. Boston, MA The National Kidney Foundation is an approved provider of continuing nursing 6:40 AM Glycemic Control in Patients with CKD education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Mark S. Roberts, MD, MPP Credentialing Center's Commission on Accreditation. Professor of Medicine, Health Policy and Management This program is pending approval with the American Academy of Nurse and Industrial Engineering Practitioners. Chief, Section of Decision Sciences and Clinical Systems Modeling Declaration of Disclosure Department of Medicine It is the policy of the National Kidney Foundation to ensure balance, University of Pittsburgh School of Medicine independence, objectivity, and scientific rigor in all CME activities. Faculty participating in this activity are required to disclose to the audience any Pittsburgh, PA relationship that they may have with the commercial supporters of this activity 7:00 AM How Low Should You Go? or with any other commercial organizations whose products or devices may be mentioned in their presentations. Martin J. Abrahamson, MD Unlabeled/Investigational Use Declaration 7:20 AM When and How to Use Insulin in Patients with During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty Chronic Renal Failure member is required to disclose this information to the audience when Arturo R. Rolla, MD referring to an unlabeled or investigational use. Endocrinologist, Beth Israel Deaconess Medical Center Disclaimer Associate Clinical Professor of Medicine The faculty, National Kidney Foundation, and Novo Nordiskdo not recommend Harvard Medical School and Tufts University School of Medicine the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official Boston, MA prescribing information for each product for approved indications, contraindications, and warnings. 7:40 AM Case Studies / Panel Discussion / Question and Answer Session Supported by an All Faculty educational grant from 8:00 AM Closing Remarks Sponsored by the National Kidney Foundation Martin J. Abrahamson, MD Shire_NKF AD.rev.qxp:1788 AD 8.5x11 2/20/08 3:55 PM Page 1 A symposium to be conducted at the National Kidney Foundation National Kidney Foundation (NKF) 2008 Spring Clinical Meetings 2008 Spring Clinical Meetings Dietary Phosphorus and Outcomes in Patients With CKD Trends and Challenges in Thursday, April 3, 2008 12:00 PM – 12:30 PM Registration and Lunch CKD Progression and Management 12:30 PM – 2:00 PM Symposium in Older Adults Gaylord Texan Resort and Convention Center Grapevine Ballroom C 1501 Gaylord Trail April 3, 2008 Grapevine, Texas 6:00 am – 6:30 am: Breakfast & Registration 6:30 am – 8:00 am: Symposium EDUCATIONAL OBJECTIVES Grapevine Ballroom Dt(BZMPSE5FYBOt%BMMBT 5FYBT Upon completion of this symposium, participants will be able to: • Apply dietary restriction techniques to control phosphorus (P) levels in patients with chronic kidney disease (CKD) Target Audience Declaration of Disclosure: It is the policy of the • Evaluate the efficacy of dietary P control and its effect on survival Nephrology professionals /BUJPOBM,JEOFZ'PVOEBUJPOUPFOTVSFCBMBODF ACTIVITY PURPOSE • Assess the risk of malnutrition associated with dietary P control independence, objectivity, and scientific rigor in The purpose of this symposium is to educate nephrologists, fellows, • Appropriately implement the use of phosphate binders in controlling hyperphosphatemia residents, physician assistants, nurse practitioners, nephrology nurses and BMM$.&BDUJWJUJFT'BDVMUZQBSUJDJQBUJOHJOUIJT in patients with CKD How Will You Learn? technicians, and renal and clinical dietitians interested in learning about safe This CME activity will be a live symposium consisting of three lectures and a question and activity are required to disclose to the audience any and effective control of phosphorus levels in patients with CKD. answer session. relationship they may have with the commercial HOW YOU WILL LEARN supporters of this activity or with any other The symposium is held in a panel discussion format, incorporating PROGRAM AGENDA DPNNFSDJBMPSHBOJ[BUJPOTXIPTFQSPEVDUTPSEFWJDFT case-based presentations, didactic lectures, and audience participation using Activity Purpose 12:00 PM Registration and Lunch may be mentioned in their presentations. the audience response system (ARS). This symposium will educate nephrology professionals and PCPs on proper management of TARGET AUDIENCE chronic kidney disease (CKD) and will focus on raising awareness of social and medical issues This program is designed for nephrologists, fellows, residents, physician 12:30 PM Welcome and Introduction Stuart M. Sprague, DO related to CKD in elderly patients. Unlabeled/Investigational Use Declaration: assistants, nurse practitioners, nephrology nurses and technicians, and renal Moderator and Program Chair During their presentations, faculty may discuss an and clinical dietitians. Chief, Division of Nephrology and unlabeled use or an investigational use not approved Hypertension ACCREDITATION AND CREDIT DESIGNATION STATEMENTS Evanston Northwestern Healthcare Learning Objectives for a commercial product. Each faculty member is The National Kidney Foundation is accredited by the Accreditation Council for At the conclusion of the program, participants should: Professor of Medicine required to disclose this information to the audience Continuing Medical Education to provide continuing medical education for Feinberg School of Medicine physicians. t 3FDPHOJ[FUIFIJHIQSFWBMFODFBOEJNQBDUPG$,%JOPMEFSBEVMUT when referring to an unlabeled or investigational use. Northwestern University t 6OEFSTUBOEIPXQSPHSFTTJPOPG$,%WBSJFTXJUIBHF The National Kidney Foundation designates this educational activity for a Chicago, Illinois maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim t 6OEFSTUBOEUIFSPMFBOEMJNJUBUJPOTPGHVJEFMJOFTSFMBUJWFUP$,%JOPMEFSBEVMUT Accreditation Statement: The National Kidney credit commensurate with the extent of their participation in the activity. 12:35 PM Should Phosphorus Be Controlled by Stuart M. Sprague, DO 'PVOEBUJPOJTBDDSFEJUFECZUIF"DDSFEJUBUJPO The National Kidney Foundation is an approved provider of continuing nursing Dietary Restriction or Phosphate Binders Council for Continuing Medical Education to provide education by the New York State Nurses Association, which is accredited as an in Patients With CKD? 6:30 – 6:35 am Welcome and Introductions continuing medical education for physicians. approver of continuing nursing education by the American Nurses Credentialing Ann O’Hare, MD – Program Chair Center’s Commission on Accreditation. 1:00 PM PRO: Dietary Phosphorus Control Daniel W. Coyne, MD VA Puget Sound Health Care System, Seattle, Washington Improves Survival Professor of Medicine The National Kidney This program is pending approval by the American Academy of Nurse Designation Statement: Practitioners. • Effectiveness of dietary control Renal Division 6:35 – 7:00 am Natural History and Epidemiology of CKD in the Elderly 'PVOEBUJPOEFTJHOBUFTUIJTFEVDBUJPOBMBDUJWJUZGPS • Association of phosphorus with survival Washington University School of Medicine The National Kidney Foundation is a Continuing Professional St. Louis, Missouri Brenda R. Hemmelgarn, MD a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Education (CPE) Accredited Provider with the Commission on Dietetic 6OJWFSTJUZPG$BMHBSZ 'PPUIJMMT.FEJDBM$FOUSF $BMHBSZ "MCFSUB $BOBEB Physicians should only claim credit commensurate Registration (CDR). Registered dietitians (RDs) and dietetic 1:25 PM CON: Dietary Phosphorus Control Kamyar Kalantar-Zadeh, MD, PhD, MPH with the extent of their participation in the activity. technicians, registered (DTRs) will receive 1.5 continuing professional 7:00 – 7:25 am Assessment of Kidney Function in the Elderly education units (CPEUs) for completion of this program/material. Increases Survival Associate Professor of Medicine and Lesley A. Stevens, MD, MS, FRCP • Limitations of dietary control Pediatrics 5IF/BUJPOBM,JEOFZ'PVOEBUJPOJTBOBQQSPWFE DECLARATION OF DISCLOSURE David Geffen School of Medicine Tufts-New England Medical Center, Boston, Massachusetts It is the policy of the National Kidney Foundation to ensure balance, • Effectiveness of phosphate binders provider of continuing nursing education by the New University of California, Los Angeles independence, objectivity, and scientific rigor in all CME activities. Faculty Director, Dialysis Expansion Program 7:25 – 7:50 am Challenges of Managing CKD in the Elderly participating in this activity are required to disclose to the audience any York State Nurses Association, which is accredited as and Epidemiology relationship they may have with the commercial supporters of this activity Ann O’Hare, MD an approver of continuing nursing education by the Harbor–UCLA Medical Center or with any other commercial organizations whose products or devices may Los Angeles, California VA Puget Sound Health Care System, Seattle, Washington American Nurses Credentialing Centers Commission be mentioned in their presentations. on Accreditation. 7:50 – 8:00 am Questions and Answers UNLABELED/INVESTIGATIONAL USE DECLARATION 1:50 PM Panel Discussion/Q&A During their presentations, faculty may discuss an unlabeled use or an This program is pending approval with the American investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when 2:00 PM Adjourn Academy of Nurse Practitioners. referring to an unlabeled or investigational use. DISCLAIMER Disclaimer: The faculty, National Kidney The faculty, National Kidney Foundation, and Shire Pharmaceuticals do not :PVNVTUCFSFHJTUFSFEGPSUIF/,'4QSJOH$MJOJDBM.FFUJOHT 'PVOEBUJPO BOE0SUIP#JPUFDI1SPEVDUT -1 EPOPU recommend the use of any pharmaceutical, diagnostic test, or device outside to attend this symposium and receive credit. recommend the use of any pharmaceutical, diagnostic of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindi- REGISTRATION test, or device outside of the labeled indications as cations, and warnings. BQQSPWFECZUIF'%"1MFBTFSFGFSUPUIFPGGJDJBM To ensure participation, preregistration is strongly recommended by March, 31, 2008. prescribing information for each product for approved Sponsored by the National Kidney Foundation. To register for this symposium, please call the Registration Center at 1-866-890-2945. indications, contraindications, and warnings. On-site registration will begin at 12:00 PM in Grapevine Ballroom C, Gaylord Texan Supported by an unrestricted educational Resort and Convention Center, Grapevine, Texas. Seating priority will be given to grant from Shire Pharmaceuticals. preregistered attendees; however, walk-ins are encouraged and will be admitted on Please note that spouses, guests, or children are not a first-come, first-served basis, as space permits. Sponsored by the National Kidney Supported by an educational grant from permitted to attend. This is an educational program 'PVOEBUJPO 0SUIP#JPUFDI1SPEVDUT -1 for healthcare professionals only. You must be registered for the NKF 2008 Spring Clinical Meetings to attend this symposium and receive credit. Shire_NKF AD.rev.qxp:1788 AD 8.5x11 2/20/08 3:55 PM Page 1 National Kidney Foundation (NKF) 2008 Spring Clinical Meetings Dietary Phosphorus and Outcomes in Patients With CKD Thursday, April 3, 2008 12:00 PM – 12:30 PM Registration and Lunch 12:30 PM – 2:00 PM Symposium Gaylord Texan Resort and Convention Center Grapevine Ballroom C 1501 Gaylord Trail Grapevine, Texas EDUCATIONAL OBJECTIVES Upon completion of this symposium, participants will be able to: • Apply dietary restriction techniques to control phosphorus (P) levels in patients with chronic kidney disease (CKD) • Evaluate the efficacy of dietary P control and its effect on survival ACTIVITY PURPOSE • Assess the risk of malnutrition associated with dietary P control The purpose of this symposium is to educate nephrologists, fellows, • Appropriately implement the use of phosphate binders in controlling hyperphosphatemia residents, physician assistants, nurse practitioners, nephrology nurses and in patients with CKD technicians, and renal and clinical dietitians interested in learning about safe and effective control of phosphorus levels in patients with CKD. HOW YOU WILL LEARN The symposium is held in a panel discussion format, incorporating PROGRAM AGENDA case-based presentations, didactic lectures, and audience participation using the audience response system (ARS). 12:00 PM Registration and Lunch TARGET AUDIENCE This program is designed for nephrologists, fellows, residents, physician 12:30 PM Welcome and Introduction Stuart M. Sprague, DO assistants, nurse practitioners, nephrology nurses and technicians, and renal Moderator and Program Chair and clinical dietitians. Chief, Division of Nephrology and Hypertension ACCREDITATION AND CREDIT DESIGNATION STATEMENTS Evanston Northwestern Healthcare The National Kidney Foundation is accredited by the Accreditation Council for Professor of Medicine Continuing Medical Education to provide continuing medical education for Feinberg School of Medicine physicians. Northwestern University The National Kidney Foundation designates this educational activity for a Chicago, Illinois maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. 12:35 PM Should Phosphorus Be Controlled by Stuart M. Sprague, DO The National Kidney Foundation is an approved provider of continuing nursing Dietary Restriction or Phosphate Binders education by the New York State Nurses Association, which is accredited as an in Patients With CKD? approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 1:00 PM PRO: Dietary Phosphorus Control Daniel W. Coyne, MD This program is pending approval by the American Academy of Nurse Improves Survival Professor of Medicine Practitioners. • Effectiveness of dietary control Renal Division • Association of phosphorus with survival Washington University School of Medicine The National Kidney Foundation is a Continuing Professional St. Louis, Missouri Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional 1:25 PM CON: Dietary Phosphorus Control Kamyar Kalantar-Zadeh, MD, PhD, MPH education units (CPEUs) for completion of this program/material. Increases Survival Associate Professor of Medicine and Pediatrics DECLARATION OF DISCLOSURE • Limitations of dietary control • Effectiveness of phosphate binders David Geffen School of Medicine It is the policy of the National Kidney Foundation to ensure balance, University of California, Los Angeles independence, objectivity, and scientific rigor in all CME activities. Faculty Director, Dialysis Expansion Program participating in this activity are required to disclose to the audience any and Epidemiology relationship they may have with the commercial supporters of this activity Harbor–UCLA Medical Center or with any other commercial organizations whose products or devices may Los Angeles, California be mentioned in their presentations. UNLABELED/INVESTIGATIONAL USE DECLARATION 1:50 PM Panel Discussion/Q&A During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when 2:00 PM Adjourn referring to an unlabeled or investigational use. DISCLAIMER The faculty, National Kidney Foundation, and Shire Pharmaceuticals do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindi- REGISTRATION cations, and warnings. To ensure participation, preregistration is strongly recommended by March, 31, 2008. Sponsored by the National Kidney Foundation. To register for this symposium, please call the Registration Center at 1-866-890-2945. On-site registration will begin at 12:00 PM in Grapevine Ballroom C, Gaylord Texan Supported by an unrestricted educational Resort and Convention Center, Grapevine, Texas. Seating priority will be given to grant from Shire Pharmaceuticals. preregistered attendees; however, walk-ins are encouraged and will be admitted on a first-come, first-served basis, as space permits. You must be registered for the NKF 2008 Spring Clinical Meetings to attend this symposium and receive credit. 08-07 FMC Ad 2/21/08 1:36 PM Page 1 Evidence-Based Review of the Management of Hyperphosphatemia and its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008 Held During the National Kidney Foundation 2008 Spring Clinical Meetings Thursday, April 3, 2008, 7:30 p.m. - 9:30 p.m. The Gaylord Texan | Grapevine Ballroom C | Grapevine, Texas PROGRAM PURPOSE Hyperphosphatemia has been implicated in a myriad of negative consequences including the pathogenesis of cardiovascular calcification and is independently associated with increased mortality in patients with stage 5 chronic kidney disease (CKD). Therefore adequate control of phosphate is essential in these patients; however the most appropriate therapy has been a matter of much debate. This symposium will review recently published studies evaluating phosphate binder and its impact on efficacy, patient outcomes, and pharmacoeconomics, especially as it relates to treatment selection and the attainment of KDOQI guidelines for mineral metabolism disorders in the United States. TARGET AUDIENCE This program has been designed to meet the learning objectives of Physicians, Researchers, Fellows, Residents, and may be beneficial to nurses and dietitians. AGENDA AND SPEAKERS: PROGRAM OBJECTIVES 7:30 p.m. Registration and Dinner At the conclusion of the program, participants will be able to: 8:00 p.m. Introduction by Program Moderator Vincent W. Dennis, M.D. • Discuss the epidemiology of hyperphosphatemia in Senior Medical Adviser patients with stage 5 CKD Ambulatory Services of America • Summarize the salient findings from recent clinical Brentwood, Tennessee trials that investigated the outcomes, including mortality rates, among patients with stage 5 CKD 8:10 p.m. A Review of Recent Clinical Studies of Patients who were treated with various phosphate binders with Stage 5 CKD: Impact on Clinical Practice • Understand the recent pharmacoeconomic data for Lynda Szczech, M.D. phosphate binder selection and the impact of Associate Professor of Medicine applying the 2003 KDOQI guidelines for bone Duke Clinical Research Institute metabolism and disease in the United States Duke University Medical Center Durham, North Carolina Educational Method This CME activity will be a live symposium consisting of lectures and panel discussion with audience participation. 8:40 p.m. Phosphate Binder Choice in the Treatment of Accreditation Patients with Stage 5 CKD: Health-Economic The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Considerations Designation Wolfgang C. Winkelmayer, M.D., ScD The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA Assistant Professor of Medicine PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Harvard Medical School The National Kidney Foundation is an approved provider of continuing nursing education by the Cambridge Brigham and Women's Hospital New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Boston, Massachusetts This program is pending approval with the American Academy of Nurse Practitioners. Declaration of Disclosure 9:10 p.m. Question and Answer Session It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity, Faculty and scientific rigor in all CME activities. Faculty participating in this activity are required to disclose to the audience any relationship that they may have with the commercial supporters of this activity or with any other commercial organizations whose products or devices may be 9:30 p.m. Closing Remarks mentioned in their presentations. Vincent W. Dennis, M.D. Unlabeled/Investigational Use Declaration During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use. Disclaimer The faculty, National Kidney Foundation, and Fresenius Medical Care – North America (FMC-NA) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information SYMPOSIUM REGISTRATION for each product for approved indications, contraindications, and warnings. • Pre-registration for this symposium is not required. We recommend arriving at the symposium early. Seating is limited and will be available on a first come, first serve basis. Sponsored by the National Kidney Foundation Supported by an educational grant from • You must be registered for the NKF 2008 Spring Clinical Meetings to attend this symposium and receive credit. NKF_AdNEW2 3/3/08 4:06 PM Page 1 Friday April 4, 2008 Gaylord Texan Grapevine Ballroom D 1501 Gaylord Trail Assessing the Role Grapevine, Texas of Proteinuria in the Breakfast / Live Clinical Experts Progression of Roundtable Program: 6:00 AM Q & A: ...... 7:45 AM Chronic Kidney Disease Adjourn: ...... 8:00 AM National Kidney Foundation 2008 Spring Clinical Meetings ACTIVITY PURPOSE PANELISTS To familiarize attendees with the availability of published guidelines for Barry M. Brenner, MD the management of patients with CKD and to acquire a knowledge Brigham and Woman's Hospital base for implementing these guidelines into clinical practice. As a Boston, Massachusetts result of attending this session, Healthcare First anticipates a change in attitudes regarding the early detection and aggressive primary and David G. Warnock, MD secondary prevention of disease progression in these patients. University of Alabama Birmingham Birmingham, Alabama TARGET AUDIENCE Daniel C. Batlle, MD Physicians, fellows, residents, physician's assistants, nurse Northwestern University Medical School practitioners, and nephrology nurses and technicians interested in or Chicago, Illinois involved with the management of CKD. ACCREDITATION LEARNING OBJECTIVES The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing • Review Treatment Guidelines (JNC-7, KDOQI) as they relate to medical education for physicians. treatment of CKD with hypertension and proteinuria • Review the relations between urine protein excretion, DESIGNATION STATEMENT cardiovascular risk and CKD The National Kidney Foundation designates this educational activity for TM • Review the therapeutic approaches to hypertension and a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should proteinuria in CKD only claim credit commensurate with the extent of their participation in the activity. • Develop a conceptual framework for stopping the progression of CKD: treatment goals for hypertension and proteinuria The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is AGENDA accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. • Slide Presentation One – Proteinuria and Progression: Primary and Secondary Prevention This program is pending approval with the American Academy of Nurse Practitioners. - Barry M. Brenner, MD DECLARATION OF DISCLOSURE • Slide Presentation Two – Fabry Nephropathy; Proteinuria It is the policy of the National Kidney Foundation to ensure balance, Without Hypertension: Targets for Therapy independence, objectivity, and scientific rigor in all CME activities. - David G. Warnock, MD Faculty participating in this activity are required to disclose to the audience any relationship they may have with the commercial • Slide Presentation Three – Progression From supporters of this activity or with any other commercial organizations Normoalbuminuria to Overt Proteinuria and CKD in Type I whose products or devices may be mentioned in their presentations. Diabetes: Role of Nocturnal Hypertension - Daniel C. Batlle, MD UNLABELED/INVESTIGATIONAL USE DECLARATION During their presentations, faculty may discuss an unlabeled use or an HOW YOU WILL LEARN investigational use not approved for a commercial product. Each This CME activity will be a live symposia consisting of presentations, faculty member is required to disclose this information to the audience panel exchange, and audience participation. when referring to an unlabeled or investigational use. DISCLAIMER The faculty, National Kidney Foundation, and Genzyme do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer Sponsored by the to the official prescribing information for each product for approved National Kidney Foundation. indications, contraindications, and warnings. The National Kidney Foundation and Healthcare First reserve the right to cancel or modify the activity content, faculty, and activities, if necessary. You must be registered for the NKF 2008 Spring Clinical Meetings to attend this symposia and receive credit. Supported by an unrestricted medical education grant from advert 21/2/08 15:44 Page 1 AMAG_NKF AD.rev.qxp:1788 AD 8.5x11 3/5/08 9:06 AM Page 1 A dinner symposium to be held at the NKF 2008 SPRING CLINICAL MEETINGS National Kidney Foundation 2008 Spring Clinical Meetings Optimal Patient Outcomes: Identification and Treatment of Iron Deficiency Friday, April 4, 2008 Program Agenda 7:00 PM – 9:00 PM Anemia in Early Chronic Kidney Disease 7:00 pm – 7:30 pm Registration and Dinner Grapevine Ballroom D, Gaylord Texan 7:30 pm – 7:45 pm Chair’s Introduction Dallas, Texas Mark J. Sarnak, MD, MS Friday, April 4, 2008 7:00 PM – 9:00 PM 7:45 pm – 8:05 pm Sudden Cardiac Death in Pre-dialysis CKD Patients and in Patients Undergoing Dialysis Gaylord Texan Resort and Convention Center Charles A. Herzog, MD Grapevine Ballroom C Professor of Medicine, University of Minnesota 1501 Gaylord Trail Director, Cardiovascular Special Studies Center Grapevine, Texas United States Renal Data System Director, Cardiac Ultrasound Lab, HCMC 8:05 pm – 8:25 pm Calcium and Phosphorus as Cardiovascular Risk Factors Educational Objectives David A. Bushinsky, MD Upon completion of this symposium, participants will be able to: Professor of Medicine Activity Purpose University of Rochester School of Medicine and Dentistry The purpose of this symposium is to educate nephrologists, fellows, • Discuss the prevalence of iron deficiency anemia in CKD and Rochester, NY residents, physician assistants, nurse practitioners, nephrology nurses associated complications and technicians, and renal and clinical dietitians interested in learning • Outline current clinical practice guidelines and examine recent clinical data 8:25 pm – 8:45 pm Coronary Artery Disease: Screening and Therapy about the identification and treatment of iron deficiency in patients Mark J. Sarnak, MD, MS with CKD. regarding patient identification, testing, and treatment goals Associate Professor of Medicine • Review current and future therapeutic approaches to the management of Tufts University School of Medicine How You Will Learn iron deficiency anemia in CKD Boston, MA The symposium is held in a panel discussion format, incorporating 8:45 pm – 9:00 pm Questions and Answers case-based presentations, didactic lectures, and audience participation using the audience response system (ARS). Program Agenda Target Audience 7:00 PM Registration and Dinner This program is designed for nephrologists, fellows, residents, physician assistants, nurse practitioners, nephrology nurses and 7:30 PM Welcome and Introduction technicians, and renal and clinical dietitians. Anatole Besarab, MD Accreditation and Credit Designation Statements Moderator and Program Chair The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide 7:40 PM Prevalence and Diagnosis of Anemia in Patients With CKD continuing medical education for physicians. Allen R. Nissenson, MD The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only Pre-dialysis and Dialysis claim credit commensurate with the extent of their participation in the 8:05 PM State of the Art in Treatment of Iron Deficiency Anemia: activity. Current and Future Directions Accreditation Statement(s) Disclaimer:The faculty, NKF, and Genzyme Activity Purpose The National Kidney Foundation is an approved provider of continuing Ajay K. Singh, MB, MRCP do not recommend the use of any nursing education by the New York State Nurses Association, which is pharmaceutical, diagnostic test, or device The purpose of this symposium is to examine the link between elevated phosphorus and calcium levels accredited as an approver of continuing nursing education by the The National Kidney Foundation is accredited 8:30 PM Case Review and Panel Discussion by the Accreditation Council for Continuing outside of the labeled indications as and the high incidence of cardiovascular (CV) disorders in patients with chronic kidney disease (CKD) American Nurses Credentialing Center’s Commission on Accreditation. Medical Education to provide continuing approved by the FDA. Please refer to the and to discuss how appropriate screening and therapy can help minimize the impact of heart disease in Anatole Besarab, MD medical education for physicians. official prescribing information for each these patients. CV disorders are a major cause of morbidity and mortality in patients with CKD, and This program is pending approval with the American Academy product for approved indications, sudden death is the leading cause of CV mortality in dialysis patients. Early intervention is important to of Nurse Practitioners. The National Kidney Foundation designates contraindications, and warnings. prolong survival in patients on hemodialysis. Elevated serum phosphorus and calcium concentrations 8:50 PM Questions and Answers this educational activity for a maximum of 1.5 are associated with increased risk of CV events and death in patients with end-stage renal disease. The National Kidney Foundation is a Continuing Professional TM Declaration of Disclosure: It is the policy AMA PRA Category 1 Credit(s) . Physicians Recently published data comparing mortality among CKD patients treated with phosphate binders is of Education (CPE) Accredited Provider with the Commission on of the National Kidney Foundation to ensure should only claim credit commensurate with great interest to practicing nephrologists and renal dietitians. In addition, recent evidence suggests that Dietetic Registration (CDR). Registered dietitians (RDs) and 9:00 PM Adjourn balance, independence, objectivity, and the extent of their participation in the activity. routine screening of new dialysis patients for vascular calcification may allow early identification of scientific rigor in all CME activities. Faculty dietetic technicians, registered (DTRs) will receive 1.5 those at risk for progressive coronary artery disease (CAD) who would benefit from non-calcium The National Kidney Foundation is an participating in this activity are required to continuing professional education units (CPEUs) for approved provider of continuing nursing disclose to the audience any relationship they containing phosphate binders as suggested by the KDOQI guidelines. completion of this program/material. education by the New York State Nurses may have with the commercial supporters of This symposium will also explore such issues as the epidemiology of sudden death in dialysis patients, Association, which is accredited as an this activity or with any other commercial how different phosphate binders may affect mortality, the proper role of screening for CAD in Declaration of Disclosure Registration approver of continuing nursing education by organizations whose products or devices may asymptomatic CKD patients, and the most appropriate therapy for established CAD in dialysis patients. It is the policy of the National Kidney Foundation to ensure balance, the American Nurses Credentialing Centers be mentioned in their presentations. To ensure participation, preregistration is strongly recommended by March 31, 2008. independence, objectivity, and scientific rigor in all CME activities. Commission on Accreditation. To register for this symposium, please call the Registration Center at 1-866-324-9148. Unlabeled/Investigational Use Target Audience Faculty participating in this activity are required to disclose to the audi- This program is pending approval with the Declaration: During their presentations, ence any relationship they may have with the commercial supporters On-site registration will begin at 7:00 PM in Grapevine Ballroom C, Gaylord Texan American Academy of Nurse Practitioners. faculty may discuss an unlabeled use or an Physicians, pharmacists, physician assistants, nephrology nurses, nurse practitioners, dietitians, of this activity or with any other commercial organizations whose Resort and Convention Center, Grapevine, Texas. Seating priority will be given to investigational use not approved for a nephrology social workers. You must be registered for the NKF 2008 commercial product. Each faculty member is products or devices may be mentioned in their presentations. preregistered attendees; however, walk-ins are encouraged and will be admitted Spring Clinical Meetings to attend this required to disclose this information to the on a first-come, first-served basis, as space permits. symposium and receive credit. audience when referring to an unlabeled or How You Will Learn Unlabeled/Investigational Use Declaration investigational use. During their presentations, faculty may discuss an unlabeled use or an You must be registered for the NKF 2008 Spring Clinical Meetings to attend this This CME activity will be a live symposium consisting of lectures with a question-and-answer session for the audiences. investigational use not approved for a commercial product. Each faculty symposium and receive credit. member is required to disclose this information to the audience when Learning Objectives referring to an unlabeled or investigational use. • Learn about the epidemiology of sudden death and possible interventions in dialysis patients Disclaimer • Learn about the cardiovascular effects of calcium and phosphorus The faculty, National Kidney Foundation, and AMAG Pharmaceuticals, Sponsored by the National Kidney Foundation. • Learn about the controversies on coronary artery screening and therapy in CKD Inc. do not recommend the use of any pharmaceutical, diagnostic test, Sponsored by the National Kidney Foundation Supported by an educational grant from Genzyme • Learn about the controversies on peripheral vascular disease in dialysis patients or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product Supported by an unrestricted educational for approved indications, contraindications, and warnings. grant from AMAG Pharmaceuticals, Inc. AMAG_NKF AD.rev.qxp:1788 AD 8.5x11 3/5/08 9:06 AM Page 1 NKF 2008 SPRING CLINICAL MEETINGS Optimal Patient Outcomes: Identification and Treatment of Iron Deficiency Anemia in Early Chronic Kidney Disease Friday, April 4, 2008 7:00 PM – 9:00 PM Gaylord Texan Resort and Convention Center Grapevine Ballroom C 1501 Gaylord Trail Grapevine, Texas Educational Objectives Upon completion of this symposium, participants will be able to: Activity Purpose The purpose of this symposium is to educate nephrologists, fellows, • Discuss the prevalence of iron deficiency anemia in CKD and residents, physician assistants, nurse practitioners, nephrology nurses associated complications and technicians, and renal and clinical dietitians interested in learning • Outline current clinical practice guidelines and examine recent clinical data about the identification and treatment of iron deficiency in patients with CKD. regarding patient identification, testing, and treatment goals • Review current and future therapeutic approaches to the management of How You Will Learn iron deficiency anemia in CKD The symposium is held in a panel discussion format, incorporating case-based presentations, didactic lectures, and audience participation using the audience response system (ARS). Program Agenda Target Audience 7:00 PM Registration and Dinner This program is designed for nephrologists, fellows, residents, physician assistants, nurse practitioners, nephrology nurses and 7:30 PM Welcome and Introduction technicians, and renal and clinical dietitians. Anatole Besarab, MD Accreditation and Credit Designation Statements Moderator and Program Chair The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide 7:40 PM Prevalence and Diagnosis of Anemia in Patients With CKD continuing medical education for physicians. Allen R. Nissenson, MD The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the 8:05 PM State of the Art in Treatment of Iron Deficiency Anemia: activity. Current and Future Directions The National Kidney Foundation is an approved provider of continuing Ajay K. Singh, MB, MRCP nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the 8:30 PM Case Review and Panel Discussion American Nurses Credentialing Center’s Commission on Accreditation. Anatole Besarab, MD This program is pending approval with the American Academy of Nurse Practitioners. 8:50 PM Questions and Answers The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and 9:00 PM Adjourn dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material. Declaration of Disclosure Registration It is the policy of the National Kidney Foundation to ensure balance, To ensure participation, preregistration is strongly recommended by March 31, 2008. independence, objectivity, and scientific rigor in all CME activities. Faculty participating in this activity are required to disclose to the audi- To register for this symposium, please call the Registration Center at 1-866-324-9148. ence any relationship they may have with the commercial supporters On-site registration will begin at 7:00 PM in Grapevine Ballroom C, Gaylord Texan of this activity or with any other commercial organizations whose Resort and Convention Center, Grapevine, Texas. Seating priority will be given to products or devices may be mentioned in their presentations. preregistered attendees; however, walk-ins are encouraged and will be admitted on a first-come, first-served basis, as space permits. Unlabeled/Investigational Use Declaration During their presentations, faculty may discuss an unlabeled use or an You must be registered for the NKF 2008 Spring Clinical Meetings to attend this investigational use not approved for a commercial product. Each faculty symposium and receive credit. member is required to disclose this information to the audience when referring to an unlabeled or investigational use. Disclaimer The faculty, National Kidney Foundation, and AMAG Pharmaceuticals, Sponsored by the National Kidney Foundation. Inc. do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product Supported by an unrestricted educational for approved indications, contraindications, and warnings. grant from AMAG Pharmaceuticals, Inc. 545-074-02-08-SC-NKF-2-Program-Ad-v7:NKF-1 Advertisement 2/27/08 4:10 PM Page 1 168 Ad.qxd:168 Ad 3/6/08 9:05 AM Page 1 Exploring the Link Between Friday, April 4th, 2008 A Breakfast Symposium during the National Kidney Foundation 6:00 AM – 8:00 AM � Gaylord Texan � Grapevine Ballroom C Chronic Kidney Disease and 2008 Spring Clinical Meetings Cardiovascular Disease Optimizing A CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings Evidence-Based Best Practices Gaylord Texan Saturday, April 5, 2008 Dallas, Texas for the Hemodialysis Team 6:00 AM – 8:00 AM Grapevine Ballroom D PROGRAM OVERVIEW FACULTY This symposium examines the association of cardiovascular disease in patients Louisa Tammy Ho, MD Kamyar Kalantar-Zadeh,MD,PhD with chronic kidney disease. Recent data indicates a much higher incidence of Assistant Professor of Medicine Associate Professor of Medicine and Symposium Registration: You must be registered for the NKF 2008 cardiovascular disease and mortality linked to cardiovascular risk factors Division of Nephrology and Pediatrics observed in chronic kidney disease patients. The session highlights current Hypertension Division of Nephrology and Activity Purpose Program Objectives Spring Clinical Meetings to attend this symposium and receive credit. To epidemiologic data, mechanisms contributing to pathophysiological processes Northwestern University Hypertension This interactive learning activity is designed to � List two factors that have been register for this symposium, please e-mail your name and e-mail address or fax number to [email protected]. Onsite registration will be and cardiovascular risk factors, and therapies that can reduce risk and improve Evanston, Illinois Los Angeles Biomedical Research enhance the performance of dialysis health- demonstrated to contribute to high first- survival in chronic kidney disease patients. This symposium will review current available just prior to the symposium at our registration desk outside of Institute care providers in the use of evidence-based year mortality among incident End-Stage therapies for attenuating vascular calcification and bone resorption, provide Ravi I. Thadhani, MD, MPH At Harbor–UCLA Medical Center Grapevine Ballroom C, starting at 6:00 AM on Friday, April 4, 2008. clinical strategies and best practices to Renal Disease (ESRD) patients and may be insight into classical and non-classical actions of vitamin D analogs, and Director of Clinical Research in Torrance, California This CME/CE symposium will incorporate an improve the health and quality of life of modifiable through optimal pre-ESRD care. How You Will Learn: management strategies for reducing cardiovascular risk factors associated with Nephrology interactive multi-disciplinary panel discussion of patient cases as well as chronic kidney disease. Massachusetts General Hospital patients on hemodialysis. � Describe the relationship between the an audience response system (ARS) to include audience participation in Associate Professor of Medicine Fistula First initiative and hemodialysis the panel discussion. Harvard Medical School Target Audience central venous catheter use in the Accreditation Statement: The National Kidney Foundation is accredited Boston, Massachusetts The live symposium is designed for nephrol- United States. ogy nurses, renal and clinical dietitians, and by the Accreditation Council for Continuing Medical Education to provide � Explain the technique for assessing continuing medical education for physicians. LEARNING OBJECTIVES nephrology social workers. • Identify cardiovascular risk factors associated with chronic kidney disease. multiple outcomes targets simultaneously Designation Statement: The National Kidney Foundation designates to improve dialysis patient outcomes. this educational activity for a maximum of 1.5 AMA PRA Category 1 • Understand the mechanisms that contribute to pathophysiologic processes Credit(s)™. Physicians should only claim credit commensurate with the and risk factors for chronic kidney disease patients. AGENDA extent of their participation in the activity. 6:00 AM – 6:25 AM • Review current management strategies to reduce vascular calcification and Saturday, April 5, 2008 Registration and Buffet Breakfast Available The National Kidney Foundation is an approved provider of continuing bone resorption in chronic kidney disease patients. nursing education by the New York State Nurses Association, which is 6:25 AM – 6:30 AM Welcome and Introductions 6:00 AM Registration accredited as an approver of continuing nursing education by the Bruce Robinson, MD, MSCE – Moderator American Nurses Credentialing Center’s Commission on Accreditation. TARGET AUDIENCE: This CME-certified symposium is directed towards 6:30 AM Welcome and Introduction This program is pending approval with the American Academy of nephrologists and clinicians who treat patients with chronic kidney disease. Vice President – Research Louisa Tammy Ho, MD Arbor Research Collaborative for Health, Ann Arbor, Michigan Nurse Practitioners. HOW YOU WILL LEARN: This CME activity will be a live symposium consisting 6:35 AM “Exploring the Association Between Cardiovascular The National Kidney Foundation is a Continuing Professional of lectures with panel audience participation Disease and Chronic Kidney Disease” 6:30 AM – 7:00 AM Improving Delivery of Pre-ESRD Care, Education (CPE) Accredited Provider with the Commission on Louisa Tammy Ho, MD Dietetic Registration (CDR). Registered dietitians (RDs) and ACCREDITATION STATEMENT: The National Kidney Foundation is accredited Case Discussion dietetic technicians, registered (DTRs) will receive 1.5 con- by the Accreditation Council for Continuing Medical Education to provide 7:00 AM “Mechanisms that Contribute to Altered Cardiovascular Ronald Pisoni, PhD, MS tinuing professional education units (CPEUs) for completion continuing medical education for physicians. Regulation in Chronic Kidney Disease” of this program/material. Director of Analytical Support – DOPPS Ravi Thadhani, MD DESIGNATION STATEMENT: The National Kidney Foundation designates this Arbor Research Collaborative for Health, Ann Arbor, Michigan Declaration of Disclosure: It is the policy of the National Kidney TM educational activity for a maximum of 1.5 AMA PRA Category 1 Credit . 7:25 AM “Management Strategies for Reducing Cardiovascular Risk Foundation to ensure balance, independence, objectivity, and scientific Physicians should only claim credit commensurate with the extent of their Factors in Chronic Kidney Disease” 7:00 AM – 7:30 AM Has Catheter Use Increased Due to rigor in all CME activities. Faculty participating in this activity are required participation in the activity. Kamyar Kalantar-Zadeh, MD Fistula First? No! Case Discussion to disclose to the audience any relationship they may have with the com- The National Kidney Foundation is an approved provider of continuing nursing mercial supporters of this activity or with any other commercial organiza- education by the New York State Nurses Association, which is accredited as an 7:50 AM Q&A/Discussion Lawrence Spergel, MD, FACS tions whose products or devices may be mentioned in their presentations. approver of continuing nursing education by the American Nurses Credentialing Clinical Chair, Fistula First National Breakthrough Initiative Center’s Commission on Accreditation. Unlabeled/Investigational Use Declaration: During their presentations, Director, Dialysis Management Medical Group faculty may discuss an unlabeled use or an investigational use not This program is pending approval with the American Academy of Nurse Practitioners. San Francisco, California approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled DECLARATION OF DISCLOSURE: It is the policy of the National Kidney REGISTRATION: You must be registered for the NKF 2008 Spring Clinical Foundation to ensure balance, independence, objectivity, and scientific rigor in Meetings to attend this symposia and receive credit. 7:30 AM – 8:00 AM Managing Multiple Targets for Best Patient or investigational use. all CME activities. Faculty participating in this activity are required to disclose Outcomes, Case Discussion Disclaimer: The faculty, National Kidney Foundation, and Amgen do not to the audience any relationship they may have with the commercial supporters DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do not recommend the use of any pharmaceutical, diagnostic test, or device of this activity or with any other commercial organizations whose products or recommend the use of any pharmaceutical, diagnostic test, or device outside of the David Mendelssohn, MD, FRCPC outside of the labeled indications as approved by the FDA. Please refer to devices may be mentioned in their presentations. labeled indications as approved by the FDA. Please refer to the official prescribing Chief and Physician Director, Department of Nephrology the official prescribing information for each product for approved indica- information for each product for approved indications, contraindications, and Program AgendaHumber River Regional Hospital and University of Toronto tions, contraindications, and warnings. warnings. UNLABELED / INVESTIGATIONAL USE DECLARATION: During their Toronto, Canada presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to Supported by an unrestricted Sponsored by the Sponsored by the National Kidney Foundation Supported by an educational grant from AMGEN disclose this information to the audience when referring to an unlabeled or medical educational National Kidney investigational use. grant from Abbott. Foundation 168 Ad.qxd:168 Ad 3/6/08 9:05 AM Page 1 Friday, April 4th, 2008 A Breakfast Symposium during the National Kidney Foundation 6:00 AM – 8:00 AM � Gaylord Texan � Grapevine Ballroom C 2008 Spring Clinical Meetings Optimizing Evidence-Based Best Practices for the Hemodialysis Team Symposium Registration: You must be registered for the NKF 2008 Activity Purpose Program Objectives Spring Clinical Meetings to attend this symposium and receive credit. To This interactive learning activity is designed to � List two factors that have been register for this symposium, please e-mail your name and e-mail address or fax number to [email protected]. Onsite registration will be enhance the performance of dialysis health- demonstrated to contribute to high first- available just prior to the symposium at our registration desk outside of care providers in the use of evidence-based year mortality among incident End-Stage Grapevine Ballroom C, starting at 6:00 AM on Friday, April 4, 2008. clinical strategies and best practices to Renal Disease (ESRD) patients and may be This CME/CE symposium will incorporate an improve the health and quality of life of modifiable through optimal pre-ESRD care. How You Will Learn: interactive multi-disciplinary panel discussion of patient cases as well as patients on hemodialysis. � Describe the relationship between the an audience response system (ARS) to include audience participation in Target Audience Fistula First initiative and hemodialysis the panel discussion. central venous catheter use in the Accreditation Statement: The National Kidney Foundation is accredited The live symposium is designed for nephrol- United States. ogy nurses, renal and clinical dietitians, and by the Accreditation Council for Continuing Medical Education to provide � Explain the technique for assessing continuing medical education for physicians. nephrology social workers. multiple outcomes targets simultaneously Designation Statement: The National Kidney Foundation designates to improve dialysis patient outcomes. this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 6:00 AM – 6:25 AM Registration and Buffet Breakfast Available The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is 6:25 AM – 6:30 AM Welcome and Introductions accredited as an approver of continuing nursing education by the Bruce Robinson, MD, MSCE – Moderator American Nurses Credentialing Center’s Commission on Accreditation. Vice President – Research This program is pending approval with the American Academy of Arbor Research Collaborative for Health, Ann Arbor, Michigan Nurse Practitioners. The National Kidney Foundation is a Continuing Professional 6:30 AM – 7:00 AM Improving Delivery of Pre-ESRD Care, Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and Case Discussion dietetic technicians, registered (DTRs) will receive 1.5 con- Ronald Pisoni, PhD, MS tinuing professional education units (CPEUs) for completion of this program/material. Director of Analytical Support – DOPPS Arbor Research Collaborative for Health, Ann Arbor, Michigan Declaration of Disclosure: It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity, and scientific 7:00 AM – 7:30 AM Has Catheter Use Increased Due to rigor in all CME activities. Faculty participating in this activity are required Fistula First? No! Case Discussion to disclose to the audience any relationship they may have with the com- mercial supporters of this activity or with any other commercial organiza- Lawrence Spergel, MD, FACS tions whose products or devices may be mentioned in their presentations. Clinical Chair, Fistula First National Breakthrough Initiative Unlabeled/Investigational Use Declaration: During their presentations, Director, Dialysis Management Medical Group faculty may discuss an unlabeled use or an investigational use not San Francisco, California approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled 7:30 AM – 8:00 AM Managing Multiple Targets for Best Patient or investigational use. Outcomes, Case Discussion Disclaimer: The faculty, National Kidney Foundation, and Amgen do not recommend the use of any pharmaceutical, diagnostic test, or device David Mendelssohn, MD, FRCPC outside of the labeled indications as approved by the FDA. Please refer to Chief and Physician Director, Department of Nephrology the official prescribing information for each product for approved indica- Program AgendaHumber River Regional Hospital and University of Toronto tions, contraindications, and warnings. Toronto, Canada Sponsored by the National Kidney Foundation Supported by an educational grant from AMGEN Join Us for a Breakfast Symposium Saturday, April 5, 2008 from 6:00 am–8:00 am in Grapevine C. Chronic Kidney Disease Interventions: IMPROVING CKD AND CVD OUTCOMES I. KEEP overview and social conceptions of kidney disease: myths vs. realities II. Glycemic control in kidney disease I]ZAVg\Zhi8@9 III. Interventions and CVD interactions in diabetics with proteinuria 9ZiZXi^dcEgd\gVb IV. Impact of blood pressure control in CKD 1. Provide update on the NKF’s Kidney heart disease. Best practice recom- Early Evaluation Program (KEEP), a mendations impact both CKD and community-based screening initiative CVD outcomes. to identify those at increased risk for 4. Decribe how global risk reduction can kidney disease. be applied to both renal and cardio- 2. Present current views and miscon- vascular systems. ceptions regarding the management 5. Utilize NKF’s KEEP cohort and other and treatment of kidney disease. cohorts to demonstrate opportunities 3. Poor glycemic control and blood pres- for improvement in the detection and sure are the leading causes of kidney management of CKD. failure and signifi cantly contribute to Faculty: 7YYh[Z_jWj_ed0 Allan J. Collins, MD, FACP Samy I. McFarlane, MD, MPH, ǩ HOW YOU WILL LEARN: This CME activity will be a live symposium consisting of lectures with President, National Kidney FACP, FACE panel audience participation. Foundation Professor of Medicine ǩ ACCREDITATION STATEMENT: The National Professor of Medicine Chief, Division of Endocrinology, Diabetes Kidney Foundation is accredited by the Ac- University of Minnesota and Hypertension creditation Council for Continuing Medical Education Minneapolis, MN State University of New York to provide continuing medical education for Health Science Center at Brooklyn physicians. Peter A. McCullough, MD, Brooklyn, NY ǩ DESIGNATION STATEMENT: The National Kidney Foundation designates this educational MPH, FACC, FACP, FAHA, FCCP © 2008 National Kidney Foundation, Inc. All Rights Reserved. activity for a maximum of&#*6B6EG68Vi" Vice Chair, NKF KEEP Steering George Bakris, MD Z\dgn&8gZY^i h # Physicians should only claim credit commensurate with the extent of Committee Chair, NKF KEEP Steering their participation in the activity. Consulting Cardiologist and Chief Committee ǩ DECLARATION OF DISCLOSURE: It is the Division of Nutrition and Preventive Professor of Medicine policy of the National Kidney Foundation to Medicine Director, Hypertensive Diseases Center ensure balance, independence, objectivity, and scientifi c rigor in all CME activities. Faculty William Beaumont Hospital Section of Endocrinology, participating in this activity are required to Health Center Diabetes & Metabolism disclose to the audience any relationship they may have with the commercial supporters Royal Oak, MI University of Chicago – of this activity or with any other commercial Pritzker School of Medicine organizations whose products or devices may be mentioned in their presentations. Chicago, IL Sponsored by ǩ UNLABELED/INVESTIGATIONAL USE DEC� LARATION: During their presentations, faculty may discuss an unlabeled use or an investi- gational use not approved for a commercial KEEP is supported by product. Each faculty member is required to disclose this information to the audience when Primary Sponsor referring to an unlabeled or investigational use. ǩ DISCLAIMER: The faculty and National Kidney Associate Sponsors Foundation do not recommend the use of any 02-35-284A pharmaceutical, diagnostic test, or device out- Contributing Sponsors side of the labeled indications as approved by the FDA. Please refer to the offi cial prescribing Additional support provided by H^ZbZchBZY^XVaHdaji^dch9^V\cdhi^Xh!A^[ZhXVc!>cX#!6WWdiCjig^i^dc! information for each product for approved indications, contraindications, and warnings. DXZVcHegVn8gVcWZgg^Zh!>cX# Join Us for a Breakfast Symposium Dear Saturday, April 5, 2008 from 6:00 am–8:00 am in Grapevine C. Colleague Chronic Kidney Disease Interventions: Welcome to the NKF 2008 Spring Clinical Meetings! On behalf of the National Kidney Foundation and the Program Committee, it is our pleasure to welcome you to IMPROVING CKD AND CVD OUTCOMES the NKF 2008 Spring Clinical Meetings. This year’s conference was designed to provide a balanced curriculum I. KEEP overview and social conceptions of kidney disease: myths vs. realities that will meet the needs of the kidney healthcare team to stay current in advances in renal disease. II. Glycemic control in kidney disease We hope you find that the next few days provide you with stimulating and useful updates. Please be sure to I]ZAVg\Zhi8@9 III. Interventions and CVD interactions in diabetics with proteinuria complete the evaluations so we can continue to improve the meeting. 9ZiZXi^dcEgd\gVb IV. Impact of blood pressure control in CKD Have a great meeting! 1. Provide update on the NKF’s Kidney heart disease. Best practice recom- Early Evaluation Program (KEEP), a mendations impact both CKD and community-based screening initiative CVD outcomes. FPO FPO to identify those at increased risk for 4. Decribe how global risk reduction can kidney disease. be applied to both renal and cardio- Micheal Allon, MD Beth Piraino, MD 2. Present current views and miscon- vascular systems. Program Chair Program Co-Chair ceptions regarding the management 5. Utilize NKF’s KEEP cohort and other and treatment of kidney disease. CM08 CM08 cohorts to demonstrate opportunities 3. Poor glycemic control and blood pres- for improvement in the detection and sure are the leading causes of kidney management of CKD. failure and signifi cantly contribute to National Kidney Foundation Continuing Medical Education (CME) Program Mission Statement Faculty: 7YYh[Z_jWj_ed0 The mission of the National Kidney Foundation (NKF) Continuing Medical Education Program is to provide education for academic as well as private Allan J. Collins, MD, FACP Samy I. McFarlane, MD, MPH, ǩ HOW YOU WILL LEARN: This CME activity will practitioners in nephrology and related disciplines. These education activities are offered to regional, national and international audiences. be a live symposium consisting of lectures with President, National Kidney FACP, FACE Purpose: panel audience participation. Foundation Professor of Medicine To provide all members of the kidney healthcare community with current, state-of-the-art science information on prevention, diagnosis and treatment Professor of Medicine ǩ ACCREDITATION STATEMENT: The National Chief, Division of Endocrinology, Diabetes of kidney and urinary tract diseases in order to improve the care of individuals with chronic kidney disease (CKD) and those at risk for developing it. Kidney Foundation is accredited by the Ac- University of Minnesota and Hypertension creditation Council for Continuing Medical Content Area: Education Minneapolis, MN State University of New York Topics are selected based on physician gaps in knowledge regarding the care and treatment of individuals with kidney disease. KDOQI evidence-based to provide continuing medical education for Health Science Center at Brooklyn physicians. guidelines and the latest peer-reviewed clinical science provide the foundation for developing much of the content as well as professional interests, Peter A. McCullough, MD, Brooklyn, NY expert opinions, literature reviews and needs assessment data from patients and caregivers that identify gaps in quality of care relative to physician ǩ DESIGNATION STATEMENT: The National Kidney Foundation designates this educational MPH, FACC, FACP, FAHA, FCCP implementation of the science. © 2008 National Kidney Foundation, Inc. All Rights Reserved. activity for a maximum of&#*6B6EG68Vi" Vice Chair, NKF KEEP Steering George Bakris, MD Z\dgn&8gZY^i h # Physicians should only Target Audiences: claim credit commensurate with the extent of Committee Chair, NKF KEEP Steering Practicing physicians, residents, and fellows in nephrology, internal medicine, cardiology, endocrinology, family practice, physician assistants, nurse their participation in the activity. Consulting Cardiologist and Chief Committee practitioners and other specialties who care for individuals who are at increased risk for, or affected by, CKD. ǩ DECLARATION OF DISCLOSURE: It is the Division of Nutrition and Preventive Professor of Medicine Types of Activities: policy of the National Kidney Foundation to Medicine Director, Hypertensive Diseases Center Live activities include conferences, symposia, courses, hands-on workshops, audience response sessions, and debates. Enduring materials include ensure balance, independence, objectivity, and scientifi c rigor in all CME activities. Faculty William Beaumont Hospital Section of Endocrinology, monographs, videotapes, CD-ROM, web-based, PDA/Pocket PC software and audiotape. Adult learning principles and critical thinking strategies are participating in this activity are required to Health Center Diabetes & Metabolism incorporated into all education activities by ensuring that participants are given an opportunity to explore new applications and or strategies. disclose to the audience any relationship they may have with the commercial supporters Royal Oak, MI University of Chicago – Expected Results: of this activity or with any other commercial Pritzker School of Medicine Improve physician practice patterns in order to maximize the quality of care given to patients and improve patient outcomes. This will be accomplished organizations whose products or devices may by providing comprehensive educational activities that are current, largely based on evidence-based practice guidelines and expert opinion and by offer- be mentioned in their presentations. Chicago, IL Sponsored by ing a variety of learning formats to meet the diverse needs of our participants. Results will be evidenced by post testing and reviewing responses from ǩ UNLABELED/INVESTIGATIONAL USE DEC� activity evaluations that ask if participants plan to make any changes in their practice as a result of this activity and to identify these changes. Follow- LARATION: During their presentations, faculty ing our annual Spring Clinical Meeting, participants will be sent additional web-based evaluation questions which include if they are willing to provide may discuss an unlabeled use or an investi- gational use not approved for a commercial KEEP is supported by contact information for follow-up. Telephone surveys will then be conducted three to six months following an activity with those who have agreed to product. Each faculty member is required to follow-up contact. disclose this information to the audience when Primary Sponsor referring to an unlabeled or investigational use. ǩ DISCLAIMER: The faculty and National Kidney Associate Sponsors Foundation do not recommend the use of any 02-35-284A pharmaceutical, diagnostic test, or device out- Contributing Sponsors side of the labeled indications as approved by the FDA. Please refer to the offi cial prescribing Additional support provided by H^ZbZchBZY^XVaHdaji^dch9^V\cdhi^Xh!A^[ZhXVc!>cX#!6WWdiCjig^i^dc! information for each product for approved indications, contraindications, and warnings. DXZVcHegVn8gVcWZgg^Zh!>cX# Spring Clinical Meetings ’08 What’s Inside… 17 CM08 Program Committee 18 NKF Leadership 19 NKF Distinguished Lectures and Awards 27 NKF Professional Council Awards 28 Contributors 31 Exhibit Hall/Poster Information 32 General Information 32 Program Objectives 34 Corporate Partners 36 Corporate Supported Symposia 37 Disclosure Information Program Tracks: 42 Physician 63 Advanced Practitioner 72 Nephrology Nurse and Technician 82 Renal and Clinical Dietitian 94 Nephrology Social Worker 100 Clinical Conversations Lunches 102 Exhibit Hall Map and Listings 113 Research Grant Recipients 114 Hotel Map 115 Faculty National Kidney Foundation Program Committee Michael Allon, MD Andrea DeKam, LMSW Ivan D. Maya, MD Program Chair Nephrology Social Worker Program Co-Chair University of Alabama University of Alabama University of Michigan Dialysis Birmingham, AL Birmingham, AL Livonia, MI Michele H. Mokrzycki, MD, MS Beth Piraino, MD Peter B. DeOreo, MD, FACP Montefiore Medical Center Program Co-Chair Centers For Dialysis Care Albert Einstein College of Medicine University of Pittsburgh Shaker Heights, OH Bronx, NY Pittsburgh, PA Marrianne Hutton, RD, CDE Ann O’Hare, MD Sharon Adler, MD Renal & Clinical Dietitian University of Washington UCLA Medical Center Program Co-Chair Seattle, WA Torrance, CA Fresenius Medical Care North America Milagros D. Samaniego, MD Santa Rosa, CA Carolyn Atkins, RN, BS, CCTC University of Wisconsin Nephrology Nurse and Technician Kamyar Kalantar-Zadeh, MD Madison, WI Program Chair Harbor-University of California Stuart M. Sprague, DO Children’s Medical Center Torrance, CA Northwestern University Dallas, TX Pamela S. Kent, MS, RD, CSR, LD Evanston, IL Joanne M. Bargman, MD, FRCPC Renal & Clinical Dietitian Program Chair Stephanie Stewart, LICSW Toronto General Hospital Genzyme Renal Nephrology Social Worker Program Chair Toronto, Ontario, Canada Vermilion, OH Mayo Clinic Srinivasan Beddhu, MD Bobbie Knotek, RN, BSN, CNN, LPHQ Rochester, MN University of Utah Health Sciences Center Nephrology Nurse and Technician Maria Taylor, PharmD Salt Lake City, UT Program Co-Chair University of Alabama ESRD Network of Texas, Inc. Laurie E. Benton, RN, PA-C, BS, MPAS Birmingham, AL Dallas, TX Advanced Practitioner Program Co-Chair Miguel Vazquez, MD Scott & White Hospital Julia Lewis, MD University of Texas-Southwestern Temple, TX Vanderbilt University Medical Center Dallas, TX Nashville, TN Jeffrey Berns, MD Ex-Officio University of Pennsylvania School of Medicine Charmaine Lok, MD Allan J. Collins, MD, FACP Philadelphia, PA Toronto General Hospital Joseph Vassalotti, MD Toronto, Ontario, Canada Michael J. Choi, MD Johns Hopkins University School of Medicine Barbara Weis Malone, BSN, RN, CFNP Baltimore, MD Advanced Practitioner Program Co-Chair University of Colorado Health Sciences Center Golden, CO Spring Clinical Meetings ’08 p.17 Leadership National Kidney Foundation President Chairman Allan J. Collins, MD, FACP 2006–2008 Tom McDonough 2008–2010 Past Presidents Past Chairmen Over its 58-year history, the NKF has grown to David Warnock, MD 2004–2006 Charles B. Fruit 2005–2007 become the preeminent voluntary health care Brian J.G. Pereira, MD 2002–2004 Fred L. Brown, MBA, FACHE 2003–2005 organization dedicated to improving outcomes William F. Keane, MD 2000–2002 Andrew Baur 2001–2003 for people covering the entire spectrum of Joel D. Kopple, MD 1998–2000 Frederick A. Herbert 1999–2001 chronic kidney and urologic diseases. Garabed Eknoyan, MD 1996–1998 Joseph L. Brand 1997–1999 Alan R. Hull, MD 1994–1996 Wendy Brown, MD 1995–1997 The Foundation has made tremendous advances Neil A. Kurtzman, MD 1992–1994 A. Bruce Bowden 1993–1995 in its mission through the visionary leadership Shaul G. Massry, MD 1990–1992 Donald R. Wilson 1991–1993 of the National Presidents and Chairmen. Saulo Klahr, MD 1988–1990 Charles E. Westcott 1989–1991 The mission of the National Kidney Foundation Richard J. Glassock, MD 1986–1988 William P. Hunter, Jr. 1987–1989 is to prevent kidney and urinary tract Robert W. Schrier, MD 1984–1986 The Honorable diseases, improve the health and well-being David A. Ogden, MD 1982–1984 John N. Kirkendall 1985–1987 of individuals and families affected by these Richard M. Freeman, MD 1980–1982 John Hoag 1983–1985 diseases and increase the availability of all Stuart A. Kleit, MD 1978–1980 E. Burns McLindon 1981–1983 organs for transplantation. Arvin Weinstein, MD 1976–1978 Oliver W. Porter 1979–1981 James C. Hunt, MD 1973–1976 Harold D. Schwartz 1977–1979 E. Lovell Becker 1970–1973 Jack C. Kent 1975–1977 George E. Schreiner 1968–1970 Jordan E. Ringel 1973–1975 George Lingua 1967–1968 The office of Chairman was created in 1973. William J. Jones, MD 1966–1967 Wallace W. McCrory, MD 1964–1966 Daniel P. Richman, MD 1960–1964 William A. Wargo 1959–1960 Henry Kessler, MD 1954–1959 Mrs. John E. Tedford 1952–1954 Mrs. Ada U. DeBold 1950–1952 (Founder) p.18 National Kidney Foundation Distinguished Lectures and Awards The Shaul G. Massry Distinguished Lecture The Donald W. Seldin Award This lectureship was established to honor Dr. Shaul G. Massry for his The Donald W. Seldin Award was established to recognize excellence scientific achievements and his contributions to the kidney health in clinical nephrology in the tradition of one of the foremost teachers care community and the National Kidney Foundation. The 2008 and researchers in the field, Dr. Donald W. Seldin. The 2008 award honored lecturer is Tom Greene, PhD. Dr. Greene will be presenting recipient is Thomas D. DuBose, Jr., MD. “Randomized and Observational Studies in Nephrology: How Strong Dr. DuBose is the Tinsley R. Is the Evidence?” on Thursday, April 3rd. Harrison Professor and Chair of After receiving his PhD in Internal Medicine and Professor statistics from Cornell, Dr. Greene of Physiology and Pharmacology served as an Assistant Profes- at Wake Forest University School sor of Statistics at the University of Medicine. His training in Inter- of Kentucky from 1985 to 1989. nal Medicine was accomplished He moved to the Department of at Parkland Memorial Hospital Statistics and Epidemiology at the Thomas D. DuBose, Jr., MD in Dallas, Texas. A research and Cleveland Clinic Foundation in clinical fellowship in Nephrology was completed at the University of Tom Greene, PhD 1991, where Dr. Greene joined the Texas Southwestern Medical Center under Drs. Juha P. Kokko and department’s Data Coordinating Center for multi-center clinical trials. Donald W. Seldin. Dr. Greene’s close relationship with the field of nephrology began soon Dr. DuBose was initially appointed Assistant Professor of Medicine at thereafter, and in 1993 Dr. Greene became the lead statistician for the the University of Texas Health Science Center at Dallas, Southwestern data analyses of the Modification of Diet in Renal Disease Study. This Medical School and was subsequently recruited to the University work provided Dr. Greene the opportunity to interact closely with many of Texas Medical Branch, Galveston where he became Professor of researchers in the field. In subsequent years, Dr. Greene and his Medicine and of Physiology and Biophysics, and served as Chief of the colleagues at the Cleveland Clinic Foundation coordinated other major Division of Nephrology. From 1991–1999, Dr. DuBose was Professor clinical trials in nephrology, including the Hemodialysis Study, the of Internal Medicine and of Integrative Biology, Pharmacology, and African American Study of Kidney Disease, the Dialysis Access Consor- Physiology and Director of the Division of Renal Diseases and Hyper- tium, the Focal Segmental Glomerulosis Study, and the Frequent tension at the University of Texas Medical School–Houston, where he Dialysis Network. Collaborations in association with these studies also served as Vice Chair of Internal Medicine. Prior to being recruited led to methodological research into clinical trial designs, outcome to Wake Forest University School of Medicine, Dr. DuBose served as measures in kidney disease, kinetic modeling, and estimation of renal the Peter T. Bohan Professor and Chair of the Department of Internal function. Dr. Greene is continuing his collaborations in nephrology Medicine at the University of Kansas, School of Medicine. after moving to the University of Utah in 2006. Past Shaul G. Massry Distinguished Lecture Recipients The overall goal of investigation by his laboratory is to illuminate factors involved in the molecular regulation of tubule transporters 2007 eberhard Ritz, MD responsible for urinary acidification and potassium homeostasis. 2006 giuseppe Remuzzi, MD, FRCP Several translational studies from this group have explained the 2005 edmund J. Lewis, MD pathophysiological basis of classical distal renal tubular acidosis with 2004 Hans-Henrik Parving, MD, DMSc hypokalemia (Type 1) and the generalized distal nephron defect re- 2003 robert Alpern, MD sulting in Type 4 RTA with hyperkalemia. He and his co-workers have 2002 Joseph V. Bonventre, MD, PhD advanced a new model of urinary acidification which has placed the 2001 andrzej S. Krolewski, MD, PhD regulation of ammonia production and transport as pivotal for acid- 2000 richard J. Glassock, MD base homeostasis and have elucidated the consequences of abnormal 1999 giuseppe Bianchi, MD potassium balance on acidosis and alkalosis, respectively. Current 1998 Josephine Briggs, MD studies have identified the contribution of the colonic H+, K+-ATPase 1997 gary E. Striker, MD to the maintenance of metabolic alkalosis. This investigator has been 1996 alfred Michael, MD funded continually by the NIH since 1981. Spring Clinical Meetings ’08 p.19 Dr. DuBose served as President of the American Society of Nephrology, David M. Hume Memorial Award 2005–2006 and was an elected member of Council for seven years. At The David M. Hume Award was created in memory of one of the the ASN he was most closely identified with development of the Public National Kidney Foundation’s most distinguished members. The Policy Board, and served as Chair of the ASN Grants Program. In the Hume Award is the highest honor given to a distinguished scientist- latter position, he expanded the scope and size of the awards available clinician in the field of kidney and urologic diseases. It is bestowed for academic career development and innovation among established upon an individual who exemplifies the high ideals of scholarship investigators. The initiative of his presidency was to encourage nephrol- and humanitarianism in an outstanding manner. The 2008 award ogists, primary care physicians, and federal funding agencies to work recipient is Lawrence Hunsicker, MD. in partnership and to recognize that chronic kidney disease is a public health issue requiring a coordinated response. He helped organize a Dr. Hunsicker is Professor of multi-society task force involving all kidney organizations to be more Internal Medicine and Medical effective in educating the public and funding agencies on placing Director of Organ Transplantation chronic kidney disease within existing programs in cardiovascular at the University of Iowa, College diseases and diabetes. of Medicine. His research interests include progressive kidney disease, Dr. DuBose has held several leadership positions in the American transplantation medicine, the Heart Association Council on the Kidney in Cardiovascular Disease and design and performance of clinical was Chair 2002–2004. In 2005, Dr. DuBose received the Distinguished Lawrence Hunsicker, MD trials, and the analysis of large Science Award from the AHA. national medical databases. In 1979 he founded with Dr. Edmund Lewis the Collaborative Study Group (CSG), which has demonstrated a striking DuBose is an author of 147 published papers and chapters in textbooks. benefit from blockade of the renin-angiotensin system in patients with Along with Dr. Lee Hamm, he co-edited the text: Acid-Base and diabetic kidney disease. This group is now studying the efficacy of Electrolyte Disorders. The second edition of this textbook is scheduled sulodexide in diabetic kidney disease. Dr. Hunsicker was also one of to be published in 2008. the PIs in the Modification of Diet inR enal Disease Study. Dr. Hunsicker Past Donald W. Seldin Award Recipients played major roles in the design of the data registries of the United 2007 l. Lee Hamm, MD, FACP Network for Organ Sharing (UNOS) and the United States Renal Data 2006 Heine Murer, MD and Bernard Rossier, MD System (USRDS). He was also the Principal Investigator for the Economic 2005 roland C. Blantz, MD Special Studies Center of the USRDS. 2004 gerhard H. Giebisch, MD Dr. Hunsicker was one of the founders and later President of the 2003 William M. Bennett, MD American Society of Transplantation and in 2000 was awarded their 2002 Professor Carl Erik Mogensen Roche Lifetime Achievement Award. He has been President of the 2001 Friedrich K. Port, MD, MS, FACP National Kidney Foundation of Iowa and Regional President of the 2000 Tilman B. Drüeke, MD National Kidney Foundation. He has served as President of UNOS 1999 Shaul G. Massry, MD and was also the first Medical Advisor to the American Organ Pro- 1998 alan R. Hull, MD curement Organization. He served from 2001 to 2004 on the initial 1997 Thomas F. Parker, III, MD HHS Secretary’s Advisory Committee on Organ Transplantation. He 1996 Floyd C. Rector, MD has been a member and chair of many NIH Study Sections and is 1995 Barry M. Brenner, MD presently a member of the FDA Advisory Committee on Antivirals. 1994 Manuel Martinez-Maldonado p.20 National Kidney Foundation Past David M. Hume Memorial Award Recipients The Garabed Eknoyan Award 2007 William G. Couser, MD The Garabed Eknoyan Award was created to recognize an individual 2006 Frank Delmonico, MD who has promoted the mission of the National Kidney Foundation in 2005 roland C. Blantz, MD Making Lives Better for people with kidney disease through excep- 2004 John Stewart Cameron, MD tional contributions to key initiatives of NKF such as the Kidney Disease 2003 Franklin H. Epstein, MD Outcomes Quality Initiative (KDOQI) or clinical research in the field of 2002 Barry M. Brenner, MD kidney disease. The 2008 award recipient is Adeera Levin, MD, FRCPC. 2001 William E. Mitch, MD 2000 [No Award] Dr. Levin is currently a Clinical 1999 Neil A. Kurtzman, MD Professor of Medicine at the 1998 Jared J. Grantham, MD University of British Columbia 1997 Thomas E. Andreoli, MD (BC), Co-director of the Clinical 1996 edmund G. Lowrie, MD Investigator Program at UBC. She 1995 Joseph W. Eschbach, MD is the Executive Director of the 1994 Wadi N. Suki, MD BC Provincial Renal Agency, an 1993 Joel D. Kopple, MD organization which manages and Adeera Levin, MD, FRCPC 1992 Saulo Klahr, MD coordinates the care of patients 1991 Professor August Heidland with kidney disease in the province of BC, and which has developed 1990 richard J. Glassock, MD and maintained the provincial registry for renal patients. 1989 Professor Priscilla Kincaid-Smith Dr. Levin is the Past Chair of the Kidney Foundation of Canada Biomedical 1988 Shaul G. Massry, MD Fellowship and Scholarship Committee, and serves as Chair of the 1987 robert W. Schrier, MD Curriculum Committee for a new innovative program for the train- 1986 robert Heptinstall, MD ing of Canadian clinical scientists in kidney disease (KRESCENT). In 1985 Willem J. Jolff, MD addition she is Chair of the NKF KDOQI clinical Practice Guideline 1984 Charles R. Kleeman, MD initiative process, and is on the Board of Directors and Executive com- 1983 robert W. Berliner, MD mittee of the newly formed KDIGO, an international group providing 1982 Professor Hugh E. de Wardener collaborative structure for outcomes research and guideline develop- 1981 Donald W. Seldin, MD ment in CKD. 1980 george E. Schreiner, MD 1979 John P. Merrill, MD Her research and clinical activities focus on chronic kidney disease, 1978 Thomas E. Starzl, MD co-morbidities associated with CKD, mechanisms of disease, and health 1977 Henry L. Barnett, MD outcomes research. She is active in mentoring young investigators in 1976 Carl. W. Gottschalk, MD kidney-related research, and holds numerous grants for clinical studies. 1975 Belding Scribner, MD Dr. Levin has over 135 peer-reviewed publications, numerous book 1974 robert M. Kark, MD chapters, and has been guest editor for sections in Current Opinion in 1973 Jean Hamburger, MD Nephrology and Hypertension for two consecutive years, as well as serv- ing on the editorial board for NDT, JASN and AJKD. She reviews papers for Circulation, New England Journal of Medicine, Annals of Internal Medicine, Canadian Family Practice and Kidney International as well. Dr. Levin was recently awarded a team-planning grant from Michael Smith to create an active research team, INTEGRATION, to develop a research strategy for the study of complex patients; and was also awarded a Provincial Treasury Board administered Health Innovation Fund grant to develop and assess novel methods of care Spring Clinical Meetings ’08 p.21 delivery for patients with Diabetes, Kidney Disease and Heart Disease KDOQI Distinguished Service Award in the province of BC. In recognition of their longtime dedication and effectiveness in improving clinical research in the fields of kidney and urologic disease, Past Garabed Eknoyan Award Recipients the National Kidney Foundation wishes to honor Dr. Lawrence Y.C. 2007 Norbert H. Lameire, MD Agodoa, Dr. Paul W. Eggers, and Dr. John W. Kusek with a special 2006 Francesco Locatelli, MD KDOQI Distinguished Service Award. This award was established 2005 Nathan W. Levin, MD, FACP to recognize significant contributions in the area of chronic kidney 2004 Neil R. Powe, MD, MPH, MBA disease health care and research. 2003 Bertram L. Kasiske, MD 2002 andrew S. Levey, MD Dr. Agodoa graduated from the Cornell University College of Medicine, New York, NY in 1971. He completed internship and Joel D. Kopple Award residency training in Internal The Joel D. Kopple Award is an annual award honoring an individual who Medicine at the University of has made significant contributions to the field of renal nutrition. This Washington Hospitals in Seattle, year’s Joel D. Kopple Award recipient is Alison L. Steiber, PhD, RD, LD WA, and training in clinical and who will be speaking on “Dietitian: Powerhouse Behind the Patients.” Lawrence Y.C. Agodoa, MD, FACP biomedical research in Nephrology Alison Steiber is the Director of and Renal Pathology. the Coordinated Dietetic Intern- He was appointed Chief of the Nephrology Service at the Madigan ship/Master’s Degree Program at Army Medical Center, Tacoma, WA. in 1976. In 1981, he returned to Case Western Reserve Univer- the University of Washington and completed two years of clinical and sity in Cleveland, Ohio. Allison research training in Rheumatology and Immunology. In 1983, he was received her Bachelor’s Degree assigned to the Walter Reed Army Medical Center as Assistant Chief in Dietetics from Mankato State of the Nephrology Service and the Nephrology Training Program, and University, followed by her Mas- Alison Steiber, PhD, RD, LD was appointed to the Faculty of Medicine at the Uniformed Services ter’s Degree from the University University of the Medical Sciences (USUMS), Bethesda, Maryland. In of Kansas Medical Center. She earned her Doctorate in Nutrition from 1985, he was appointed Director of the Military Medical Research Michigan State University. Her dissertation was on carnitine levels Fellowship at the Walter Reed Army Institute of Research. in patients receiving hemodialysis as well as supplementation with carnitine to study the effects on clinical parameters and quality of life. In 1987, Dr. Agodoa was appointed Director of the Clinical Affairs Pro- She was the recipient of a CRN National Research Grant in 2004 to gram in the Division of Kidney, Urologic, and Hematologic Diseases at conduct the “North American Subjective Global Assessment Valida- the National Institute of Diabetes, Digestive and Kidney Diseases of tion Project” which was published recently in the Journal of Renal the National Institutes of Health (NIH) in Bethesda, Maryland. Nutrition. Dr. Steiber has published numerous articles, abstracts and CPE modules and has been a phenomenal force in encouraging and fostering renal dietitians in research and excellence in practice. Past Joel D. Kopple Award Recipients 2007 Kamyar Kalantar-Zadeh, MD, PhD, MPH 2006 Mary Pat Kelly, MS, RD, GNP 2005 Jerrilynn D. Burrowes, PhD 2004 Judith Beto, PhD, RD, FADA 2003 linda M. McCann, RD, LD, CSR 2002 linda Moore, RD, LDN p.22 National Kidney Foundation Presently, he is Professor of Medicine at the Uniformed Services Uni- John W. Kusek received his PhD versity of the Health Sciences, F. Edward Hebert School of Medicine, from the University of Michigan. and Program Director at the National Institutes of Health. His current He is currently at the Division of duties include the following: Kidney, Urologic and Hematologic n Director, Office of Minority Health Research Coordination at the Diseases, National Institute of National Institute of Diabetes and Digestive and Kidney Diseases Diabetes and Digestive and Kid- (NIDDK), National Institutes of Health. ney Diseases (NIDDK), National n Director of the Minority Health Program in the Division of Kidney, Institutes of Health. Prior to Urologic and Hematologic Diseases (DKUHD). John W. Kusek, PhD coming to the NIH in 1983 he was n Program Scientist and Coordinator of the multi-center clinical trial, a faculty member in the Department of Epidemiology and Biometry, The African American Study of Kidney Disease and Hypertension School of Public Health, University of Illinois at Chicago. For the past (AASK) Cohort. 18 years he has worked on major clinical research studies in chronic n Co-Project Officer of the ESRD renal database, the United States kidney disease and urologic diseases. He has served as Project Sci- Renal Data System (USRDS). entist or Assistant Project Scientist on the following studies of chronic kidney disease: The Modification of Diet in Renal Disease Study, the Dr. Eggers is the Program Direc- African American Study of Kidney Disease and Hypertension, the tor for Kidney and Urology Epide- Hemodialysis Study, the Dialysis Access Consortium, the Folic Acid for miology at the National Institute Vascular Reduction in Renal Transplants, the Chronic Kidney Disease of Diabetes and Digestive and Epidemiology Collaboration and the Chronic Renal Insufficient Cohort Kidney Diseases. He oversees the Study. He has also served as Project Scientist for a large number of United States Renal Data System clinical research studies in urology, including the Medical Therapy (USRDS), the Urologic Diseases of Prostatic Symptoms Trial, the Chronic Prostatitis Collaborative in America (UDA) project, the Research Network, the Interstitial Cystitis Clinical Research Network, Paul W. Eggers, PhD Boston Area Community Health the Urinary Incontinence Research Network, the Minimally Invasive (BACH) Study, the Frequent Hemodialysis Network (FHN) Clinical Surgical Therapy Network, the Complementary and Alternative Medi- Trial, the NIDDK data repository, and the RAND Interstitial Cystitis cine for Urological Symptoms trial and the Boston Area Community Epidemiology (RICE) survey. In addition, he oversees a variety of epi- Health Survey. He has published over 100 articles on chronic kidney demiological grants in the area of kidney and urologic diseases. disease and urology, over 200 abstracts, and several book chapters. Prior to joining NIDDK, Dr. Eggers was Director of the Division of He has received two NIH Director’s Awards, the NIH Award of Merit Beneficiary Research in the Office of Strategic Planning at the Health and a special achievement award from the NIDDK. He has reviewed Care Financing Administration (HCFA). He worked on research and manuscripts for over a dozen leading medical journals. evaluation studies at HCFA since 1978. He has conducted studies and John W. Kusek is married to Jody, a Senior Investigator for Monitoring evaluations of Medicare enrollment in HMOs, the Prospective Pay- and Evaluation at the World Bank, specializing in HIV/AIDS in Africa. They ment System, Physician Payment Reform, and the hospice benefit. have two daughters, Jessica, a lawyer currently serving as a clerk for a His major area of expertise is the End Stage Renal Disease Program. state of Maryland circuit court judge and Jenna, a high school senior. His research on ESRD includes epidemiological studies of mortality and morbidity among ESRD beneficiaries, transplantation studies and cost studies of dialysis and transplantation. He has over 60 publica- tions concerning various issues relating to the Medicare program, and ESRD in particular. Spring Clinical Meetings ’08 p.23 CM08 International Distinguished Medal Recipients Dr. Hoy is Professor of Medicine The International Distinguished Medal was established in 1990 to and Director of the Center for honor the achievement of individuals who have made significant Chronic Disease at the University contributions to the field of kidney disease and extended the goals of of Queensland, Australia. Her the National Kidney Foundation. The Foundation President presents work on high-risk populations in medals each year to recognize the accomplishments of individuals the USA and Australia has helped through their clinical work, roles in academia, scientific discoveries promote expansion of nephrolo- or volunteer work in organizations similar to the Foundation. gy’s focus beyond ESRD to early Wendy Hoy, MD markers of risk and disease, Dr. Charra was born April 19, and the notion of their integration with other chronic diseases. Her 1942, in Décazeville, in the central research addresses the epidemiology of renal disease, hypertension, part of France. He spent his early type 2 diabetes and cardiovascular disease, and determinants of ac- youth in France, then in Morocco. centuated susceptibility to disease, including intrauterine and early life events, and their structural markers. It also addresses primary Dr. Charra’s family took summer and secondary prevention, outcomes research, health services and vacations at his mother’s home in policy and cost-effectiveness evaluations. She advocates for programs Coligny near Switzerland, where of systematic surveillance and management of chronic kidney disease Bernard Charra, MD he met Marie-Jo his wife-to-be. in high risk groups, and has modeled their success in Australian He attended medical school in Aboriginal groups. She advocates for a needs-based system of health Montpellier between 1961 and 1968. He married Marie-Jo in 1966. They care delivery at the community level, and, working on protocols for lived two years in Seattle where he was a senior fellow in nephrology primary pharmacologic prevention. Her awards include: Austin Doyle under B.H.Scribner with their two first children; Claire, an oncologist, Award, High Blood Pressure Research Council of Australia, 1997; and Vincent, a professor of history. Wyeth Award, Best manuscript in MJA , Australian Medical Association, The two years spent in Seattle left an indelible impression on Bernard 2000; Wyeth Award, Best manuscript in MJA, Australian Medical and Marie-Jo. Dr. Charra was strongly influenced in his career by Association, 2002; Australian Kidney Foundation Clinical Nephrology B.H. Scribner who became a close friend over the years and corresponded Award: 2002. Best oral presentation 38th Annual Meeting of the daily. Dr. Charra joined Dr. Laurent in Tassin near Lyon in 1979 where he ANZSN, 2002; Australian Kidney Foundation Clinical Nephrology spent the following 26 years as a nephrologist and ultimately as the Award: 2004. Best oral presentation 40th Annual Meeting of the head of the unit. They had two more children, a son Clément, a general ANASN, 2004; Barry M. Brenner Endowed Lectureship: American practitioner, and Camille, a designer. Society of Nephrology, 2006. Dr. Charra’s favorite motto in life is taken from Reinhold Neibuhr: “God, grant me the serenity to accept the things I cannot change, cour- age to change things I can, and the wisdom to know the difference.” p.24 National Kidney Foundation Professor Michel Jadoul, born in European Representative of the Council of the Transplantation Soci- 1958, is married and has three ety. Dr. Vanrenterghem is the Vice-Chairman of the Global Alliance for children, aged 22, 19 and 15. He Transplantation. Since 2005 he is a Member of the KDIGO Board. He completed his medical studies in has been the principal investigator of several international multi-center 1983 at the Université Catholique trials on new immunosuppressive agents after kidney transplantation. de Louvain, Brussels, Belgium. In 1987 he was the winner of the 20th Eurotransplant Anniversary He trained in internal medicine Award. From 1996 till 2001 he was the holder of the Baxter Chair for and nephrology with Professor Renal Transplantation. Michel Jadoul, MD Charles van Ypersele de Strihou Past International Distinguished Medal Recipients as his mentor and spent a year in the Academic Hospital in Utrecht 2007 (Professors Dorhout Mees and Koomans) in the Netherlands. Mona Al-Rukhaimi, MD, Dubai, United Arab Emirates He is the head of the Department of Nephrology of the Cliniques Dick de Zeeuw, MD, PhD, Groningen, The Netherlands Universitaires Saint Luc since 2003 and Clinical Professor at the Sayyid Ali Jaffer Naqvi, MD, Karachi, Pakistan Université Catholique de Louvain. His main clinical research interests Susumu Takahashi, MD, PhD, Tokyo, Japan relate to Beta2microglobulin-amyloidosis, hepatitis C in dialysis and, Christoph Wanner, MD, Wurzburg, Germany more recently, falls and bone fractures in hemodialysis patients and 2006 cardiovascular complications in kidney transplant recipients. He is Jorge Cannata-Andia, MD, Oviedo, Spain an associate editor of the American Journal of Kidney Diseases and a Prakesh Keshaviah, MD, Dehradun, Uttaranchal, India member of the Editorial Board of Nephrology Dialysis Transplantation Gabriel Mircescu, MD, Bucharest, Romania and Clinical Nephrology. Professor Jadoul is country investigator Yusuke Tsukamoto, MD, Tokyo, Japan with Professor Norbert Lameire for DOPPS in Belgium and cochair with Haiyan Wang, MD, Beijing, China Professor David Roth of the Kidney Disease Improving Global Outcomes Hepatitis C in CKD Clinical Practice Guideline Work group. 2005 John Dirks, MD, Toronto, Ontario, Canada Yves Vanrenterghem, MD, PhD, re- Saraladevi Naicker, MD, Johannesburg, South Africa ceived his MD degree in 1973 from Luis Revert, MD, Barcelona, Spain the Catholic University of Leuven, Wu Chang Yang, MD, Taiwan, China Belgium. He then undertook a Research Fellowship at the Queen 2004 Elisabeth Foundation for Medical Peter G. Blake, MB, FRCP, Toronto, Canada Research in Brussels, Belgium. Kai-Uwe Eckardt, MD, Berlin, Germany At present he is affiliated with the S. Adibul Hasan Rizvi, MBBS, FRCS, FRCSE, FCPS, FRCP, Yves Vanrenterghem, MD, PhD University Hospital Gasthuisberg Karachi, Pakistan in Leuven, Belgium, where he is Chairman of the Department of Bernardo Rodriguez-Iturbe, MD, Maracaibo, Venezuela Nephrology and Professor of Medicine. Since 1993 he is a member of Claudio Ronco, MD, Vicenza, Italy the Board of Eurotransplant International of which he was the President between 1996 and 2005. Previously he was Treasurer of the European 2003 Society for Organ Transplantation and a member of the Scientific Georgi Abraham, MD, Chennai, India Committee of the EDTA Registry. Professor Vanrenterghem is Subject Shanyan Lin, MD, Shanghai, China Editor of Nephrology Dialysis and Transplantation (NDT), Associate Editor Nester Schor, MD, PhD, São Paolo, Brazil of the American Journal of Transplantation and a member of the Carmine Zoccali, MD, Reggio, Italy Editorial Board of Transplantation. Recently he was elected as the Spring Clinical Meetings ’08 p.25 Past International Distinguished Medal Recipients (continued) 2002 1994 Gavin Becker, MD, Victoria, Australia Stefan Angielsi, MD, Gdansk, Poland Francesco Locatelli, MD, Lecco, Italy Natale G. De Santo, MD, Naples, Italy Sergio Mezzano, MD, Valdivia, Chile Professor Miroslaw Mydilk, Kosice, Slovac Republic Giuseppe Piccoli, MD, Torino, Italy 1993 Wladyslaw Sulowica, MD, PhD, Kracow, Poland Jamie Herrera-Acosta, MD, Mexico City, Mexico 2001 Jose L. Rodicio, MD, Madrid, Spain Elvira Emilia Arrizurieta, MD, Buenos Aires, Argentina Professor Sandor, Sonkodi, Hungary Hans-Henrick Parving, MD, DMSC, Copenhagen, Denmark Visith Sitprija, MD, Bangkok, Thailand Yahya Sagliker, MD, Adana, Turkey 1992 Fernando Valderrababo, MD, PhD, Madrid, Spain Professor Albert Valek, Czechoslovakia 2000 Professor Mary G. McGeown, Belfast, Ireland Vittorio Andreucci, MD, PhD, Naples, Italy Professor Ori Better, Haifa, Israel Norbert Lameire, MD, PhD, Ghent, Belgium Professor Rashad Barsoum, Cairo, Egypt Florian Lang, MD, PhD, Tubingen, Germany Professor Karl M. Koch, Hannover, Germany M. Derome Tremblay, France 1999 Jonas Bergstrom, MD, PhD, Huddinge, Sweden 1991 Walter H. Hörl, MD, PhD, Vienna, Austria Professor Nobuhiro Sugino, Tokyo, Japan Vincenzo Savica, MD, Messina, Italy Professor K.S. Chugh, Mumbai, India Gianfranco Guarnieri, MD, Trieste, Italy Professor Renee Habib, Paris, France Professor Franciszek Kokot, Poland 1998 Professor Sevrin Ringoir, Ghent, Belgium Professor Rosario Maiorca, Brescia, Italy John Walls, MD, Leicester, England 1990 Shaul M. Shasha, MD, Nahariya, Israel Professor Kazimierz Baczyk, Poznan, Poland Professor Jean-Pierre Grunfeld, Paris, France Professor Vittorio Bonomini, Bologna, Italy Professor J. Stewart Cameron, London, England 1997 T.T. Durai, MD, Singapore Professor Guido Bellinghieri, Sicily, Italy Professor Henri Jahn, Strasbourgh-Cedex, France Professor Hirotoshi Morii, Osaka, Japan Professor Eberhard Ritz, Heidelberg, Germany Professor Momir H. Polenakovic, Skopje, Macedonia Professor Boleslaw Rutkowski, Gdansk, Poland 1996 Professor Judit Nagy, Pecs, Hungary Professor Karel Opatrny, Pizen, Czech Republic Miguel C. Riella, MD, Curitba, Brazil 1995 Maurice Slapak, MD, Hampshire, England Guy Laurent, MD, Tassin, France David N. Kerr, MD, London, England Alexander P. Disney, MD, Adelaide, South Australia Andrzej Ksiazek, MD, Lublin, Poland p.26 National Kidney Foundation CM08 NKF Professional Council Awards Each year, NKF Professional Councils recognize individuals who have made outstanding contributions in the field of renal health. It is an Council on Renal honor to announce some of those individuals who will be formally Nutrition (CRN) recognized at this year’s meeting. Joel D. Kopple Award Alison L. Steiber, PhD, RD, LD Council of Nephrology Please see page 22 for biographical information. Social Workers (CNSW) Susan Knapp Excellence in Education Award Jane Greene, MS, RD, CSR, LDN CNSW Lifetime Achievement Award Jane Greene is the Education Coordinator for the Renal Clinic and Patricia McKevitt, ACSW, LCSW is a Renal Dietitian at Vanderbilt University Medical Center. In addition, Patricia McKevitt is celebrating 35 years in renal health. She began Jane is a Preceptor for the Dietetic Internship at Vanderbilt University her career in 1973 — just as Medicare made dialysis available on a Medical Center for the past 18 years. She is also involved in the broad scale. Since 1981 she has been the Director of Social Work at education of her peers and other health care professionals including Chromalloy American Kidney Center and a Research Associate in a preceptor for the Adult Acute Care Nurse Practitioner Program and Medicine, Washington University School of Medicine. She is truly one of the Nephrology Fellowship program. Additionally, Jane participates in the founders of CNSW, having served as its third Chair as well as many community outreach by providing classes and overseeing educational other positions. She has also been continually active with NKF and her materials and care plans for CKD patients through the Vanderbilt local Chapter as well as the Network Coordinating Council. She serves Nephrology Clinic. Jane has been an invited speaker at over 40 local, on the editorial boards of five journals/magazines. She also contrib- state and national meetings in addition to publishing over a dozen uted heavily to the CNSW CQI Manual. She has been a leader in Renal peer-reviewed journal articles. She is active with local and national social work through presentations and publications from the beginning CRN activities serving as Regional Representative for Region 2. Jane of her career. She has served on the National Advisory Board of the is truly passionate about education and the patients she cares for. longitudinal, International National Dialysis Outcomes and Practice Recognized Renal Dietitian Patterns Study (DOPPS). Pat’s career is certainly exemplary. Marianne Vennegoor, RD, HPC The 2008 CNSW Merit Award Marianne Vennegoor is the first dietitian to receive this award outside Judy Caldwell, LMSW, ACSW, DaVita Garden West, Westland, MI of the United States. She studied and earned her degree in Nutrition Judy has been a leader for the Michigan CNSW Chapter and has served and Dietetics in the Netherlands. She also completed a middle man- on the Program Committee as Chair and Co-Chair for the Annual agement course at Guy’s and St. Thomas’ Hospital where she worked Symposium. She has worked with the Discharge Planners Outreach for 31 years. She has traveled the world as an ambassador for renal Program Committee, a special program to increase the communication dietitians and has shared her expertise in the United Kingdom, Austria, between hospitals and the dialysis units. She is also sharing her skills France, Czech Republic, Greece, Germany, Italy, Israel, Japan, Mexico, through mentoring new social workers and those wishing to become Philippines, Russia, Estonia, Spain and Sweden. Marianne has been involved in the Michigan NKF and CNSW. the contact for the European CRN for the past 14 years. Additionally, Diane Perry, LISW, Edina Dialysis of DaVita, Edina, MN she remains active with the International Society of Renal Nutrition and Diane has been an active member of the Upper Midwest NKF Gift of Metabolism, the International Congress of Dietetics and the Interna- Life program promoting and educating patients, families, and staff tional Society for Peritoneal Dialysis. She is a founding member and about organ donation and transplantation. She has also helped coordi- Chair of the Dietetic Subgroup of the European Dialysis and Transplant nate the local KEEP program, which promotes early detection of CKD. Nurses Association European Renal Care (EDTNA/ERCA). She is also Diane worked with State Services for the Blind to implement a books- Chair of the Education Committee of the International Federation on-tape program for blind patients. of Kidney Foundations. Marianne has also been a member of the Spring Clinical Meetings ’08 p.27 editorial Board for Advances in Renal Replacement Therapy, the and completed the new orientation manual for new executive Journal of Renal Nutrition and the Journal of the EDTNA/ERCA. Committee Members. 2008 CNNT Distinguished Service Award Kay Hall, RN, CNN, BSN COuNCil OF NePHrOlOgy Kay has served as Chair for region 2 for the past four years. in addi- NurSeS aND TeCHNiCiaNS tion to her normal duties as Chair, she has written numerous articles for RenaLink in regulatory issues and helped the council with issues (CNNT) related to CMS and survey regulations. She has also co-authored the orientation manual for new Council Members with Dadi Ding. The 2008 CNNT Distinguished Service Award Dadi Ding, RN, CNN Dadi has been on the CNNT executive Committee for two terms as region 3 Chair. She has worked very closely with our two councils (illinois and iowa) to assist with recertifi cation and communication. in addition, she and Kay Hall, outgoing region 2 Chair, developed CM08 Contributors The National Kidney Foundation gratefully acknowledges the support of the following organizations who helped make the NKF 2008 Spring Clinical Meetings possible: Primary Contributors: Meeting Contributors: Corporate Supported Symposia additional Conference Materials Keryx Biopharmaceuticals, inc. and events abbott genzyme MedComp aMag Pharmaceuticals, inc. Novo Nordisk abbott Merck amgen Ortho Biotech Products, l.P. amgen Omron Fresenius Medical Care Shire Pharmaceuticals astellas Pharma uS, inc. Ortho Biotech Products, l.P. Bard Shire Pharmaceuticals Baxter Healthcare Watson Pharma, inc. Boehringer ingelheim genzyme p.28 National Kidney Foundation What’s In store? A Curriculum for CKD Risk Reduction and Care store hours: Thursday Friday Saturday April 3 April 4 April 5 8:00 a.m. – 6:30 p.m. 7:00 a.m. – 6:00 p.m. 7:00 a.m. – 5:00 p.m. Store is located at Ballroom Foyer in the NKF Registration Area. Use YoUr coUpon to save FIve Dollars on pUrchases oF $25 or more One COupOn per purChase Be a part oF oUr raFFle DraWIngs everY DaY © 2008 National Kidney Foundation, Inc. All rights reserved. 02-10-491A exhibit hall 2008 Exhibit Hall and Poster Presentation Hours Thursday, April 3 6:00pm–7:30pm Opening Ceremonies and Faculty Reception – Visit Posters/Exhibits Friday, April 4 7:00am–8:00am Posters/Exhibits and Continental Breakfast 10:00am–2:00pm Posters/Exhibits and Lunch 5:30pm–7:00pm Networking Reception – Posters/Exhibits Saturday, April 5 9:00am–1:00pm Posters/Exhibits and Brunch Poster Presentations CMO8 provides an opportunity to meet with over 300 authors to discuss their research experiences and significant areas of development in chronic kidney disease. All participants will have an opportunity to view a stimulating selection of poster presentations in the Exhibit Hall, starting Thursday, April 3 at 6:00pm and ending Saturday, April 5 at 1:00pm. Authors available for questions at the Exhibit Hall Opening and Networking Reception on Thursday. Spring Clinical Meetings ’08 p.31 General Information Meeting Objectives CME/CEU Poster Presentations Participants will learn about new and evolving Information pertaining to CMEs or CEUs can be Over 300 abstracts will be presented as poster concepts related to kidney disease through found at the beginning of each program track. presentations. Posters are available for view- workshops, debates, interactive courses ing in the Exhibit Hall during exhibit hours CME & CEU Session Tracking and traditional didactic sessions. The meet- noted on page 31. NKF offers an online system for tracking your ings’ learning objectives are to increase the CME/CEUs. With an easy swipe of a badge, CM08 Evaluations – Your Feedback participants’ understanding, knowledge and attendance at sessions will automatically be Really Matters competency regarding improving patient care recorded—no more forms to complete! CME Evaluations will be distributed at the begin- in the following areas: and CEU credit information will be uploaded ning of each session and collected at the end. n Methods to preserve hemodialysis access instantaneously to a web site for easy viewing. There will also be evaluation drop-off locations and prevent infectious complications You are able to print a certificate of attendance around the meeting area. Evaluations are very n Acute kidney injury, long-term impact, and at your own convenience and without any hassle! important to all of us. The planning and execu- strategies for preventing AKI Access this system conveniently by visiting tion of useful and sound continuing education n Causes of secondary hypertension www.expobadge.com/certification/nkf2008 programs are largely guided by input provided n What’s new on nephrogenic systemic fibrosis by program participants. Your responses will n Understanding the controversies regarding The online service is available through help ensure that future programs are informa- living donors for kidney transplantation July 4, 2008. tive and meet your educational needs. Please n The controversy over the target hemoglobin take a few minutes to let us know what you in CKD. NKF Registration, Ticket Sales and Information think, because your feedback really matters! NKF’s Expectation of Presenters Located in the Foyer, Ballroom Level. Through the National Kidney Foundation Spring Clinical Meetings and continuing edu- Registration Hours are: cation programs, NKF promotes excellence Tuesday 3:00pm–8:00pm in kidney health care education. NKF expects Wednesday 7:00am–6:00pm that all presenters affiliated with the NKF 2008 Thursday 5:30am–6:00pm Spring Clinical Meetings will provide informa- Friday 7:00am–5:00pm tive and fully accurate content that reflects the Saturday 7:00am–5:00pm highest level of scientific rigor and integrity. Sunday 7:00am–1:00pm (information only) Target Audience The National Kidney Foundation 2008 Spring Tickets for activities requiring separate Clinical Meetings are designed for kidney doc- registration and/or a separate fee are available tors in the private sector and academia, fellows at the Ticket Sales Booth in the Registration and residents with a special interest in kidney Area. Staff are available at the Meeting Infor- disease, general internists, pharmacists, physi- mation Booth to answer any questions that cian assistants, nephrology nurses and techni- you may have. cians, nurse practitioners, nephrology social Badges workers, renal and clinical dietitians, and any Please wear your registration badge for other clinician involved in the care and treat- admission to all meeting activities. There ment of individuals with kidney disease. is a $25.00 replacement fee for lost badges. p.32 National Kidney Foundation National Young Investigator’s Forum Have you ever wondered what you are going display with authors present. Top poster Wednesday, April 2 to do when you finish your Nephrology train- presenters announced. ing? “Career Choices in Nephrology” is your n Friday, April 4, for a Networking Reception Participation by invitation only. opportunity to hear from individuals who work held in the Exhibit Hall from 5:30pm–7:00pm. in all aspects of Nephrology. The session is for Meet colleagues for cocktails and hors The National Kidney Foundation is pleased to fellows and residents who are trying to decide d’oeuvres in a relaxed atmosphere before you host the Third National Young Investigators what career path to choose in nephrology, and attend one of the dinner symposia. Forum chaired by Paul Sanders, MD and how to go about getting there. The session Robert Toto, MD. Participants include the win- Membership Questions? will begin with a panel discussion by individu- ners of the five regionalY oung Investigators NKF professional membership provides als currently active in academic medicine as Forums held in the first quarter of 2008 as well numerous benefits for physicians, pharma- educators and researchers, private practice, as those from the 2007 Forums. Presenters cists, advanced practitioners, nurses, techni- interventional nephrology, and industry. Learn will compete in the Clinical Research or Basic cians, dietitians and social workers. Stop by why these Nephrologists decided on their Research categories. A panel of faculty judges the Membership Booth located in the NKF career paths, their backgrounds, what they will select the award winners in each category. Registration Area to learn more about how to did to secure their jobs, and if (and how) they become an NKF member. NKF gratefully acknowledges the support of would do it again if they were starting over. Amgen who has made this program possible. After the panel discussion, there will be time The Learning Continues for questions and answers followed by a beer/ Internal Medicine and Pediatric Recordings wine reception and hors d’oeuvres. This is a Trainees Program Most sessions will be audio taped.* Tapes great time to network. and MP3 audio CD-ROMs will be sold in the We are pleased to welcome Internal Medicine Registration Area at the “Conference Copy, Inc.” and Pediatric Trainees to CM08. This special National Kidney Foundation Kidney table will be available following the meeting. program encourages highly-qualified and Learning System (KLS) Store Please refer to the topic list included in your interested individuals to enter the field of Center Foyer, Ballroom Level tote bag for more information or you can kidney disease. The program provides Internal The NKF KLS store has many items for pro- check the NKF web site for this information. Medicine and Pediatric trainees concentrated fessional and patient education and public exposure to cutting-edge clinical and experi- * Speaker permission must be granted in order awareness. Please stop by to pick up single, mental Nephrology in the stimulating learning to tape a session or a particular speaker. complimentary copies of KLS brochures, to environment. The goals of the program are see newly available materials and to browse Faculty Slide Presentations to shed light on the broader aspects of the and purchase resources related to CKD care. Final slide presentations* will be posted on subspecialty than what house staff experience the NKF web site at the conclusion of the on the wards in their daily routine. The (KLS) store hours are: meeting and will be made available to Fellows Event: Career Choices in Thursday 8:00am–6:30pm registrants of CM08. Friday 7:00am–6:00pm Nephrology/Fellows Reception * Presentations available with faculty Saturday 7:00am–6:00pm Held in association with Women in Nephrology permission only. Exhibit Hall Information Participation by invitation only. Exhibits and posters are located in the Exhibit Saturday, April 5, 5:30pm–7:00pm Hall. Exhibitors are a vital part of the NKF Spring Clinical Meetings. The NKF thanks our Coordinators: Sharon Moe, MD, and exhibitors for their continued support of our Milagros D. Samaniego, MD educational programs, and cordially invites Panelists: Sharon Adler, MD, Sumit Kumar, MD, attendees to the following receptions: n Chris Lu, MD, Lauren McDonald, MD, Thursday, April 3, for the Exhibit Hall Open- Jose Menoya, MD, Robert Toto, MD, and ing Reception which will be held at 6:00pm Miguel Vazquez, MD in the Exhibit Hall. Posters will also be on Spring Clinical Meetings ’08 p.33 CM08 Corporate Partners The National Kidney Foundation gratefully acknowledges our corporate partners who have supported the Foundation and enabled us to work towards its mission of preventing kidney and urinary tract diseases, improving the health and well-being of individuals and families affected by these diseases, and increasing the availability of all organs for transplantation. A percentage of funds raised are also directed toward the Foundation’s research program. Interested corporations may call Geraldine C. Connors at 800.662.9010 x215 for information. The NKF wishes to recognize and thank the following corporate partners: Platinum GlaxoSmithKline Abbott Nutrition Friend Abbott Affymax Inc. Ortho Biotech Schwarz Pharma, Inc Amgen Products, L.P. Bard Peripheral The Coca-Cola Vascular Genzyme Novartis Pharmaceu- Company ticals Corporation DaVita Roche Watson Laboratories, Inc. Golf Digest Wyeth Pharmaceuticals Bronze GSW Worldwide C O R E (Center Contributor Lockheed Martin for Organ Recovery Bristol-Myers Squibb Diamond & Education) Satellite Laboratory Company Merck & Co., Inc. Services Fresenius Medical Strides for Care Sigma-Tau Pharma- Nephropathy ceuticals Gold Keryx Biopharmaceu- Takeda Pharmaceuti- Embassy of the ticals The Binding Site, Inc. cals North United Arab Emirates Musculoskeletal America, Inc Tourneau Transplant United Healthcare Foundation (MTF) Silver Supporter Astellas Pharma NCCC-Charity PING US, Inc. Pfizer,I nc. Boehringer Ingelheim Quest Diagnostics Pharmaceuticals, Inc CB Richard Ellis p.34 National Kidney Foundation WHERE THERE’S A THERE’S A WAY TO SAVE A LIFE! You can give the gift of life... even when yours is over... through the National Kidney Foundation’s Planned Giving Program. Your financial contribution to fight kidney disease can come by way of your will... life insurance... real estate or gifts of securities, and your estate can even enjoy a tax break! For more information contact the National Kidney Foundation. 1.800.622.9010 www.kidney.org Breakfast, Lunch and Dinner Symposia Wednesday, April 2 12:00pm–2:00pm 7:00pm–9:00pm 7:30pm–9:30pm Dietary Phosphorus and Outcomes Cardiovascular Disease in CKD Patients Association of Mineral Metabolism, in Patients with CKD Pre-Dialysis and on Dialysis Vitamin D Therapy, and Calcimimetrics on Supported by an educational grant from Supported by an educational grant from Genzyme Chronic Kidney Disease Patient Survival Shire Pharmaceuticals 7:00pm–9:00pm Supported by an educational grant from Abbott 7:30pm–9:30pm Optimal Patient Outcomes: Identification An Evidence-Based Review of the and Treatment of Iron Deficiency Anemia Thursday, April 3 Management of Hyperphosphatemia and in Early CKD 6:00am–8:00am its Pharmacoeconomic Impact on Patients Supported by an educational grant from with Stage 5 CKD: New Perspectives for AMAG Pharmaceuticals, Inc. Effectsf o Glycemic Control on Outcomes Optimal Outcomes in 2008 in Diabetics with Chronic Kidney Disease Supported by an educational grant from Supported by an educational grant from Fresenius Medical Care – North America Saturday, April 5 Novo Nordisk 6:00am–8:00am 6:00am–8:00am Friday, April 4 Chronic Kidney Disease Interventions: Improving CKD and CVD Outcomes Trends and Challenges in CKD Progression 6:00am–8:00am and Management in Older Adults 6:00am–8:00am Supported by an educational grant from Assessing the Role of Proteinuria in the Ortho Biotech Products, L.P. Progression of Chronic Kidney Disease Exploring the Link Between Chronic Supported by an educational grant from Genzyme Kidney Disease and Cardiovascular Disease: Reducing Mortality 6:00am–8:00am Supported by an educational grant from Abbott New DOPPS Findings on Optimizing Practices for the Hemodialysis Team Supported by an educational grant from Amgen p.36 National Kidney Foundation DISCLOSURE OF planners and FACULTY COMMERCIAL RELATIONSHIPS The National Kidney Foundation is required by the Accreditation Council The faculty member is also required to disclose to the activity audience for Continuing Medical Education to disclose significant support or sub- when an unlabeled use of a commercial product, or an investigational stantial financial relationships between planners, presenters and com- use not yet approved for any purpose, is discussed during an educa- mercial entities for all Continuing Medical Education (CME) activities. tional activity. The intent of this disclosure is to provide attendees with information prior to their participation in the educational activity. NKF sent a “Faculty Disclosure Form” to the faculty participating in the 2008 Spring Clinical Meetings (April 2–6, 2008, in Dallas, Texas). All invited speakers for the National Kidney Foundation 2008 Spring All faculty members participating in a NKF-sponsored activity are Clinical Meetings are expected to complete a “Faculty Disclosure expected to disclose to the participants prior to the educational activity Form.” Speakers who did respond, but have nothing to disclose, are the existence of any significant financial or other relationships held listed with no information next to their name. Speakers who did not by themselves, and/or family members, with the manufacturer(s) of complete a disclosure form prior to presentation are not allowed to any commercial product(s) or provider(s) of any commercial service(s) present as per the Foundation’s Disclosure Policy. Meeting participants discussed in an educational presentation. may also refer to the Session Chair introductory remarks for each session for final listings of disclosures and off-label or unapproved usages of a product. Faculty Disclosure listing Kara Abbas Stephen Ash Joanne Bargman Martin Abrahamson Officer/director or holder of more: Lois Bates Grant/research support: Pfizer; Speaker’s Ash Access Technologies Daniel Batlle bureau: Eli Lilly, GlaxoSmithKline, Merck, Arif Asif Gerald Beck Novo Nordisk, Novartis, Pfizer, Sanofi- Cassandra Aspinall Srinivasan Beddhu Aventis, Takeda John Asplin Ann Beemer Cotton Kenneth Abreo Full/Part time employment: Litholink Cor- Filitsa Bender Beth Adams poration; Consultant/scientific advisor: Altus Laurie Benton Sharon Adler Pharmaceuticals Suzanne Bergman Grant/research support: Aspreva, Genzyme, Carolyn Atkins Tomas Berl Genentech Mary Ann Baily Jeffrey Berns Anil Agarwal George Bakris Zalman Agus Grant/research support: NIH (NIDDK/NHLBI) Anatole Besarab Consultant/scientific advisor: VascAlert Michael Allon Glaxo-Smith Kline, Forest; Consultant/ Judith Beto Gerald Appel scientific advisor:A bbott, Boerhinger- Consultant/scientific advisor: Amgen; Grant/research support: Merck, Pfizer,A spreva; Ingelheim, BMS/Sanofi-Aventis, Forest, Speaker’s bureau: Amgen, Shire Consultant/scientific advisor: Merck, Pfizer, Glaxo-Smith Kline, Merck, Novartis, Astra Zeneca, Aspreva, Genentech; Walgreens, Gileada, Sankyo; Speaker’s Peter Blake Speaker’s bureau: Merck, Pfizer, Astra; bureau: Abbott, Boerhinger-Ingelheim, BMS/ Mary Ellen Brabec Zeneca, Aspreva, Genentech Sanofi-Aventis, Forest, Glaxo-Smith Kline, Speaker’s bureau: Shire Pharmaceuticals Merck, Novartis, Walgreens, Gileada, Sankyo George Aronoff Kathleen Brady Lynda Ball Speaker’s bureau: Abbott Julie Barboza Emmauel Bravo Spring Clinical Meetings ’08 p.37 Faculty Disclosure listing Barry Brenner Abbott, Roche, INEOS, Watson; Speaker’s Genzyme, Ineos, Mitsubishi; Speaker’s Consultant/scientific advisor: Genzyme, bureau: Abbott, Amgen, Watson bureau: Amgen, Genzyme, Mitsubishi Novartis Ronald Crossno Robert Duncan K. Bridget Brosnihan Full/Part time employment: VistaCare Paul Eggers Teri Browne John Crouch Karen Egloso John Burkart Jim Curtis Richard Eisenstaedt Grant/research support: Baxter, Genzyme, Other financial or material support: Home Speaker’s bureau: Ortho Biotech Abbott, Watson, NxStage; Consultant/ Dialysis Plus Garabed Eknoyan scientific advisor: Baxter, Genzyme, Kirsten de Groot Kimberly English NxStage; Speaker’s bureau: Baxter Consultant/scientific advisor: Aspreva; Jessica Farrell David Bushinsky Speaker’s bureau: Roche Daniel Feig Consultant/scientific advisor: Amgen, Jan Deane Speaker’s bureau: TAP Pharmaceticals Genzyme, Shire, Ilypso, Relypsz; Speaker’s Andrea DeKam bureau: Amgen, Genzyme, Shire, Ilypso, Harvey Feldman Francis Delmonico Relypsz; Officer/director or holder of more: Harold Feldman Speaker’s bureau: Astellas, Roche; Amgen Fredric Finkelstein Other financial or material support: Wyeth; Jessica Cabness Full/Part time employment: New England Michael Flessner Mary Beth Callahan Organ Bank, The Transplantation Society Charles Foulks Donna Calvin Laura Dember Speaker’s bureau: Amgen Ellen Case Grant/research support: Neurochem, Inc. Stanley Franklin Claire Casselman Vincent Dennis Consultant/scientific advisor: AtCor Medical, Bristol-Myers Squibb, Merck, Pfizer; Speak- Lee Cauble Consultant/scientific advisor: Fresenius er’s bureau: Merck, Bristol Myers Squibb, Sheldon Chaffer Medical Corporation Boehringer Ingelheim Christopher Chan Peter DeOreo Allon Friedman Alfred Cheung Thomas Depner Barbara Fromm Dolph Chianchiano David DeWalch Joel Glickman Michael Choi Lesley Dinwiddie Consultant/scientific advisor: Arrow Interna- Deborah Glidden Louise Clement tional, Graftcath, Inc., Excelsior; Speaker’s Speaker’s bureau: Amgen, Abbott Carolyn Cochran bureau: Hoffmann La Roche of Canada Elaine Go Jean Colaneri Bradley Dixon David Goldfarb Speaker’s bureau: Amgen Consultant/scientific advisor: Proteon Consultant/scientific advisor: Altus Allan Collins Therapeutics, Pervasis Therapeutics Pharmaceuticals, OxThera, TAP Grant/research support: Amgen, Roche, Bart Dolmatch Pharmaceuticals NxStage, Baxter; Consultant/scientific Consultant/scientific advisor: Edwards Thomas Golper advisor: Amgen, Roche, NxStage Lifesciences, Bard Consultant/scientific advisor: Baxter Danilo Concepcion Mary Ann Dooley Thomas Gonwa Bonnie Conrad Consultant/scientific advisor: Aspreva, Grant/research support: Wyeth, Genzyme Gabriel Contreras Teva, Genentech, Amgen, Human Genome Janelle Gonyea Sandra Coorough Sciences, Roche, IDEC, UCB John Gowan Daniel Coyne Tilman Drueke Michael Grasso Grant/research support: Abbott, Amgen, Grant/research support: Amgen, Genzyme, Consultant/scientific advisor: Karl Storz, Roche, Watson; Consultant/scientific advisor: Shire; Consultant/scientific advisor: Amgen, Boston Scientific, Cook Urological p.38 National Kidney Foundation Faculty Disclosure listing Tom Greene Priscilla Hollander Norma Knowles Grant/research support: Keryx Corporation Consultant/scientific advisor: Pfizer, Novo Stephen Korbet Loic Guillevin Nordisk, Sanofi Aventis; Speaker’s bureau: Andrea Kostick Pfizer Kay Hall Csaba Kovesdy Norman Hollenberg Full/Part time employment: DaVita Sumit Kumar Jean Holley Lisa Hall Dana Kumjian Tricia Howard Lee Hamm Warren Kupin Kirk Hughes Haewook Han Kristin Larson Lawrence Hunsicker Jeff Harder Thu Le Grant/research support: Keryx, Sanofi-Aventis; John Hartman Nathan Levin Consultant/scientific advisor: Keryx, Pfizer, Jeanette Hasse Grant/research support: Roche; Consultant/ Sanofi-Aventis, Isotechnika, Teijin Group, Mary Hastings Hagar scientific advisor: Fresenius, Roche CorMedix Pharmaceuticals; Speaker’s bureau: Rebecca Hays Bristol-Myers Squibb, Sanofi-Aventis Edmund Lewis Other financial or material support: Keryx Mikhaelle Heald Marianne Hutton David Hellmann Consultant/scientific advisor: Shire; Kirstie Lewis Brenda Hemmelgarn Speaker’s bureau: Shire Julia Lewis Grant/research support: Amgen, Merck Ajay Israni Grant/research support: Keryx Biopharma- Elizabeth Henery Grant/research support: Roche, Amgen, ceuticals, Novartis Johann Herberth Bristol Myers Squibb Anne Liles Consultant/scientific advisor: Amgen Bertrand Jaber Robert Lindsay Charles Herzog Consultant/scientific advisor: NxStage Robert Lockridge Grant/research support: Amgen, Medtronic, Medical, Inc., Advanced Magnetic, Inc. Consultant/scientific advisor: Astra Zeneca, NIH; Consultant/scientific Aimee Jaremowicz Renal Solutions, Inc. advisor: Amgen, Medtronic, Roche, Ortho Stephanie Johnstone Charmaine Lok BioTech, Guidant, CorMedix; Other financial Sheila Jowsey Cynthia Lord or material support: RoFAR Peter Juergensen Elena Lucio Jonathan Himmelfarb Kamyar Kalantar-Zadeh Cathi Martin Deborah Hinnen Grant/research support: Abbott, Amgen, Consultant/scientific advisor: Shire; Consultant/scientific advisor:L illy, Aventis, Shire, Watson, Genzyme; Speaker’s bureau: Speaker’s bureau: Amgen, Shire Intuity; Speaker’s bureau: Lilly, Aventis, Abbott, Amgen, Shire, Watson, Genzyme Arthur Matas Roche, APhA, AADE Marcia Kalista Richards Ivan Maya L. Tammy Ho Judith Kari Maureen McCarthy Consultant/scientific advisor: Abbott; Pamela Kent William McClellan Speaker’s bureau: Orthobiotec Full/Part time employment: Genzyme Consultant/scientific advisor: Amgen, Roche Kimberly Hodge Rita-An Kiely Peter McCullough Consultant/scientific advisor: NxSTAGE Medical Paul Kimmel Lauren McDonald Consultant/Scientific advisor: Pfizer, Officer/director or holder of more: Fresenius R. Michael Hofmann Fresenius; Stockholder: Johnson & Johnson, Medical Care Ronald Hogg Amgen, Merck, Lilly, Pfizer, Fresenius Samy McFarlane Grant/research support: Pronova Biocare, Lisa Kindy Merck, Roche Jennifer McGuoirk Alan Kliger Full/Part time employment: Abbott Jeffrey Hoggard Bobbie Knotek Laboratories Spring Clinical Meetings ’08 p.39 Faculty Disclosure listing Stephanie McIntyre Allen Nissenson Roger Rodby Dianne McKay Grant/research support: Amgen, Hoffman- James Rodrigue Pat McKevitt La Roche, NIH; Consultant/scientific advisor: Carol Roe Advanced Magnetics, Affymax, DaVita OCMO, Beth McQuiston Arturo Rolla Amgen, Hoffman-La Roche; Speaker’s Rajnish Mehrotra Speaker’s bureau: Lilly, Novo Nordisk, bureau: Watson Pharma Speaker’s bureau: Baxter Health Care GlaxoSmithKline, Roche Ann O’Hare Ravindra Mehta Jamie Ross Edmond O’Riordan Mark Meier Prabir Roy-Chaudhury Emil Paganini David Mendelssohn Bharat Sachdeva Grant/research support: Quark Pharmaceuti- Antoine Samaha Joe Merighi cals, Biosite, Inc., Amgen; Consultant/scien- Jeffery Metzger tific advisor: NxStage Medical, Quark Phar- Milagros Samaniego Miriam Michael maceuticals, Biosite, Inc., Amgen; Speaker’s Speaker’s bureau: Genzyme Cindy Miller bureau: Watson Pharmaceuticals Eduardo Sanchez Speaker’s bureau: Sanofi Aventis Meredith Miller Robert Page Paul Sanders Ronald Miller Speaker’s bureau: Pfizer, Astra-Zeneca Gail Sansivero Richard Mishler Joni Pagenkemper Grant/research support: Elcam Medical; Orson Moe Paul Palevsky Consultant/scientific advisor: AngioDynam- Jessie Pavlinac Sharon Moe ics, Boston Scientific, Genentech, Elcam Marc Penn Grant/research support: Genzyme; Medical Consultant/scientific advisor: Genzyme, Grant/research support: Athersys; Other Mark Sarnak Amgen, Ineos; Speaker’s bureau: Genzyme financial or material support: AcelleRX Grant/research support: Amgen Michele Mokrzycki Therapeutics Mary Schira Anne Moore Mark Perazella Kathy Schiro Harvey Speaker’s bureau: Gundersen Lutheran Beth Piraino Donald Schon Medical Foundation Marc Pohl Consultant/scientific advisor: Bard; Speak- Bruce Morgenstern Megan Prescott er’s bureau: Bard; Other financial or material Other financial or material support: Pat Preston support: MedComp, AngioDynamics Astra-Zeneca Consultant/scientific advisor: Johnson & Anton Schoolwerth Donna Morton de Souza Johnson, Ortho-McNeil Grant/research support: Amgen; Consul- Full/Part time employment: Genzyme Wajeh Qunibi tant/scientific advisor: OrthoBiotech, Inc.; Alvin Moss Grant/research support: NABI Biopharma- Speaker’s bureau: Amgen ceutical, Fresenius Salim Mujais Donna Secker Jai Radhakrishnan Mary Murphy Mary Ann Sevick Consultant/scientific advisor: Genentech Patrick Murray Edward Siew Grant/research support: NxStage Medical, Panduranga Rao Edward Silverhardt Inc.; Consultant/scientific advisor: Scios,I nc., Robert Reilly Full/Part time employment: Center for NxStage Medical, Inc.; Speaker’s bureau: Cleo Richard Applied Behavioral Sciences, DaVita Sparks Scios, Inc., NxStage Medical, Inc. Mark Roberts Dialysis Mohanram Narayanan Grant/research support: Archimedes, Inc.; Beverly Sneed Andrew Narva Consultant/scientific advisor:A rchimedes, Inc. Full/Part time employment: Abbott Ira Nemeth Bruce Robinson Laboratories Renal Care Division Marianne Neumann Michael Rocco Mi-Kyung Song p.40 National Kidney Foundation Faculty Disclosure listing Lawrence Spergel Robert Toto Barbara Weis Malone Stuart Sprague Grant/research support: Novartis; Consultant/scientific advisor: Wyeth; Consultant/scientific advisor: Abbott; Consultant/scientific advisor: Merck, Amgen; Speaker’s bureau: Amgen Speaker’s bureau: Abbott Speaker’s bureau: Merck, Amgen, Novartis Steven Weisbord Glen Stanbaugh Mandy Trolinger Grant/research support: Roche; Speaker’s Alison Steiber Lara Tushla bureau: Amgen Grant/research support: Sigma Tau Tracey Tyus-Bailey John Jason White Pharmaceuticals, Inc.; Speaker’s bureau: Mark Unruh Robert Whitlock Sigma Tau Pharmaceuticals, Inc., Grant/research support: Baxter Karen Wiesen Genzyme, Abbott Aris Urbanes Alan Wilkinson Lesley Stevens Tushar Vachharajani Wolfgang Winkelmayer Speaker's bureau: Quest Diagnostics Ramiro Valdez Grant/research support: GlaxoSmithKline, Stephanie Stewart Joseph Vande Griend Amgen, Astellas; Consultant/scientific Kristin Stockard advisor: Genzyme, Fresenius, Roche Joseph Vassalotti Dana Sturtevant Alexander Wiseman Miguel Vazquez Wadi Suki Jay Wish Joyce Vergili Grant/research support: Genzyme; Consultant/scientific advisor: Watson, Speaker’s bureau: Shire Pharmaceutical Consultant/scientific advisor: Genzyme; Amgen, Ortho Biotech, Roche; Speaker’s Thomas Vesely Speaker’s bureau: Genzyme bureau: Watson, Amgen, Ortho Biotech Consultant/scientific advisor: W.L. Gore, Mary Sundell Myles Wolf Pervasis Therapeutics, Elcam, Inc. Duane Sunwold Grant/research support: Shire; Consultant/ Ronald Victor Lynda Szczech scientific advisor: Ineos; Speaker’s bureau: Theodôr Vogels Grant/research support: Ortho Biotech Abbott, Genzyme Bradley Warady Paul Szczybor Jack Work Speaker’s bureau: Genentech Consultant/scientific advisor: Vascular Harold Szerlip Richard Ward Access; Speaker’s bureau: Vascular Access Michael Talamantes Grant/research support: Gambro Renal Linda Wright Maria Taylor Products Speaker’s bureau: Astellas Stephen Textor Kurt Wargo, David Warnock Steven Wu Ravi Thadhani Grant/research support: Genzyme, Amgen; Qingyu Wu Grant/research support: Abbott; Speaker’s Consultant/scientific advisor:G enzyme, Amgen Alexander Yevzlin bureau: Abbott, Genzyme Sarah Washburn Speaker’s bureau: Pfizer Charlie Thomas Tiffany Washington Kim Zuber Cheryl Thomas Amy Waterman Grant/research support: Amgen, Genzyme Grant/research support: Waterpik, Sonicare, Pat Weber Biotene; Other financial or material support: Full/Part time employment: Genzyme Proctor and Gamble Corporation Kathryn Thurber-Smith Matthew Weir Trent Tipple Consultant/scientific advisor: Bristol-Myers Ashita Tolwani Squibb, SanofiA ventis, MSD Pharmaceuticals, Speaker’s bureau: Gambro Renal Products Novartis, Boehringer Ingelheim; Speaker’s Faith Tootell bureau: Bristol-Myers Squibb, Sanofi Aventis, Joseph Torrealba MSD Pharmaceuticals, Novartis, Boehringer Ingelheim Spring Clinical Meetings ’08 p.41 Physician Program Pre-Conference Courses and Workshops n Know the current strategies to minimize cardiovascular morbid- Transplant Course: ity and mortality from the early stages of chronic kidney disease Transplantation Trends in the 21st Century through transplantation. Wednesday April 2, 2008 8:00am–3:45pm Preregistration and course fee of $150 are required for meeting Course Directors: Milagros D. Samaniego, MD and Dianne McKay, MD registrants. Participation is limited. Light breakfast, box lunch, Session 220 and course syllabus included. Course Description: The 2008 Transplant Course has been designed to review both the most recent advances in transplant immunosuppression time/faculty topic and diagnostics, and current interventions to increase the donor pool 8:00am–8:30am Breakfast and minimize long-term morbidity in the kidney transplant recipient. 8:30am–8:45am Introduction The course presents an update on immunosuppressants and new im- Milagros D. Samaniego, MD munosuppression trends — including steroid withdrawal and avoid- ance protocols. The new diagnostic techniques — including the recent 8:45am–9:15am New Immunosuppression Trends changes in the Banff classification of allograft pathology, and the Milagros D. Samaniego, MD state-of-the-art of genomic and proteonomic diagnostics — will be reviewed using a case discussion format and computer interaction 9:30am–10:15am Delayed Graft Function, Dialysis with the audience. R. Michael Hofmann, MD and CRRT in Organ Transplant Recipients The course will also address three challenging areas of kidney trans- plantation in the 21st century: the management of chronic kidney 10:15am–10:30am Break disease and dialysis in recipients of other solid organ transplants, the treatment of the kidney transplant candidate and recipient with chronic 10:30am–11:00am TA, IF: The ABC of Transplant infections, and the current interventions to diagnose and manage Jose Torrealba, MD Pathology – Case Presentations cardiovascular disease in the transplant candidate and recipient. Target Audience: This course is designed for community nephrologists, 11:15am–12:00pm Genomics and Proteonomics in transplant nephrologists, nephrology fellows, transplant coordinators, Edmund O’Riordan, MD Kidney Transplantation: Unravel- transplant pharmacists and other professionals involved in the care of ing the Molecular Imprinting of the kidney transplant patient. Transplant Dysfunction Course Objectives: Upon completion of this course the attendee 12:00pm–1:00pm Lunch with Faculty should be able to: n Discuss current and upcoming immunosuppressants, their mecha- 1:00pm–1:30pm Paired-Kidney Exchange nisms of action, and the new immunosuppression trends. Ajay Israni, MD, MS Programs: The Next Trend n Discuss the impact of delayed graft function in kidney transplant outcomes, and the practical aspects of dialysis in kidney and other solid organ transplant recipients with acute kidney injury or CKD. 1:40pm–2:30pm Management of the Transplant n Be familiar with the updated Banff 2005 classification of allograft Alexander Wiseman, MD Patient with Chronic Infection: pathology with emphasis on the current terminology of acute and How I Treat My Patients chronic allograft rejection and new diagnostic categories. n Understand the concept and formats of paired kidney exchange programs, and the role of these programs to improve access of dialysis patients to kidney transplantation. n Manage kidney transplant patients and candidates with chronic viral and fungal infections. p.42 National Kidney Foundation Preregistration and course fee of $150 are required for meeting time/faculty topic registrants. Limited to 125 participants. Light breakfast, box 2:40pm–3:10pm Cardiovascular Disease: From lunch, and course syllabus included. Alan Wilkinson, MD CKD to Transplantation and Back time/faculty topic 3:20pm–3:40pm Roundtable: Questions 7:30am–8:00am Breakfast All Faculty and Answers 8:00am–8:10am Introduction 3:45pm Closing Remarks Joanne M. Bargman, MD, FRCPC 8:10am–8:50am Comparative Outcomes of Peter Blake, MD, FRCPC, FRCPI HD and PD Integrated Hemodialysis/Peritoneal 8:50am–9:20am Modality Selection and Initiation Dialysis Course John M. Burkart, MD of Dialysis Wednesday April 2, 2008 9:20am–10:00am The Hemodialysis Prescription 7:30am–5:30pm Robert D. Toto, MD and Monitoring Solute Clearance Course Director: Joanne M. Bargman, MD, FRCPCC Session 221 10:00am–10:40am Prescribing PD: Why PD is Not HD Course Description: This course is designed with multiple goals for the Joanne M. Bargman, MD, FRCPC kidney health care professional involved in identifying the physiology and techniques of peritoneal dialysis and hemodialysis. The relationship 10:40am–10:55am Break between clinical outcomes and different renal replacement modalities to treat chronic kidney disease will be addressed. The attendee will also 10:55am–11:30am Blood Pressure and Euvolemia in gain an understanding of infectious and noninfectious complications, Robert D. Toto, MD Hemodialysis the importance of proper access in both PD and HD, potential compli- cations of access problems, and learn how to identify treatment related 11:30am–12:05pm Blood Pressure and Euvolemia complications and discuss treatment strategies. John M. Burkart, MD in PD Target Audience: Practicing nephrologists, nephrology fellows 12:05pm–1:00pm LUNCH – Intradialytic Complica- in training, advanced practitioners and nephrology nurses. Bertrand L. Jaber, MD, FASN tions: Selected Case Studies Course Objectives: Upon completion of this course, the attendees 1:00pm–1:30pm Vascular Access for Hemodialysis should be able to: Jack Work, MD – Case Studies (Noninfectious) n Identify the physiology and techniques of peritoneal dialysis and hemodialysis 1:30pm–2:00pm Insertion and Management of the n Understand the relationship between clinical outcomes and different Beth Piraino, MD PD Catheter renal replacement modalities to treat chronic kidney disease. n Understand the basis and practical application of dialysis dose pre- 2:00pm–2:40pm Hemodialysis-Related Infections scription in peritoneal and hemodialysis. Laura Dember, MD n Understand the infectious and noninfectious complications of perito- neal and hemodialysis. 2:40pm–3:20pm PD-Related Infections n Understand the importance of proper access in both peritoneal dialy- Beth Piraino, MD sis and hemodialysis and potential complications of access problems. n Identify treatment-related complications in peritoneal and hemodi- alysis and discuss potential treatment strategies. Spring Clinical Meetings ’08 p.43 Physician Program Pre-Conference Courses and Workshops time/faculty topic time/faculty topic 3:20pm–3:35pm Break 7:15am–7:45am Breakfast 3:35pm–4:15pm Noninfectious Complications 7:45am–8:00am Welcome and Introduction Joanne M. Bargman, MD, FRCPC of PD Kenneth Abreo, MD and Arif Asif, MD 4:15pm–5:00pm Home Hemodialysis Therapies Christopher Chan, MD 8:00am–8:15am Vascular Anatomy of Importance Kenneth Abreo, MD to the Interventional Nephrologist 5:00pm–5:30pm It’s About the Money: Reimburse- Thomas Golper, MD, FASN, FACP ment Guidelines in the Care of 8:15am–8:30am Road Map for the Interventionilist: Dialysis Patients Richard Mishler, MD Types of AVFs and AVGs 5:30pm Closing Remarks 8:30am–8:45am How to Increase the Number Alexander Yevzlin, MD and Quality of Incident Arterio- Venous Fistulas 8:45am–9:00am The Art of Access Examination Interventional Nephrology Tushar Vachharajani, MD, Course FASN, FACP Wednesday April 2, 2008 9:00am–9:15am Examining Arteriovenous Grafts 7:45am–4:30pm Ivan Maya, MD for Problems Course Co-Directors: Kenneth Abreo, MD and Arif Asif, MD Session 222 9:15am–9:30am The ABCs of Surveillance: Course Description: Diagnostic and interventional procedures are criti- Anatole Besarab, MD Is it Necessary? cal to the care of nephrology patients. This course introduces a variety of interventional and diagnostic procedures that are critical to the care of 9:30am–9:45am Fistula Maturation: kidney patients. The procedures include: renal biopsy, placenebt ad reni- Bart Dolmatch, MD The Interventionalist’s Role vak of temporary and permanent central venous catheters and perito- neal dialysis catheters, and monitoring as well as salvage procedures for 9:45am–10:15am Break failing or thrombosed fistulas and grafts and insertion of intravascular coils and stents. Recent updates on hand ischemia and its management 10:15am–10:30am Excellent Vascular Access but Ter- as well as intravascular stent insertion and its benefits will also be pro- Arif Asif, MD rible Hand Pain: What Do You Do? vided. In addition to didactic sessions, workshops to provide hands-on training, focusing on insertion of tunneled dialysis catherers, percutane- 10:30am–10:45am The Dos and Don’ts of Balloon ous balloon angioplasty and declotting procedures. Steven Wu, MD Angioplasty Target Audience: This course is designed for nephrologists, fellows and 10:45am–11:00am The Swollen Arm: Diagnosis and other kidney health care professionals. Anil Agarwal, MD Treatment of Central Vein Stenosis Preregistration and course fee of $150 are required for meeting 11:00am–11:15am The Thrombosed Vascular Access: registrants. Participation is limited. Light breakfast, box lunch, Jeffrey Hoggard, MD Thrombolysis and Angioplasty and course syllabus included. 11:15am–11:30am The When, Where, and How of Bharat Sachdeva, MD Stents and Stent Grafts p.44 National Kidney Foundation time/faculty topic 11:30am–11:45am Complications of Endovascular Dialysis Unit Jack Work, MD Procedures: Prevention Management Course and Treatment Wednesday April 2, 2008 8:00am–5:00pm 11:45am–12:00pm Contrast Nephropathy, Contrast Course Director: Peter B. DeOreo, MD, FACP Aris Q. Urbanis, MD Allergy, and Conscious Sedation: Session 223 Minimizing the Dangers Course Description: The emphasis of this course will be on the role of 12:00pm–1:30pm Lunch the key members of the facility management in leading the physician and patient care staff toward quality outcomes. In the coming era of 1:30pm–1:45pm Tunneled Hemodialysis diminished reimbursement, reimbursement contingent on achieving Stephen R. Ash, MD, FACP Catheters: Hate Them but Can’t quality outcomes, the facility leadership will increasingly be faced Do Without Them with choices and trade-offs. Efficient management leads to the operating margin that sustains the quality mission. Topics will include the 1:45pm–2:00pm The Bad and The Ugly of Tunneled understanding of national quality goals, trade-offs in cost, quality and Jamie Ross, MD Hemodialysis Catheters value as well as understanding the ethical dilemmas created by quality contingent reimbursement. 2:00pm–2:15pm Peritoneal Dialysis: The Endan- Gabriel Contreras, MD, MPH gered Dialysis Modality Target Audience: Designed for physician directors and nurse managers. The course will also be of interest to patient care supervisors, adminis- 2:15pm–2:30pm Where Do I Begin: Interventional trators and quality managers. Donald Schon, MD Training and Interventional Centers Course Objectives: Upon completion of this course, the attendees should be able to: Workshop Sessions n Understand the national quality goals n Understand the trade-offs in cost, quality, value 2:30pm–4:30pm n Understand the ethical dilemmas created by quality contingent Workshop A Location: San Antonio 1 reimbursement (Leader: Stephen R. Ash, Tunneled Hemodialysis Catheter n Understand the impact of bundling on facility revenue MD, FACP) Insertion n Understand the role of the key professionals in measuring and Jamie Ross, MD managing quality Anil K. Agarwal, MD n Understand the new AAMI water standards and water system Ivan D. Maya, MD disaster recovery Sumit Kumar, MD Steven Wu, MD Preregistration and course fee of $150 are required for meeting registrants. Limited to 125 participants. Light breakfast, box Workshop B Location: San Antonio 4 lunch, and course syllabus included. (Leader: Donald Schon, MD) Balloon Angioplasty Workshop Aris Q. Urbanis, MD Alexander S. Yevzlin, MD Bharat Sachdeva, MD Tushar Vachharajani, MD Jeffrey Hoggard Spring Clinical Meetings ’08 p.45 Physician Program Pre-Conference Courses and Workshops time/faculty topic 8:00am–8:30am Welcome and Breakfast Nephrology Recertification: An Audience Participation Forum for Fun, Education and ABIM Credit 8:30am–9:30am The National Quality Agenda Pay Wednesday, April 2, 2008 Jay B. Wish, MD for Performance 9:00am–5:00pm Session 224 9:30am–10:30am The Ethics of Adverse Selection in Course Director: Harold M. Szerlip, MD Mary Ann Baily, PhD the Era of Pay for Performance Course Description: One of the requirements for nephrology recertifica- 10:30am–10:45am Break tion is to successfully obtain a total of 100 points with a minimum of 20 points in medical knowledge. This hurdle must be cleared before taking 10:45am–11:45am Using Data to Drive Improvement the secure exam. Participation in the NKF’s “Nephrology Recertifica- John W. Hartman, MD “Good Enough is Good Enough” tion Audience Participations Test for Credit” is a painless, fun and an educational way to complete one of those booklets. Each multiple 11:45am–12:45pm Intelligent Design in Medication choice question will be answered by the audience using a computerized George Aronoff, MD Protocols response system. The results will be displayed and then an expert will discuss the question, present appropriate background information and 12:45pm–1:15pm Lunch Break make a conclusion as to what he/she thinks is the correct answer. Au- dience discussion will be encouraged. At this time, each member of the 1:15pm–2:15pm The Role of the Medical Director audience will have the opportunity to record their “official” answer for Alan S. Kliger, MD in Quality and Safety credit. At the end of the day you will have completed one of the require- ments for recertification, learned a great deal and have fun doing it! 2:15pm–2:45pm The Role of the Registered Nurse Carol Roe, RN, JD in Quality and Safety Course Requirements: The Nephrology Recertification Course will review SEP Nephrology Module 27-R as well as the 2007 update (A7-E). 2:45pm–3:00pm Break For those attendees already enrolled in the ABIM Maintenance of Certification Program (MOC), please confirm that you bring these 3:00pm–3:45pm What’s Happening in Financing booklets and the answer sheets on-site. Peter B. DeOreo, MD, FACP of ESRD Course Objectives: Upon completion of this course, participants will be able to: 3:45pm–4:45pm Update on AAMI Water Standards n Identify aspects of general nephrology Richard A. Ward, PhD and Water System Disaster Recovery n Identify new developments in the field n Obtain credit towards recertification in nephrology. 4:45pm–5:00pm Questions and Closing Comments Preregistration and course fee of $150 are required for meeting registrants. Limited to 75 participants. Light breakfast, box lunch, and course syllabus included. p.46 National Kidney Foundation Course Faculty: Pre-registration and course fee of $50 ($25 for fellows) are required John Jason White, MD for meeting registrants. Participation is limited. Light breakfast, Harold M. Szerlip, MD, FACP, FCCP box lunch, and course syllabus included. time topic time topic 7:30am–8:00am Breakfast 7:30am–8:00am Registration and Continental- Breakfast 8:00am–11:30am Review of SEP Nephrology Module 27-R 8:00am–8:15am Welcome, Introduction, and Some Marc A. Pohl, MD Reflections onR ay W. Gifford, Jr., MD 11:30am–12:00pm Question and Answer Session 8:15am–8:45pm Concurrent Use of Pulse Pressure 12:00pm–1:00pm Lunch Stanley S. Franklin, MD, FACP, and Mean Arterial Pressure Best FACC Defines Hypertensive Cardiovascular 1:00pm–4:30pm Review of the 2007 Update (A7-E) Risk: New Data from the Framingham Heart Study 4:30pm–5:00pm Question and Answer Session 8:45pm–9:15pm Is There a Blood Pressure That Is 5:00pm Concluding Remarks Larry G. Hunsicker, MD Too Low? 9:15pm–9:30pm Discussion 9:30pm–10:00pm What is Someone from the North- Ray W. Gifford Jr., MD Norman K. Hollenberg, MD, PhD east USA Doing in a Tropical Rain Hypertension Symposium Forest, and What Has That Got to Do with Well Being? Session 225 Wednesday April 2, 2008 10:00pm–10:30pm Genetic Determinants of Hyper- 7:30am–5:30pm Thu H. Le, MD tension and Kidney Injury in a Course Director: Marc A. Pohl, MD Mouse Model of Chronic Kidney Target Audience: This activity is designed for advanced nephrologists, Disease physicians in training, as well as other physicians who are interested and involved with the management of hypertension and cardiovascular 10:30pm–10:45pm Discussion disease. 10:45pm–11:00pm Break Course Objectives: Upon completion of this course, attendees will be able to: 11:00pm–11:30pm ACE2 and Ang-(1-7) in Normoten- n Review the latest advances in basic physiology, biochemistry, and mo- K. Bridget Brosnihan, PhD sive and Hypertensive Pregnancy lecular biology relative to hypertension, vascular damage, myocardial infarction, and heart failure 11:30pm–12:00pm BOLD MR to Evaluate Tissue Oxy- n Acquire the latest information and new direction in the management Stephen C. Textor, MD genation in Renovascular Disease of atherosclerosis and cardiovascular disease n Review the pathophysiology of hypertension and the implications 12:00pm–12:15pm Discussion for therapy n Examine recent clinical trials in hypertension 12:15pm–1:15pm LUNCHEON Spring Clinical Meetings ’08 p.47 Physician Program Pre-Conference Courses and Workshops time topic 1:15pm–1:45pm Heart Felt Lesson on Stem Cell Marc Penn, MD, PhD Based Ischemic Tissue Repair 1:45pm–2:15pm The Cardiac Protease Corin and Qingyu Wu, MD, PhD Hypertension 2:15pm–2:30pm Discussion 2:30pm–3:00pm Dietary Salt and Endothelial Paul W. Sanders, MD Function 3:00pm–3:30pm Uric Acid: A Mediator of Early Daniel I. Feig, MD, PhD, MS Onset Essential Hypertension 3:30pm–3:45pm Discussion 3:45pm–4:00pm BREAK 4:00pm–4:30pm The Sympathetic Nervous System Ronald G. Victor, MD in Hypertensive Disorders 4:30pm–5:00pm Aldosterone and the Kidney: Emmanuel L. Bravo, MD From Bench to Bedside 5:00pm–5:15pm Discussion 5:15pm–5:30pm Concluding Remarks 5:30pm Adjourn Nephrology 201 For Advanced Practitioners Session 620 Wednesday April 2, 2008 7:30am–5:30pm Please see page 64 for course details. Separate Registration and Fee Required. p.48 National Kidney Foundation L e a d i n g t h e W a y . . . yesterday, today & tomorroW. Since the 1970s, Novartis researchers have been actively working to improve quality of life and survival for every person undergoing transplant surgery. Today, Novartis remains committed to research and development, targeting new ways to ensure even greater transplant success. By researching new pathways, Novartis strives to improve the function and sustainability of every transplanted organ with reduced side effects from treatment. Together we can make a bigger difference. ©2007 Novartis 2/07 NTP-OT-0059-A notp04_Journal Ad_Final.indd 1 3/7/08 10:31:06 AM WORKSHOPS Separate Registration and Fee Required Management of Hyperphosphatemia Using Calcium vs. Non-Calcium Based Binders An additional fee of $30 per workshop is required (includes a box lunch). Tickets for these workshops may be purchased at the NKF Session 232 Ticket Sales Booth in the Registration Area. Space is limited, so Friday, April 4, 12:00pm–1:15pm participation is available on a first-come, first-served basis. Chair: Stuart M. Sprague, DO Controversies in Living Volume Overload in the Donor Transplantation Dialysis Patient Session 230 Session 233 Thursday, April 3, 12:00pm–1:30pm Saturday, April 5, 12:00pm–1:15pm Chair: Milagros D. Samaniego, MD Chair: Joel Glickman, MD, FACP Access to kidney transplantation has been curtailed by the lack of Chronic fluid overload is a major cause of left ventricular hypertrophy sufficient deceased donor organs. In order to overcome the imbalance (LVH) in dialysis patients. Moreover, since LVH may be a modifiable risk between organ demand and offer, living donors have become the pre- factor, volume control may improve life expectancy by decreasing car- ferred source of organs for kidney transplantation. To increase living diovascular risk. Given that prevention is always the best strategy, the donation, the monetary compensation of the donor or the provision of first talk will address novel methods to increase dietary sodium adher- medical care following donation has been proposed. These proposi- ence. In the second talk, we will review the benefits of diuretic use to tions pose both financial and ethical difficulties. provide consistent and improved volume status. We will conclude with a lively question and answer period — please feel free to bring a To discuss the alternatives and current proposals in front of Congress, challenging case! two world leaders in kidney transplantation: Dr. Francis Delmonico – former President of the Board of Directors of UNOS, and Dr. Arthur Matas – current President of the American Society of Transplant Surgeons, will discuss the different alternatives to increase Hemoglobin Targets for living donation, the current initiatives to eliminate the sale of organs Anemia Management in CKD abroad, and the Pros and Cons of donor compensation. Session 234 Saturday, April 5, 12:00pm–1:15pm Chair: Jeffrey Berns, MD Impact of Surveillance on Recent randomized controlled trials in patients with CKD, showing AV Graft Outcomes either lack of benefit or harm with targeting hemoglobin levels above 12 or 13 g/dl with ESA therapy have led to reexamination of the ap- Session 231 propriate hemoglobin target in these patients. Additional information Friday, April 4, 12:00pm–1:15pm regarding risks of ESA therapy in patients with cancer appears to have Co-Chairs: Charmaine Lok, MD and Michael Allon, MD influenced considerations about the appropriate hemoglobin target in This workshop promises a high energy debate on the impact of access CKD patients. The FDA has also focused attention in this matter. There surveillance on arteriovenous grafts outcomes. The various methods has also been much discussion of the difference between hemoglobin of access surveillance, their advantages, challenges, and costs will be “target” and achieved hemoglobin levels. This discussion will consider reviewed and examined in this dynamic lunchtime session. Extra time the pros and cons of targeting and maintaining hemoglobin levels is provided to allow the participant to interact with expert speakers to above and below 12 g/dl. explore the future directions in this important area of access care. p.50 National Kidney Foundation Physician Program Accreditation Note: Acquiring 40.5 hours requires continu- Credit Hours: Pre-Conference Courses The National Kidney Foundation is accredited ous participation from Wednesday morning 5.25 Transplant Trends in the by the Accreditation Council for Continuing through Saturday morning. Many participants 21st Century Medical Education to provide continuing medi- opt for periodic breaks, which make their re- 9.0 integrated Hemodialysis/Peritoneal cal education for physicians. The National ported credit hours somewhat less. Additional Dialysis Kidney Foundation takes responsibility for the credits are provided for courses requiring 6.75 interventional Nephrology content, quality and scientific integrity of this separate registration, as noted ahead. 7.5 Dialysis Unit Management CME activity. 8.0 Nephrology Recertification 7.5 Nephrology 201 for Advanced CME Credit Practitioners The National Kidney Foundation designates 8.0 gifford Hypertension Symposium this educational activity for a maximum of 40.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Vist the KDIGO booth #719. The First Global Nephrology Guidelines Are Now Available Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease, published in Kidney International, April 2008 www.kdigo.org ©2008 National Kidney Foundation, Inc. All rights reserved. 02-77-435A Spring Clinical Meetings ’08 p.51 Pahysici n Program Wednesday, April 2 time/location session # session notes Course Director(s) credits 8:00am–3:45pm | Texas D 220 | Transplantation Trends in the 21st Century Milagros D. Samaniego, MD 5.25 Dianne McKay, MD 7:30am–5:30pm | Texas C 221 | Integrated Hemodialysis/Peritoneal Joanne M. Bargman, MD, FRCPC 9.0 Dialysis Course | Grapevine 1 225 | Ray W. Gifford Jr., MD Hypertension Symposium Marc A. Pohl, MD 8.0 Supported by an educational grant from Merck & Co., Inc. 8:30am–5:30pm | Texas 6 222 | Interventional Nephrology Course Kenneth Abreo, MD 6.75 A arif Asif, MD 8:00am–5:00pm | Texas 1/2 223 | Dialysis Unit Management Course Peter B. DeOreo, MD, FACP 7.5 9:00am–5:00pm | Texas 3/4 224 | Nephrology Recertification Course Herald M. Szerlip, MD 8.0 7:30pm–9:30pm | Grapevine D 801 | Association of Mineral Metabolism, Vitamin D Chair: Myles Wolf, MD, MMSc 1.5 Therapy, and Calcimimetrics on Chronic Kidney Disease Patients Survival Supported by an educational grant from Abbott Joint with Councils ¯ | Welcome and Introductions Myles Wolf, MD, MMSc | Associations of Mineral Metabolism with Myles Wolf, MD, MMSc Patient Survival | Impact of Vitamin D Therapy on Patient Survival Daniel Coyne, MD | Does Direct Modulations of the CaR Affect Stuart Sprague, DO Patient Survival? | Questions and Answers all Faculty Joint with Physicians with Joint · Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.52 National Kidney Foundation Thursday, April 3 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 802 | The Impact of Glycemis Control in Patients Chair: Martin J. Abrahamson, MD 1.75 with Diabetes and Chronic Kidney Disease Supported by an educational grant from Novo Nordisk | Welcome and Introductions Martin J. Abrahamson, MD | Glycemic Control in Patients with CKD Mark S. Roberts, MD, MPP | How Low Should You Go? Martin J. Abrahamson, MD | When and How to Use Insulin in Patients with Chronic Renal Failure arturo R. Rolla, MD | Panel Discussion/Question and Answer Session all Faculty | Grapevine D 803 | Trends and Challenges in CKD Progression Chair: Ann O’Hare, MD 1.5 and Management in Older Adults Supported by an educational grant from Ortho Biotech, L.P. | Epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FRCPC ˘ Older Adults Separate Registration and/or Fee Required | Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD in the Elderly | Reasons Why Evidence for the Management ann O’Hare, MD of CKD in Younger Individuals May Not Be generalizable to Older Adults with CKD 8:00am–9:45am | Texas C 260 | Secondary Hypertension Chair: Marc A. Pohl, MD 1.75 | When to Suspect Secondary Hypertension ronald Victor, MD | Endocrine Causes of Hypertension emmanuel Bravo, MD | Secondary Hypertension Due to Drugs Matthew R. Weir, MD | Texas 1/2 272 | Controversies in Transplantation Co-Chairs: Alan Wilkinson, MD 1.75 · and R. Michael Hofmann, MD Joint with Physicians | Re-Transplantation: Patient Selection and Panduranga S. Rao, MD, DNB, MS Management of Candidates on Dialysis | Kidney Transplantation for Other Solid-Organ Thomas A. Gonwa, MD, FASN, FACP recipients: A Nephrologist’s Point of View | Transplantation of the Elderly alan Wilkinson, MD | From CKD to Transplantation: Dianne McKay, MD ¯ Management of the Pregnant Patient Joint with Councils Spring Clinical Meetings ’08 p.53 Physician Program rThu sday, April 3 Continued time/location session # session notes faculty credits 8:00am–9:45am | Texas D 261 | Nephrogenic Systemic Fibrosis Chair: Kamyar Kalantar-Zadeh, MD 1.75 | Lessons Learned from the NSF Registry Mark A. Perazella, MD | Pathophysiology and Treatment Options robert Reilly, MD for NSF: What are the Data? | Risk-Benefit ofG adolinium vs. Iodinated roger Rodby, MD Contrast in CKD | 9:45am–10:00am | Break 10:00am–12:00pm | Texas C 262 | Acute Kidney Injury Co-Chairs: Michele Mokryzcki, MD 2.0 and Ravindra Mehta, MD | Impact of AKI on Long-Term Kidney Outcomes Paul W. Eggers, PhD | Impact of AKI on Patient Outcomes ravindra Mehta, MD | Urinary Markers for AKI Paul M. Palevsky, MD | Strategies for Prevention of Contrast Nephropathy emil Paganini, MD | Texas D 263 | Improving Vascular Access Outcomes Co-Chairs: Ivan D. Maya, MD 2.0 and Charmaine Lok, MD | Salvage of Early Fistula Failure antoine Samaha, MD | Pharmacologic Strategies to Delay Access Stenosis Prabir Roy-Chaudhury, MD | Debate: Fistula First – Is It Right for Everyone? yes arif Asif, MD Joint with Councils ¯ No Thomas Vesely, MD 12:00pm–1:30pm | Ft. Worth 6/7 230 | Workshop: Controversies in ˘ Chair: Milagros D. Samaniego, MD 1.5 Living Donor Transplantation | Debate: Increasing the Donor Pool: is It Time to Compensate Donors? Pro arthur Matas, MD Joint with Physicians with Joint · Con Francis Delmonico, MD 12:00pm–2:00pm | Grapevine C 804 | Dietary Phosphorus and Outcomes in Chair: Stuart Sprague, DO 1.5 Patients with CKD Supported by an educational grant from Shire Pharmaceuticals | DEBATE: Should Phosphorus be Controlled by Dietary Restrictions in CKD? Dietary Phosphorus Control Increases Death Risk! Kamyar Kalantar-Zadeh, MD Dietary Phosphorus Control Improves Survival! Daniel Coyne, MD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.54 National Kidney Foundation Thursday, April 3 Continued time/location session # session notes faculty credits 2:00pm–3:00pm | Texas A/B 264 | NKF Presidential Address – The National allan J. Collins, MD, FACP 1.0 Kidney Foundation: Advancing Public Health in the U.S. and Around the World | Shaul Massry Distinguished Lecture – Randomized Tom Greene, PhD and Observational Studies in Nephrology: How Strong is the Evidence? | 3:00pm–3:30pm | Break 3:30pm–5:15pm | Texas A/B 265 | Late Breaking News Co-Chairs: Michael Allon, MD 1.75 and Beth Piraino, MD | Aggrenox Prevention of Graft Stenosis: Bradley Dixon, MD | Primary Results for the Dialysis Access Harold Feldman, MD | Consortium (DAC) Study Group gerald Beck, PhD | Daily Dialysis Studies: An Update | Frequent HD Network Trial Nathan Levin, MD ˘ | International Quotidian Registry robert Lindsay, MD Separate Registration and/or Fee Required | FREEDOM Study Bertrand L. Jaber, MD 6:00pm–7:30pm | Exhibit Hall | Opening Ceremonies in the Exhibit Hall – Visit Posters/Exhibits 7:30pm–9:30pm | Grapevine C 815 | An Evidence-Based Review of the Chair: Vincent Dennis, MD 1.5 Management of Hyperphosphatemia and Its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008 Supported by an educational grant from Fresenius Medical Care – North America | A Review of Recent Clinical Studies of Patients lynda Szczech, MD · Joint with Physicians with Stage 5 CKD: Impact on Clinical Practice | A Pharmacoeconomic Analysis of Phosphate Wolfgang Winkelmayer, MD Binders in the Treatment of Patients with Stage 5 CKD: Impact on the Health Care System ¯ Joint with Councils Spring Clinical Meetings ’08 p.55 Physician Program FRiDay, April 4 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 809 | Assessing the Role of Proteinuria in the 1.5 Progression of Chronic Kidney Disease Supported by an educational grant from Genzyme | Proteinuria and Progression: Primary and Barry Brenner, MD Secondary Prevention | Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD Targets for Therapy | Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD in Progression of CKD | Grapevine C 810 | New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen | Improving Delivery of Pre-ESRD Care, Case Discussion ronald Pisoni, PhD, MS | Has Catheter Use Increased Due to Fistula First? lawrence Spergel, MD, FACS No! Case Discussion | Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC Case Discussion | 7:00am–8:00am | Continental Breakfast in Exhibit Hall – Visit Posters/Exhibits 8:00am–10:00am Joint with Councils ¯ | Texas C 266 | Update on Nephrolithiasis Co-Chairs: Michael J. Choi, MD 2.0 and David Goldfarb, MD | Obesity, Dieting and Kidney Disease Orson Moe, MD | Bariatric Surgery and Kidney Stones John Asplin, MD | Urologic Treatment of Stone Disease Michael Grasso, MD | Case Discussions Michael J. Choi, MD Joint with Physicians with Joint · | Texas D 267 | Management of AKI Chair: Ivan D. Maya, MD 2.0 | Management of Cardio-Renal Syndrome Patrick Murray, MD | Management of Hepato-Renal Syndrome Warren Kupin, MD | Debate: CRRT vs. IHD for ARF CRRT is Bettter ashita Tolwani, MD, MSc iHD is Better emil Paganini, MD | Texas B 284 | What’s New in PD Chair: Michael Flessner, MD, PhD 2.0 Optimizing Peritoneal Membrane Transport and Function Michael Flessner, MD, PhD | Prevention and Treatment of Peritonitis Beth Piraino, MD | PD for Management of CHF John M. Burkart, MD | 10:00am–10:15am | Break Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.56 National Kidney Foundation Friday, April 4 Continued time/location session # session notes faculty credits 10:15am–12:00pm | Texas D 268 | End-of-Life Issues in CKD Chair: Beth Piraino, MD 1.75 | Incorporating Palliative Care into the Dialysis Unit alvin Moss, MD | CPR vs DNR in the Dialysis Unit Jean L. Holley, MD | Withholding and Withdrawing Dialysis Mi-Kyung Song, PhD, RN 12:00pm–1:15pm | Exhibit Hall | Lunch in the Exhibit Hall – Visit Posters/Exhibits | Austin 1/2/3 231 | Workshop: Impact of Surveillance on ˘ Co-Chairs: Charmine Lok, MD 1.25 AV Graft Outcomes and Michael Allon, MD | Debate: Access Surveillance Improves Graft Outcomes yes! anatole Besarab, MD No! Jack Work, MD 12:00pm–1:15pm | Austin 4/5/6 232 | Workshop: Management of Hyperphosphatemia ˘ Chair: Stuart M. Sprague, DO 1.25 Using Calcium vs. Non-Calcium Based Binders ˘ | Non-Calcium Binders Wadi N. Suki, MD Separate Registration and/or Fee Required | Calcium Binders Wajeh Qunibi, MD 1:15pm–3:15pm | Texas C 269 | Home Dialysis for the 21st Century Chair: Beth Piraino, MD 2.0 | Innovative Approaches to Dialysis Modalities robert S. Lockridge, Jr., MD | Assessing Adequacy Across Dialysis Modalities/ Joanne M. Bargman, MD, FRCP Timing of Home Dialysis Modalities | Debate: Is Conventional Dialysis Outdated? HD 3x weekly vs. Daily HD Pro Michael Rocco, MD, MSCE Con Thomas Depner, MD | Texas D 270 | Obesity and CKD Chair: Srinivasan Beddhu, MD 2.0 · | Late-Breaking Controlled Trials: Sulodexide vs. Placebo Joint with Physicians for Treatment of Diabetic Nephropathy edmund J. Lewis, MD | Interactions Between Obesity and Inflammation in CKD Srinivasan Beddhu, MD | Debate: Is Obesity Good or Bad in CKD Patients? Obesity is “Good” Csaba Kovesdy, MD, FASN Obesity is “Bad” allon Friedman, MD | 3:15pm–3:30pm | Break ¯ Joint with Councils Spring Clinical Meetings ’08 p.57 Physician Program Friday, April 4 Continued time/location session # session notes faculty credits 3:30pm–5:30pm | Texas D 271 | Fluid and Electrolytes Chair: Miguel Vazquez, MD 2.0 | Update on Management of Hyperkalemia Daniel Batlle, MD | Update of Hypophosphatemia Zalman S. Agus, MD | Update on Hyponatremia Therapy Tomas Berl, MD | Update on Metabolic Alkalosis l. Lee Hamm, MD | Texas B 285 | International and National Guideline Activities: 2008 Co-Chairs: Garabed Eknoyan, MD 2.0 and Michael Rocco, MD, MSCE | KDIGO: Opening Remarks and Guideline Update: garabed Eknoyan, MD Hepatitis C in CKD; Care of the Transplant Patient | An Overview of the KDIGO CKD-MBD Guidelines Sharon Moe, MD, and Tilman Drüeke, MD | KDOQI 2008 and Beyond Michael Rocco, MD, MSCE | KDOQI Clinical Practice Guidelines for Nutrition in Bradley Warady, MD, and | Children with CKD: 2008 Update Donna Secker, PhD 5:30pm–7:00pm | Exhibit Hall | Networking Reception in the Exhibit Hall – Visit Posters/Exhibits 7:00pm–9:00pm | Grapevine D 811 | Cardiovascular Disease in CKD Patients Chair: Mark J. Sarnak, MD 1.5 Pre-Dialysis and On Dialysis Supported by an educational grant from Genzyme Joint with Councils ¯ | Sudden Cardiac Death in Pre-Dialysis CKD Charles Herzog, MD Patients and in Patients Undergoing Dialysis | Calcium and Phosphorus as Cardiovascular David Bushinsky, MD risk Factors | Coronary Artery Disease: Screening and Therapy Mark J. Sarnak, MD | Grapevine C 812 | Optimal Patient Outcomes: Identification and Treatment Chair: Anatole Besarab, MD 1.5 of Iron Deficiency Anemia in Early CKD Joint with Physicians with Joint · Supported by an educational grant from AMAG Pharmaceuticals, Inc. | Prevalence and Diagnosis of Anemia in Patients with CKD allen R. Nissenson, MD | State of the Art in Treatment of Iron Deficiency Anemia: ajay K. Singh, MB, MRCP Current and Future Directions | Case Review and Panel Discussion anatole Besarab, MD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.58 National Kidney Foundation Saturday, April 5 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 814 | Exploring the Link Between Chronic Kidney Chair: Tammy Ho, MD 1.5 Disease and Cardiovascular Disease: Reducing Mortality Supported by an educational grant from Abbott | Welcome and Introductions Tammy Ho, MD | Exploring the Association Between Cardiovascular Tammy Ho, MD Disease and Chronic Kidney Disease | Mechanisms that Contribute to Altered ravi Thadhani, MD Cardiovascular Regulation in Chronic Kidney Disease | Management Strategies for Reducing Kamyar Kalantar-Zadeh, MD Cardiovascular Risk Factors in Chronic Kidney Disease | Questions and Answers all Faculty | Grapevine C 813 | Chronic Kidney Disease Interventions: Chair: Peter McCullough, MD 1.5 ˘ Improving CKD and CVD Outcomes Separate Registration and/or Fee Required A Breakfast Symposium | KEEP Overview and Social Conceptions of allan J. Collins, MD Kidney Disease: Myths vs. Realities | Glycemic Control in Kidney Disease Samy McFarlane, MD | Interventions and CVD Interactions in Diabetics Peter McCullough, MD with Proteinuria | Impact of Blood Pressure Control in CKD george Bakris, MD 8:00am–10:00am | Texas A 273 | Hemodialysis Catheters: Minimizing Risk and Co-Chairs: Michele Mokrzycki, MD 2.0 Maximizing Outcomes and Charmaine Lok, MD | Prevention of HD Catheter Infections Charmaine Lok, MD · | Individualized Management of HD Catheter- Michael Allon, MD Joint with Physicians related Bacteremia | Treatment and Prevention of HD Michele Mokrzycki, MD Catheter Thrombosis | Texas B 274 | Nutrition and Inflammation in CKD Co-Chairs: Srinivasan Beddhu, MD 2.0 and Kamyar Kalantar-Zadeh, MD | Inflammation and Wasting Syndromes ravi Thadhani, MD ¯ | Is Malnutrition a Misnomer in Dialysis Patients? Srinivasan Beddhu, MD Joint with Councils | Insulin Resistance and Muscle Wasting in CKD edward Siew, MD Spring Clinical Meetings ’08 p.59 Pahysici n Program Saturday, ApriL 5 Continued time/location session # session notes faculty credits | 10:00am–12:00pm | Brunch Served in Exhibit Hall – Visit Posters/Exhibits | 10:00am–10:15am | Break 10:15am–12:00pm | Texas D 275 | Update on Primary Glomerular Disease Co-Chairs: Michael J. Choi, MD 1.75 and Gerald Appel, MD | Focal Segmental Glomerulosclerosis Stephen M. Korbet, MD | Membranous Nephropathy Jai Radhakrishnan, MD | IgA Nephropathy gerald Appel, MD | Texas C 276 | Pharmacy and CKD Co-Chairs: Maria Taylor, PharmD 1.75 and Kurt Wargo, PharmD | Drug Dosing in CKD: Which GFR Equations to Use Kurt Wargo, PharmD | Prescribing Cardiovascular Medications in alfred Cheung, MD Dialysis Patients | Pharmacist Role in the Management of CKD anne Liles, PharmD 12:00pm–1:15pm | Austin 1/2/3 233 | Workshop: Volume Overload in the Dialysis Patient ˘ Chair: Joel Glickman, MD 1.25 | Enhancing Dietary Adherence to Sodium Restriction Mary Ann Sevick, RN, ScD | Use of Diuretics in Patients on Dialysis Filitsa H. Bender, MD | Austin 4/5/6 234 | Workshop: Hemoglobin Targets for Anemia ˘ Chair: Jeffrey S. Berns, MD 1.25 Management in CKD | Debate: Should We Target Hemoglobin Joint with Councils ¯ Levels > 12 in CKD Hemoglobin > 12 g/dl is Good! Kamyar Kalantar-Zadeh, MD Hemoglobin > 12 g/dl is Bad! lynda Szczech, MD, MCSE, FASN 1:15pm–3:15pm | Texas D 277 | Why is Home Dialysis Under-Utilized in the U.S.? Chair: Fredric Finkelstein, MD 2.0 | National Disparities in PD Salim Mujais, MD | Factors Affecting Dialysis Modality Choice in the U.S. rajnish Mehrotra, MD, FACP, FASN Joint with Physicians with Joint · | Approaches to Increasing Utilization of PD in the U.S. Fredric Finkelstein, MD | Texas A 278 | Lupus Nephritis: Controversies and Consensus Co-Chairs: Julia B. Lewis, MD 2.0 and Michael J. Choi, MD | Debate: Induction Therapy of Lupus Nephritis use Cyclophosphamide edmund J. Lewis, MD use Mycophenolate gerald Appel, MD | Debate: Maintenance Therapy of Lupus Nephritis use Cyclophosphamide edmund J. Lewis, MD use Mycophernolate gerald Appel, MD | New Therapies for Lupus Nephritis Mary Anne Dooley, MD, MPH | 3:15pm–3:30pm | Break Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.60 National Kidney Foundation · ˘ ¯ Separate Registration and/or Fee Required Joint with Physicians Joint with Councils p.61 credits 2.0 2.0 2.0 AHA faculty MD Samaniego, D. Milagros Co-Chairs: John C. Stivelman, MD John C. Stivelman, and Sharon Moe, MD Moe, Sharon and Chair: Maria Taylor, PharmD Chair: Maria Taylor, MD Weisbord, Steven Mark Unruh, MD, MSc PharmD Maria Taylor, MD Finkelstein, Fredric MD Chair: William McClellan, MD William McClellan, Jonathan Himmelfarb, MD Jonathan Himmelfarb, MD H. Stanbaugh, glen notes MPH robert Duncan, ¯ Sanchez, MD, MPH eduardo MD alan S. Kliger, Nephrology/ Continued 5 L ri session Con Century; Delaying the Medicine in the 21st ESRD of CKD to Progression MD, F C. Schoolwerth, anton Performance: for Pay Debate: of Preventative A Model the Increase”: “Decrease in Choices Career Event: Fellows in CKD Patients Symptoms Patients Complaints of Dialysis Patients in Dialysis Disorders Sleep Patients Management in Dialysis Pain Patients in Dialysis Depression ESRD Quality Improvement of Quality History The ESRD Program: head? What Lies A Performance: for Pay Pro | | | | | | | | | | | Ap session # 101 490 280 279 Data improvement R Only) (By Invitation Reception Faculty Outcomes? Patient Will it Improve ay, day, ur t Sa time/location rapevine B Grapevine Texas D Texas Texas A Texas Texas C Texas 5:30pm–7:00pm | | | | 3:30pm–5:30pm Spring Clinical Meetings ’08 Spring Physician Program dSuay,n April 6 time/location session # session notes faculty credits 8:00am–10:00am | Grapevine D 281 | Secondary Nephrotic Syndrome Co-Chairs: Michael J. Choi, MD 2.0 and Gerald Appel, MD | Light Chain-Related Glomerular Disease laura Dember, MD | Debate: HIV Associated Nephropathy: Is Biopsy Needed for Diagnosis Biopsy is Not Required lynda Szczech, MD Biopsy is Required Paul Kimmel, MD | Thrombotic Microangiopathy Michael J. Choi, MD | Grapevine A 282 | Caring for the Dialysis Patient Chair: Miguel Vazquez, MD 2.0 | Treatment of Blood Pressure in Dialysis Patients John Burkart, MD | Management of Intradialytic Hypotension Thomas Depner, MD | Primary Care of the Dialysis Patient Suzanne Bergman, MD | Screening for Malignancy in the Dialysis Patient Jean L. Holley, MD | 10:00am–10:15am | Break 10:15am–12:15pm | Grapevine D 283 | ANCA Vasculitis: Treatments and Outcomes Co-Chairs: Julia B. Lewis, MD 2.0 and Kirsten de Groot, MD | Induction Therapy in ANCA Vasculitis Kirsten de Groot, MD | Maintenance Therapy in ANCA Vasculitis loic Guillevin, MD | Controversial Issues in Small Vessel David Hellmann, MD Joint with Councils ¯ vaculitis: A Rheumatologist View | Panel Discussion all Faculty | 12:15pm | Meeting Adjourns Joint with Physicians with Joint · Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.62 National Kidney Foundation aDvaNCeD PraCTiTiONer PrOgraM Program Committee Host Committee Continuing Education Information Laurie E. Benton, RN, PA-C, BS, MPAS Cheri Goldstein, PA-C aaPa accepts Category i credit from aOaC- Program Co-Chair Dallas Nephrology associates, Dallas, Tx CMe, prescribed credit from aaFP, and aMa Scott and White Hospital, Temple, Tx Category i CMe credit for the Pra from orga- Tami Hyziewicz Case, PA-C nizations accredited by aCCMe. Barbara Weis Malone, BSN, RN, CFNP Scott and White Hospital, Temple, Tx Program Co-Chair This program is pending approval with the Program Goal university of Colorado Health american academy of Nurse Practitioners. To improve patient outcomes by enhancing ScienceCenter, aurora, CO the advanced practitioners’ knowledge The National Kidney Foundation is accredited Deborah Glidden, ARNP, BC, CNN base and skills that affect the kidney and by the accreditation Council for Continuing Nephrology associates of Central Florida, clinical practice. Medical education to provide continuing medi- Orlando, Fl cal education for physicians. The National Kidney Foundation designates this educational Tricia Howard, MHS, PA-C activity for a maximum of 32.0 AMA PRA South university, Savannah, ga category 1 creditsTM. Physicians should claim credit commensurate with the extent of their participation in the activity. Join us for a special session... 2008 international and national Guideline activities: • KDIGO Update Hepatitis C and Transplant Guidelines • KDIGO Preview of KDIGO CKD-MBD Guidelines • KDOQI 2008 and Beyond • KDOQI Clinical Practice Guidelines for Nutrition in Children with CKD 2008 Update Join us on Friday, april 4, 2008 3:30 pM – 5:30 pM rooM texas c ©2008 National Kidney Foundation, Inc. All rights reserved. 02-77-435A Spring Clinical Meetings ’08 p.63 ADVANCED PRACTITIONER PRE-CONFERENCE COURSES time/faculty topic Nephrology 201 7:30am–8:00am Continental Breakfast For Advanced Practitioners 8:00am–8:15am Welcome and Introductions Session 620 Laurie E. Benton, RN, PA-C, Wednesday, April 12, 7:30am–5:30pm BS, MPAS Course Director: Laurie E. Benton, RN, PA-C, BS, MPAS Course Description: This course is designed to take you from the 8:15 am–9:45am Nephrotic vs. Nephritic Syndrome anatomy and physiology of the kidney through the clinical challenges Michael J. Choi, MD specific to the treatment of the different stages of kidney disease and co-morbidities. Lectures and topics are presented by physicians and 9:45am–10:00am Break advanced practitioners specializing in the field of nephrology. The con- tent is selected to help you understand, diagnose and treat the basic, 10:00am–11:00am Transplant Medications (all types) to the most complex, nephrology patients. Whether you are a begin- Mohanram Narayanan, ning or seasoned practitioner, it provides an outstanding opportunity to MD, FASN learn through case studies relevant to your everyday clinical practice. 11:00am–12:00pm CKD Start to Finish Target Audience: This course is designed for physician assistants and Kathleen Brady, MS, BC-ANP nurse practitioners. 12:00pm–1:00pm Lunch Preregistration and course fee of $100 are required for meeting registrants. Participation is limited. Light breakfast, box lunch, 1:00pm–2:00pm Diagnostic Dilemmas in Dialysis, and course syllabus included. Tricia Howard, MHS, PA-C Part 1 2:00pm–3:00pm Diagnostic Dilemmas in Dialysis, Deborah Gidden ARNP, Part 2 BC, CNN 3:00pm–3:15pm Break 3:15pm–4:15pm Nephrology Case Presentations Charles J. Foulks, MD 4:15pm–5:15pm Acute Renal Failure Paul Szcybor, PA-C 5:15pm–5:30pm Closing Remarks/Adjourn p.64 National Kidney Foundation Transplantation Trends in Dialysis Unit the 21st Century Management Course Session 220 Session 223 Wednesday, April 2, 8:00am–3:45pm Wednesday, April 2, 8:00am–5:00pm See page 42 for course details. See page 45 for course details. Separate Registration and Fee Required. Separate Registration and Fee Required. Integrated Hemodialysis/Peritoneal Dialysis Course Session 221 Wednesday, April 2, 7:30am–5:30pm See page 43 for course details. Separate Registration and Fee Required. ˘ Separate Registration and/or Fee Required ADVANCED PRACTITIONER Program nWed esday, april 2 time/location session # session notes Course Director(s) credits 7:30am–5:30pm | Texas 5 620 | Nephrology 201 for Advanced Practitioners ˘ laurie E. Benton, PA-C, 7.5 rN, BS, MPAS · Joint with Physicians | Texas C 221 | Integrated Hemodialysis/Peritoneal ˘· Joanne M. Bargman, MD, FRCPC 9.0 Dialysis Course 8:00am–3:45pm | Texas D 220 | Transplantation Trends in the 21st Century ˘· Milagros D. Samaniego, MD 5.25 Dianne McKay, MD 8:00am–5:00pm ¯ | Texas 1/2 223 | Dialysis Unit Management Course ˘· Peter B. DeOreo, MD, FACP 7.5 Joint with Councils Spring Clinical Meetings ’08 p.65 ADVANCED PRACTITIONER Program Wednesday, april 2 Continued time/location session # session notes faculty credits 7:30pm–9:30pm | Grapevine D 801 | Association of Mineral Metabolism, Vitamin D · Chair: Myles Wolf, MD, MMSc 1.5 Therapy, and Calcimimetrics on Chronic Kidney Disease Patients Survival Supported by an educational grant from Abbott | Welcome and Introductions Myles Wolf, MD, MMSc | Associations of Mineral Metabolism with Myles Wolf, MD, MMSc Patient Survival | Impact of Vitamin D Therapy on Patient Survival Daniel Coyne, MD | Does Direct Modulations of the CaR Affect Stuart Sprague, DO Patient Survival? | Questions and Answers all Faculty Thursday, April 3 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 802 | The Impact of Glycemis Control in Patients · Chair: Martin J. Abrahamson, MD 1.5 with Diabetes and Chronic Kidney Disease Joint with Councils ¯ Supported by an educational grant from Novo Nordisk | Welcome and Introductions Martin J. Abrahamson, MD | Glycemic Control in Patients with CKD Mark S. Roberts, MD, MPP | How Low Should You Go? Martin J. Abrahamson, MD | When and How to Use Insulin in Patients with Chronic Renal Failure arturo R. Rolla, MD Joint with Physicians with Joint · | Panel Discussion/Question and Answer Session all Faculty | Grapevine D 803 | Trends and Challenges in CKD Progression · Chair: Ann O’Hare, MD 1.5 and Management in Older Adults Supported by an educational grant from Ortho Biotech, L.P. | Epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FRCPC Older Adults | Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD in the Elderly | Reasons Why Evidence for the Management ann O’Hare, MD of CKD in Younger Individuals May Not Be generalizable to Older Adults with CKD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.66 National Kidney Foundation Thursday, April 3 Continued time/location session # session notes faculty credits 8:30am–10:00am | Austin 4/5 630 | WORKSHOP: Microscopy of Urinalysis Slides ˘ Peter Juergensen, PA-C 1.5 10:00am–11:00am | Austin 4/5 660 | The Renal Transplant Evaluation Alexander Wiseman, MD 1.0 10:00am–11:00am | Grapevine 5/6 675 | NKF and Students: A New Model for KEEP Cynthia Lord, MHS, PA-C 1.0 11:00am–12:00pm | Austin 4/5 661 | Derm Dilemmas in Nephrology Elizabeth Adams, PA, MS 1.0 | 12:00pm–2:00pm | CAP Networking Luncheon (All are welcome!) Appaloosa 4 12:00pm–2:00pm | Grapevine C 804 | Dietary Phosphorus and Outcomes in · Chair: Stuart Sprague, DO 1.5 Patients with CKD Supported by an educational grant from Shire Pharmaceuticals | DEBATE: Should Phosphorus be Controlled ˘ by Dietary Restrictions in CKD? Separate Registration and/or Fee Required Dietary Phosphorus Control Increases Death Risk! Kamyar Kalantar-Zadeh, MD Dietary Phosphorus Control Improves Survival! Daniel Coyne, MD 2:00pm–3:00pm | Texas A/B 264 | NKF Presidential Address – Allan J. Collins, MD, FACP 1.0 The National Kidney Foundation: Advancing Public Health in the U.S. and Around the World | Shaul Massry Distinguished Lecture – Tom Greene, PhD Randomized and Observational Studies in Nephrology: How Strong is the Evidence? · 3:00pm–4:00pm | Texas 5/6 662 | Hypertension and the Geriatric Patient ¯ Charles J. Foulks, MD 1.0 · 4:00pm–5:00pm Joint with Physicians | Texas 4 363 | Sleep Disorders and Restless Legs ¯ Kimberly English, RN, FNP 1.0 6:00pm–7:30pm | Exhibit Hall | Opening Ceremonies in the Exhibit Hall – Visit Posters/Exhibits ¯ Joint with Councils Spring Clinical Meetings ’08 p.67 ADVANCED PRACTITIONER Program Thursday, April 3 Continued time/location session # session notes faculty credits 7:30pm–9:30pm | Grapevine C 815 | An Evidence-Based Review of the · Chair: Vincent Dennis, MD 1.5 Management of Hyperphosphatemia and Its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008 Supported by an educational grant from Fresenius Medical Care – North America | A Review of Recent Clinical Studies of Patients lynda Szczech, MD with Stage 5 CKD: Impact on Clinical Practice | A Pharmacoeconomic Analysis of Phosphate Wolfgang Winkelmayer, MD Binders in the Treatment of Patients with Stage 5 CKD: Impact on the Health Care System FRiday, April 4 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 809 | Assessing the Role of Proteinuria in the · 1.5 Joint with Councils Progression of Chronic Kidney Disease ¯ Supported by an educational grant from Genzyme | Proteinuria and Progression: Primary and Barry Brenner, MD Secondary Prevention | Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD Targets for Therapy | Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD Joint with Physicians with Joint · in Progression of CKD | Grapevine C 810 | New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen | Improving Delivery of Pre-ESRD Care, Case Discussion ronald Pisoni, PhD, MS | Has Catheter Use Increased Due to Fistula First? lawrence Spergel, MD, FACS No! Case Discussion | Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC Case Discussion | 7:00am–8:00am | Continental Breakfast in Exhibit Hall – Visit Posters/Exhibits 8:00am–9:00am | Texas 5/6 664 | Understanding and Reading the Renal Ultrasound David DeWalch, MSPA, PA-C, MS, MA 1.0 Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.68 National Kidney Foundation · ˘ ¯ Separate Registration and/or Fee Required Joint with Physicians Joint with Councils p.69 1.75 1.75 2.0 1.5 1.0 1.0 1.0 1.25 1.0 credits 1.0 SN A NP, CNN NP, CP, F G A knoyan, MD MD knoyan, NP, NP, E A N, N, R arabed arabed G arson, arson, L . Holley, MD MD L. Holley, yung Song, PhD, RN AHA, BCPS F Co-Chairs: Co-Chairs: Chair: Mark J. Sarnak, MD Chair: Beth Piraino, MD Chair: Beth Piraino, Kristen Kristen Johann Herberth, MD, F obert Page, PharmD, FCCP, PharmD, FCCP, Robert Page, Sharon Moe, MD, and Sharon MD, and Warady, Bradley Herzog, MD Charles MD David Bushinsky, Mark J. Sarnak, MD Jean Mi-K isa Zokas Kindy, JD and Lisa Zokas Kindy, MD, MSCE and Michael Rocco, faculty E MD, MSC Michael Rocco, PhD Donna Secker, Tilman Drüeke, MD Tilman Drüeke, arif Asif, MD · · · ˘ ronald Hogg, MB, ChB notes Continued Supported by an educational grant from Genzyme from by an educational grant Supported session in the Exhibit Hall – Visit Posters/Exhibits Reception Networking Disease in CKD Patients Cardiovascular CKD Death in Pre-Dialysis Sudden Cardiac and Phosphorus as Cardiovascular Calcium and Therapy Disease: Screening Artery Coronary Guideline Activities: 2008 and National International KDIGO: Opening Remarks and Guideline Update: MD Eknoyan, garabed KDOQI 2008 and Beyond Nutrition in Guidelines for Practice KDOQI Clinical with CKD: 2008 Update Children Evaluation Chair-Side Hemodialysis Workshop: Renal Diseases Pediatric Approach A Practical Surviving Malpractice: Break Complications Medication Over-the-Counter CKD in Challenges Cholesterol Break in CKD Issues End-of-Life Unit the Dialysis into Care Palliative Incorporating Unit R in the Dialysis DN CPR vs. Dialysis Withholding and Withdrawing Lunch in the Exhibit Hall – Visit Posters/Exhibits MD Moss, lvin a ndergoing Dialysis Undergoing and in Patients Patients Hepatitis C in CKD; Care of the Transplant Patient of the Transplant Hepatitis C in CKD; Care of the KDIGO CKD-MBD Guidelines n Overview A | | | | | | | | | | | | | | | | | | | | | | | ril 4 811 668 285 631 666 667 665 268 and On Dialysis Pre-Dialysis session # risk Factors Ap FriDay, 9:00am–10:00am D Grapevine Texas 5/6 Texas B Texas Texas 5/6 Texas ntonio 1/2/3 San Antonio 5/6 Texas Texas D Texas Texas 5/6 Texas Exhibit Hall 3:15pm–3:30pm 12:00pm–1:15pm 10:00am–10:15am 1:15pm–2:15pm | | | | | 2:15pm–3:15pm | 3:30pm–5:30pm | | | | | | time/location 7:00pm–9:00pm 5:30pm–7:30pm 3:30pm–4:30pm 10:15am–12:00pm 12:00pm–1:15pm Spring Clinical Meetings ’08 Spring ADVANCED PRACTITIONER Program FriDay, April 4 Continued time/location session # session notes faculty credits 7:00pm–9:00pm | Grapevine C 812 | Optimal Patient Outcomes: Identification and Treatment · Chair: Anatole Besarab, MD 1.5 of Iron Deficiency Anemia in Early CKD Supported by an educational grant from AMAG Pharmaceuticals, Inc. | Prevalence and Diagnosis of Anemia in Patients with CKD allen R. Nissenson, MD | State of the Art in Treatment of Iron Deficiency Anemia: ajay K. Singh, MB, MRCP Current and Future Directions | Case Review and Panel Discussion anatole Besarab, MD Saturday, April 5 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 813 | Chronic Kidney Disease Interventions: Chair: Peter McCullough, MD 1.5 Improving CKD and CVD Outcomes A Breakfast Symposium | KEEP Overview and Social Conceptions of allan J. Collins, MD Kidney Disease: Myths vs. Realities | Glycemic Control in Kidney Disease Samy McFarlane, MD Joint with Councils ¯ | Interventions and CVD Interactions in Diabetics Peter McCullough, MD with Proteinuria | Impact of Blood Pressure Control in CKD george Bakris, MD | Grapevine D 814 | Exploring the Link Between Chronic Kidney Disease Chair: Tammy Ho, MD 1.5 and Cardiovascular Disease: Reducing Mortality Supported by an educational grant from Abbott | Welcome and Introductions Tammy Ho, MD Joint with Physicians with Joint · | Exploring the Association Between Cardiovascular Tammy Ho, MD Disease and Chronic Kidney Disease | Mechanisms that Contribute to Altered ravi Thadhani, MD Cardiovascular Regulation in Chronic Kidney Disease | Management Strategies for Reducing Cardiovascular Kamyar Kalantar-Zadeh, MD risk Factors in Chronic Kidney Disease | Questions and Answers all Faculty Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.70 National Kidney Foundation · ˘ ¯ Separate Registration and/or Fee Required Joint with Physicians Joint with Councils p.71 credits credits 2.0 2.0 2.0 1.0 1.0 1.0 1.0 1.0 CP A CP A azquez, MD C, MSPS A , P ande Griend, PharmD faculty faculty Chair: Miguel V MD Julia B. Lewis, Co-Chairs: . Feldman, MD, F MD, A. Feldman, Harvey ndrew S. Narva, MD, F S. Narva, Andrew Joseph V Miriam Michael, MD John Burkart, MD MD Thomas Depner, MD Jean L. Holley, Kim Zuber root, MD de Groot, and Kirsten Suzanne Bergman, MD Suzanne Bergman, MD de Groot, Kirsten David Hellmann, MD notes notes · · ¯ I II MD loic Guillevin, all Faculty Part Part Bedside Patient: Patient: to asculitis Bench Diabetic Diabetic essel essel A V asculitis the the From A V for for Updates: Continued reatments reatments T T N ril 5 heumatologist View aculitis: A Rheumatologist session session ephritis Discussion Panel Patients in Dialysis Pressure of Blood Treatment Hypotension Management of Intradialytic Patient of the Dialysis Primary Care Patient Malignancy in the Dialysis for Screening and Outcomes Treatments Vasculitis: ANCA in ANC Therapy Maintenance V in Small Issues Controversial Appropriate Reception Allied Health Networking Patient the Dialysis Caring for Lupus Care of Primary Making CKD Part Break Hall – Visit Posters/Exhibits in Exhibit Brunch Served Angle The Money Trials: Clinical Appropriate in ANC nduction Therapy I | | | | | | | | | | | | | | | | | | ril 6 Ap Ap session # session # 283 282 672 673 100 671 669 670 v ay, day, ur ay, nday, t rapevine A rapevine time/location time/location D Grapevine G Texas 5/6 Texas A Grapevine Su Texas 5/6 Texas Texas 5/6 Texas Texas 5/6 Texas Texas 5/6 Texas Sa 10:00am–10:15am 10:00am–12:00pm | | 8:00am–9:00am 9:00am–10:00am 8:00am–10:00am | | | | | | | | 1:15pm–2:15pm 2:15pm–3:15pm 6:00pm–7:00pm 10:15am–11:15am 10:15am–12:15pm Spring Clinical Meetings ’08 Spring NEPHROLOGY NURSE AND TECHNICIAN PROGRAM Program Committee Host Committee Continuing Education Information Carolyn Atkins, RN, BS, CCTC Gay Grauke, BA The National Kidney Foundation is an approved Program Chair ESRD Network of Texas, Inc., Dallas, TX provider of continuing nursing education by the Children’s Medical Center Dallas, Dallas, TX New York State Nurses Association, which is Glenda Harbert, RN, CNN, CPHQ accredited as an approver of continuing nursing Bobbie Knotek, RN, BSN, CNN ESRD Network of Texas, Inc., Dallas, TX education by the American Nurses Credential- Program Co-Chair Sandra Hinton, RN, BSN ing Center’s Commission on Accredition. ESRD Network of Texas, Inc., Dallas, TX Medical City Dallas Hospital, Dallas, TX It has been assigned code 6EXQ7J-PRV-06. Elaine Go, RN, NP Nancy Nardelli, RN, CCRC St. Joseph Hospital, Laguna Niguel, CA This educational activity has been approved Medical City Dallas Hospital, Duncanville, TX for 38.5 contact hours. Elizabeth Henry, RN, CNN Program Goal Scott and White Hospital, Temple, TX The goal of this program is to improve patient Marianne Neumann, RN, CNN outcomes by enhancing the kidney health Albany Dialysis Center, Albany, NY care professional’s knowledge base and skills which affect the kidney and clinical practice. Beverly Sneed, RN, BSN Continuing Education Chair Abbott Renal Care, Grand Prairie, TX p.72 National Kidney Foundation Nephrology Nurse and Technician Program Pre-Conference Courses and Exams time/faculty topic Chronic Kidney Disease 7:30am–8:00am Registration and (CKD) 101 Continental Breakfast Wednesday, April 2, 2008 8:00am–8:30am Review of Normal Renal Anatomy 7:30am–4:30pm Sheldon C. Chaffer, MD and Physiology Course Director: Marianne Neumann, RN, CNN Session 320 8:30am–9:15am CKD Stage 1 Course Description: The one-day intensive course discusses the five Sheldon C. Chaffer, MD stages of CKD: presentation, evaluation, complications and treat- ments. Upon completion of this course, participants will be able to de- 9:15am–10:00am CKD Stage 2 scribe normal renal anatomy and physiology, list the major causes of Sheldon C. Chaffer, MD kidney disease in the adult population, and outline treatment choices for patients with CKD who require renal replacement therapies. 10:00am–10:15am Break Target Audience: Nurses and technicians who are new to the field of 10:15am–11:00am CKD Stage 3 nephrology or who wish to refresh their knowledge. Sheldon C. Chaffer, MD Pre-conference courses require a separate registration fee of $100. 11:00am–12:00pm CKD Stage 4 and Light breakfast, box lunch, and course syllabus included. Sheldon C. Chaffer, MD Introduction to Stage 5 Participation is limited. 12:00pm–1:00pm Lunch Break 1:00pm–1:45pm Hemodialysis Marianne Neumann, RN, CNN 1:45pm–2:30pm Peritoneal Dialysis Bonnie Conrad, RN, CDN 2:30pm–2:45pm Break 2:45pm–3:30pm Vascular Access Gail Sansivero, RN, MS, ANP 3:30pm–4:15pm Introduction to Transplant Jean Colaneri, MS, ACNP 4:15pm–4:30pm Questions and Adjourn Spring Clinical Meetings ’08 p.73 Nephrology Nurse and Technician Program Pre-Conference Courses and Exams Continued Nephrology 201 Dialysis Unit For Advanced Practitioners Management Course Session 620 Session 223 Wednesday, 7:30am–5:30pm Wednesday, April 2, 8:00am–5:00pm See page 64 for course details. See page 45 for course details. Separate Registration and Fee Required. Separate Registration and Fee Required. Transplant Course: NNCO Transplantation Trends in the 21st Century Certification Exams Session 220 Session 300 Wednesday, April 2, 8:00am–3:45pm Sunday, April 6, 8:30am–12:30pm See page 42 for course details. The National Nephrology Certification Organization (NNCO) endorses the concept of voluntary, periodic certification by examination for all Separate Registration and Fee Required. individuals in the field of nephrology technology. Certification is one part of a process called credentialing. It focuses specifically on the individual and is an indication of current competence in a specialized area of practice. Certification in nephrology technology is highly valued Integrated Hemodialysis/Peritoneal and provides formal recognition in the profession of nephrology tech- Dialysis Course nology. The NNCO Examinations in Clinical Nephrology Technology and Biomedical Nephrology Technology are written examinations com- Session 221 posed of a maximum of 200 multiple-choice objective questions with Wednesday, April 2, 7:30am–5:30pm a total testing time of four (4) hours each. Certification in Nephrology See page 43 for course details. Technology is recognized for a period of four years at which time the candidate must retake and pass the current Certification Examination Separate Registration and Fee Required. in Clinical Nephrology Technology or Biomedical Nephrology Tech- nology or meet such alternative requirements as are in effect at that time in order to retain certification. Eligible candidates who pass this examination are eligible to use the registered designation CBNT after their names and will receive certificates from the NNCO. p.74 National Kidney Foundation Nephrology Nurse and Technician Program Wednesday, April 2 time/location session # session notes course director(s) credits 7:30am–4:30pm | Ft. Worth 4/5/6 320 | CKD 101 ˘ Marianne Neumann, RN, CNN 6.75 7:30am–5:30pm | Texas 5 620 | Nephrology 201 for Advanced Practitioners ¯˘ laurie E. Benton, RN, PA-C, BS, MPAS 7.5 8:00am–3:45pm | Texas D 220 | Transplantation ·˘ Milagros D. Samaniego, MD 5.25 Trends in the 21st Century Dianne McKay, MD 7:30am–5:30pm | Texas C 221 | Integrated Hemodialysis/Peritoneal ·˘ Joanne M. Bargman, MD, FRCPC 9.0 Dialysis Course 8:00am–5:00pm | Texas 1/2 223 | Dialysis Unit Management Course ·˘ Peter B. DeOreo, MD, FACP 7.5 7:30pm–9:30pm | Grapevine D 801 | Association of Mineral Metabolism, Vitamin D · Chair: Myles Wolf, MD, MMSc 1.5 Therapy, and Calcimimetrics on Chronic Kidney Disease Patients Survival ˘ Supported by an educational grant from Abbott Separate Registration and/or Fee Required | Welcome and Introductions Myles Wolf, MD, MMSc | Associations of Mineral Metabolism with Myles Wolf, MD, MMSc Patient Survival | Impact of Vitamin D Therapy on Patient Survival Daniel Coyne, MD | Does Direct Modulations of the CaR Affect Stuart Sprague, DO Patient Survival? | Questions and Answers all Faculty · Joint with Physicians ¯ Joint with Councils Spring Clinical Meetings ’08 p.75 Nephrology Nurse and Technician Program Thursday, April 3 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 803 | Trends and Challenges in CKD Progression · Chair: Ann O’Hare, MD 1.5 and Management in Older Adults Supported by an educational grant from Ortho Biotech, L.P. | Epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FRCPC Older Adults | Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD in the Elderly | Reasons Why Evidence for the Management ann O’Hare, MD of CKD in Younger Individuals May Not Be generalizable to Older Adults with CKD 8:00am–9:45am | Grapevine 1/2 560 | Multicultural Approaches to Health Care ¯ Kirk Hughes, MD 1.75 | Texas 1/2 272 | Controversies in Transplantation · Co-Chairs: Alan Wilkinson, MD 1.75 and R. Michael Hofmann, MD | Re-Transplantation: Patient Selection and Panduranga S. Rao, MD, DNB, MS Management of Candidates on Dialysis | Kidney Transplantation for Other Solid-Organ Thomas A. Gonwa, MD, FACP, FASN recipients: A Nephrologist’s Point of View | Transplantation of the Elderly Alan Wilkinson, MD Joint with Councils ¯ From CKD to Transplantation: | Management of the Pregnant Patient Dianne McKay, MD 10:00am–12:00pm | Texas D 263 | Improving Vascular Access Outcomes · Co-Chairs: Ivan D. Maya, MD 2.0 and Charmaine Lok, MD | Salvage of Early Fistula Failure Antoine Samaha, MD | Pharmacologic Strategies to Delay Access Stenosis Prabir Roy-Chaudhury, MD Joint with Physicians with Joint · | Debate: Fistula First – Is It Right for Everyone? Yes arif Asif, MD No Thomas Vesely, MD, FSIR Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.76 National Kidney Foundation Thursday, April 3 Continued time/location session # session notes faculty credits 10:00am–11:00am | Texas 1/2 360 | New Regulations: Working Together to Lessen the Carolyn Atkins, RN, BS, CCTC 1.0 Impact on the Young Adult 11:00am–12:15pm | Texas 1/2 376 | What the Dialysis Nurse Needs to Know About the Barbara Weis Malone, BSN, RN, CFNP 1.25 New Transplant Conditions of Participation Kay Hall, BSN, RN, CNN 12:30pm–2:00pm | Grapevine B 362 | CNNT Networking Luncheon and Research Presentation: Donna Calvin, APRN, BC-FNP, CNN 0.5 African Americans Perception of Risk for Diabetes Complications 2:00pm–3:00pm | Texas A/B 264 | NKF Presidential Address – Allan J. Collins, MD, FACP 1.0 The National Kidney Foundation: Advancing Public Health in the U.S. and Around the World | Shaul Massry Distinguished Lecture – Tom Greene, PhD Randomized and Observational Studies in ˘ Nephrology: How Strong is the Evidence? · Separate Registration and/or Fee Required 3:00pm–4:00pm | Texas 5/6 662 | Hypertension and the Geriatric Patient ¯ Charles J. Foulks, MD 1.0 3:00pm–5:00pm | Texas 1/2 366 | The What, Where, and Why of Data: Jan Deane, RN, CNN 2.0 How It Impacts What We Do 4:00pm–5:00pm | Texas 4 363 | Restless Leg Syndrome and Obstructive Sleep Apnea in Nephrology Patients · Kimberly English, RN, FNP 1.0 6:00pm–7:30pm | | Exhibit Hall Opening Ceremonies – Visit Posters/Exhibits · Joint with Physicians ¯ Joint with Councils Spring Clinical Meetings ’08 p.77 Nephrology Nurse and Technician Program fridAY, April 4 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 809 | Assessing the Role of Proteinuria in the · 1.5 Progression of Chronic Kidney Disease Supported by an educational grant from Genzyme | Proteinuria and Progression: Primary and Barry Brenner, MD Secondary Prevention | Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD Targets for Therapy | Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD in Progression of CKD | Grapevine C 810 | New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen | Improving Delivery of Pre-ESRD Care, Case Discussion ronald Pisoni, PhD, MS | Has Catheter Use Increased Due to Fistula First? lawrence Spergel, MD, FACS No! Case Discussion | Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC Case Discussion | 7:00am–8:00am | Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits 8:00am–11:15am Joint with Councils ¯ | Grapevine 6 364 | On Course with Cannulation Lynda Ball, BSN, CNN, RN 3.25 8:00am–9:00am | Texas 3 369 | The Fate of Dialysis Catheters Lesley Dinwiddie, MSN, 1.0 rN, FNP, CNN | Texas 1/2 365 | How to Satisfy Medicare: Helpful Hints on How to Jackie Crouch 1.0 Have Fewer Deficiencies in the Water Treatment Area Joint with Physicians with Joint · 9:00am–10:00am | Texas 1/2 361 | Improving Immunizations: The Safe and Timely Jan Deane, RN, CNN 1.0 Immunization Coalition 10:15am–12:00pm | Texas D 268 | End-of-Life Issues in CKD · Chair: Beth Piraino, MD 1.75 | I ncorporating Palliative Care Into the Dialysis Unit alvin Moss, MD | CPR vs. DNR in the Dialysis Unit Jean L. Holley, MD | Withholding and Withdrawing Dialysis Mi-Kyung Song, PhD, RN 10:15am–12:15pm | Texas 4 489 | Pediatrics and Transplant ¯ Bruce Morgenstern, MD 2.0 Sandra Coorough, ACSW, LCSW Janelle E. Gonyea, RD, LD Mary Murphy, RN, CTTC Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.78 National Kidney Foundation fridAY, April 4 Continued time/location session # session notes faculty credits | 12:15pm–1:15pm | Lunch in the Exhibit Hall – Visit Posters/Exhibits 1:15pm–3:15pm | Texas C 269 | Home Dialysis for the 21st Century · Chair: Beth Piraino, MD 2.0 | Innovative Approaches to Dialysis Modalities Robert S. Lockridge, Jr., MD assessing Adequacy Across Dialysis Modalities | Timing of Home Dialysis Modalities Joanne M. Bargman, MD, FRCP | Debate: Is Conventional Dialysis Outdated? HD 3x weekly vs yDail HD Pro Michael Rocco, MD, MSCE Con Thomas Depner, MD 1:15pm–2:15pm | Texas 3 368 | Using Research to Facilitate Self-Care Cleo J. Richard, RN, PhD 1.0 2:15pm–3:15pm | Texas 1/2 367 | Emerging Infectious Diseases: Pat Preston, MS 1.0 Impact on the Health Care Worker 3:30pm–5:30pm ˘ | Texas 1/2 375 | Bio-Terrorism: What Healthcare Jeffrey C. Metzger, MD 2.0 Separate Registration and/or Fee Required Professionals Need to Know | Texas B 285 | International and National Guideline Activities: 2008 · Co-Chairs: Garabed Eknoyan, MD 2.0 and Michael Rocco, MD, MSCE | KDIGO: Opening Remarks and Guideline Update: garabed Eknoyan, MD Hepatitis C in CKD; Care of the Transplant Patient | An Overview of the KDIGO CKD-MBD Guidelines Sharon Moe, MD, and Tilman Drüeke, MD | KDOQI 2008 and Beyond Michael Rocco, MD, MSCE | KDOQI Clinical Practice Guidelines for Nutrition in Bradley Warady, MD, and Children with CKD: 2008 Update Donna Secker, PhD 5:30pm–7:00pm · | | Networking Reception in the Exhibit Hall – Visit Posters/Exhibits Joint with Physicians 7:00pm–9:00pm | Grapevine D 811 | Cardiovascular Disease in CKD Patients · Chair: Mark J. Sarnak, MD 1.5 Pre-Dialysis and On Dialysis Supported by an educational grant from Genzyme | Sudden Cardiac Death in Pre-Dialysis CKD Charles Herzog, MD Patients and in Patients Undergoing Dialysis ¯ | Calcium and Phosphorus as Cardiovascular David Bushinsky, MD Joint with Councils risk Factors | Coronary Artery Disease: Screening and Therapy Mark J. Sarnak, MD Spring Clinical Meetings ’08 p.79 Nephrology Nurse and Technician Program Saturday, April 5 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 813 | Chronic Kidney Disease Interventions: · Chair: Peter McCullough, MD 1.5 Improving CKD and CVD Outcomes A Breakfast Symposium | KEEP Overview and Social Conceptions of allan J. Collins, MD Kidney Disease: Myths vs. Realities | Glycemic Control in Kidney Disease Samy McFarlane, MD | Interventions and CVD Interactions in Diabetics Peter McCullough, MD with Proteinuria | Impact of Blood Pressure Control in CKD george Bakris, MD 8:00am–9:00am | Texas 1/2 370 | Triaging Disaster: Lessons Learned Ira Nemeth, MD 1.0 9:00am–10:00am | Texas 1/2 371 | Earthquakes, Tornados, Floods, Oh My! Jim Curtis, CHT, CNCT 1.0 Developing Policies for Any Possible Disaster Lisa Hall, MSSW, LCSW 9:00am–12:15pm | Grapevine 6 372 | On Course with Cannulation Lynda K. Ball, BSN, CNN 3.25 | 10:00am–12:00pm | Brunch Served in Exhibit Hall – Visit Posters/Exhibits 10:15am–11:15am | Texas 4 485 | Transplant Tourism ¯ Michael Talamantes, LCSW, MSSW 1.25 10:15am–12:15pm Joint with Councils ¯ | Texas 1/2 374 | Why Advance Directives Require Physician Orders ronald Miller, MD 2.0 for Implementation 12:15pm –1:15pm | | Lunch Break 1:15pm–3:15pm | Texas B 488 | The CMS Transition to New ESRD Regulations ¯ Judith Kari 2.0 3:30pm–5:30pm Joint with Physicians with Joint · | Texas A 280 | ESRD Quality Improvement · Chair: William McClellan, MD 2.0 | The ESRD Program: History of Quality William McClellan, MD improvement Data | Pay for Performance: What Lies Ahead? Alan S. Kliger, MD | Debate: Pay for Performance: Will it Improve Patient Outcomes? Pro Jonathan Himmelfarb, MD Con John C. Stivelman, MD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.80 National Kidney Foundation Saturday, April 5 Continued time/location session # session notes faculty credits 3:30pm–4:30pm | Texas 1/2 373 | Truths, Myths and Mistakes in the Dialysis Procedure Danilo B. Concepcion, CCHT, CHT 1.0 4:30pm–5:30pm | Texas B 377 | Learning From and Listening to Their Bodies: Cleo J. Richard, RN, PhD 1.0 Clients Experiences During Hemodialysis 6:00pm–7:00pm | 100 | Allied Health Networking Reception ¯ sunday, april 6 time/location session # session notes faculty credits 8:00am–10:00am | Grapevine A 282 | Caring for the Dialysis Patient · Chair: Miguel Vazquez, MD 2.0 | Treatment of Blood Pressure in Dialysis Patients John Burkart, MD ˘ | Management of Intradialytic Hypotension Thomas Depner, MD Separate Registration and/or Fee Required | Primary Care of the Dialysis Patient Suzanne Bergman,MD | Screening for Malignancy in the Dialysis Patient Jean L. Holley, MD 8:30am–12:30pm | Appaloosa 2 300 | NNCO Certification Exam ˘ 11:15am–12:15pm | Grapevine B 590 | CKD and Diabetes Management: ¯ Debbie Hinnen, ARNP, 1.0 Clinical Pearls and Patient Teaching Strategies BC-ADM, CDE | 12:15pm | Adjourn · Joint with Physicians ¯ Joint with Councils Spring Clinical Meetings ’08 p.81 RENAL AND CLINCAL DIETITIAN PROGRAM Program Committee Host Committee Continuing Education Information Pamela S. Kent, MS, RD, CSR, LD Valerie Brinkman-Kaplan, MS, RD, LD Program Chair U.S. Renal Care/Tarrant Dialysis Centers Genzyme Renal, Vermilion, OH Central Fort Worth Fort Worth, TX Marianne Hutton, RD, CDE Program Co-Chair Donna Cavil, RD, LD A total of 48.0 CPE credits have been applied Fresenius Medical Care – North America, Haltom, TX for through the Commission on Dietetic Reg- Santa Rose, CA istration of the American Dietetic Association. Mary Ann Fuller, RD, LD Carolyn Cochran, RD, LD, MS, CDE DaVita Arlington Dialysis Dallas Nephrology Associates, Dallas, TX Lake Dallas, TX Aimee Jaremowicz, RD Mindy Gentile, MS, RD, LD DSI – Diversified SpecialtyI nstitute, Chicago, IL NutrePletionTM Resources McKinney, TX Joni Pagenkemper, MS, MA, RD, LMNT Creighton University Medical Center, Arfrances Johnson, LD, RD, MS Omaha, NE Liberty Dialysis Fort Worth, TX Mandy Trolinger, MS, RD DaVita Littleton Dialysis, Littleton, CO Nadiya Lakhani, RD, LD Fresenius Dallas, TX Debbie Lindsay, RD, LD Mansfield, XT Michelle Trahan MS, RD, LD Genzyme Renal Richardson, TX Judy Yang , RD, LD USRC/TDC-PD Clinic Fort Worth, TX p.82 National Kidney Foundation Renal and Clinical DIETITIAN Program Pre-Conference Courses time/faculty topic Strategies I: 10:00am–10:10am Break Building a Foundation 10:10am–10:30am Subjective Global Assessment Wednesday, April 2, 2008 Maureen McCarthy, MPH, RD, 7:30am–5:00pm CSR, LD Course Co-Directors: Maureen McCarthy, MPH, RD, CSR, LD, and Louise Clement, MS, RD, CSR, LD Nutrition Guidelines Session 520 Course Description: Technologies of dialysis, nutrition guidelines, 10:30am–11:40am Hemodialysis and introductions to dialysis adequacy, anemia management and Marianne Hutton, RD, CDE bone disease management will be presented. Case studies will be utilized to illustrate principles. These case studies will also 11:40am–12:15pm Peritoneal Dialysis include nutrition diagnostic statements using standardized language, Karen Wiesen, MS, RD, CSR as encouraged by the Standardized Language Task Force of the American Dietetic Association. Participants will gain a solid foundation 12:15pm–1:00pm Lunch to practice as an entry-level nutrition specialist in the dialysis setting or in other settings where treatment of chronic kidney disease, and end- 1:00pm–2:00pm Understanding Biochemical stage kidney disease, are practiced. Cathi Martin, RD, LDN Markers Target Audience: This course is designed for dietitians who are new to Special Issues renal nutrition, as well as for dietitians who work in non-renal settings but wish to strengthen their basic knowledge in this dynamic area. 2:00pm–2:35pm Diabetes and the Kidneys Patricia Weber, MS, RD, CDE This course requires a separate registration fee of $100. Light break- fast, box lunch and course syllabus included. Participation is limited. 2:35pm–2:50pm Break 2:50pm–4:20pm Basic Principles of Bone Disease Jennifer McGuoirk, MS, RD, LDN in ESRD time/faculty topic 7:30am Breakfast 4:20pm–4:50pm Basic Principles of Anemia Kara Abbas, MS, RD, CSR 7:50am–8:00am Welcome and Introductions Maureen McCarthy, MPH, RD, 4:50pm–5:00pm Closing Remarks/Evaluations CSR, LD 5:00pm Adjourn 8:00am–8:30am Physiology of the Kidneys Maureen McCarthy, MPH, RD, CSR, LD 8:30am–9:30am Technology of Hemodialysis and Lee Cauble, CHT, LPN Peritoneal Dialysis 9:30am–10:00am Introductions to the ESRD Popu- Louise Clement, MS, RD, CSR, LD lation and Programs: Overview of Government and Professional Programs, and Other Resources Spring Clinical Meetings ’08 p.83 Renal and Clinical DIETITIAN Program Pre-Conference Courses Continued time/faculty topic Strategies II: 7:15am–7:55am Registration and Applying the Principles Continental Breakfast Wednesday, April 2, 2008 8:00am–8:10am Welcome and Introductions 7:15am–5:00pm Course Director: Jessie Pavlinac, MS, RD, CSR, LD 8:10am–9:45am Nutrition Care Process and Session 521 Standardized Language for Course Description: Participants will benefit from an in-depth review Nutrition Diagnosis of cutting-edge topics in renal disease presented in this full-day course. Experts will examine advanced concepts in patient care, physical as- 9:45am–10:00am Break sessment, and research for the renal dietitian. Nationally recognized leaders in the field of renal nutrition will present topics. 10:00am–11:30am Nutrition Diagnosis Terminology and Interactive Case Studies Target Audience: This course is designed for experienced renal dietitians. 11:30am–12:30pm Lunch This course requires a separate registration fee of $100. Light break- fast, box lunch and course syllabus included. Participation is limited. 12:30pm–2:00pm Nutrition Intervention Terminology Course Faculty: and Interactive Case Studies Judith Beto, PhD, RD Maureen McCarthy, MPH, RD, CSR, LD 2:00pm–2:15pm Break 2:15pm–4:15pm Nutrition Monitoring, Evaluation and Assessment Terminology and Interactive Case Studies 4:15pm–4:55pm Implementing Standardized Language in Your Organization 4:55pm–5:00pm Closing Remarks/Evaluation 5:00pm Adjourn p.84 National Kidney Foundation RENAL AND CLINCAL DIETITIAN PROGRAM Wednesday, April 2 time/location session # session notes course director(s) credits 7:30am–5:00pm | Austin 1/2/3 520 | Strategies I: Building a Foundation ˘ Maureen McCarthy, 7.5 MPH, RD, CSR, LD L louise Clement, MS, RD, CSR, LD 7:15am–5:00pm | Austin 4/5/6 521 | Strategies II: Applying the Principles ˘ Jessie Pavlinac, MS, RD, CSR, LD 7.5 7:30pm–9:30pm | Grapevine D 801 | Association of Mineral Metabolism, Vitamin D · Chair: Myles Wolf, MD, MMSc 1.5 Therapy, and Calcimimetrics on Chronic Kidney Disease Patients Survival Supported by an educational grant from Abbott | Welcome and Introductions Myles Wolf, MD, MMSc | Associations of Mineral Metabolism with Myles Wolf, MD, MMSc Patient Survival | Impact of Vitamin D Therapy on Patient Survival Daniel Coyne, MD | Does Direct Modulations of the CaR Affect Stuart Sprague, DO ˘ Patient Survival? Separate Registration and/or Fee Required | Questions and Answers all Faculty Thursday, April 3 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 802 | The Impact of Glycemis Control in Patients · Chair: Martin J. Abrahamson, MD 1.75 with Diabetes and Chronic Kidney Disease Supported by an educational grant from · Joint with Physicians Novo Nordisk | Welcome and Introductions Martin J. Abrahamson, MD | Glycemic Control in Patients with CKD Mark S. Roberts, MD, MPP | How Low Should You Go? Martin J. Abrahamson, MD | When and How to Use Insulin in Patients with Chronic Renal Failure arturo R. Rolla, MD | Panel Discussion/Question and Answer Session all Faculty ¯ Joint with Councils Spring Clinical Meetings ’08 p.85 RENAL AND CLINCAL DIETITIAN PROGRAM Thursday, April 3 Continued time/location session # session notes faculty credits | Grapevine D 803 | Trends and Challenges in CKD Progression · Chair: Ann O’Hare, MD 1.5 and Management in Older Adults Supported by an educational grant from Ortho Biotech, L.P. | Epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FRCPC Older Adults | Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD in the Elderly | Reasons Why Evidence for the Management ann O’Hare, MD of CKD in Younger Individuals May Not Be generalizable to Older Adults with CKD 8:00am–9:45am | Grapevine 1/2 560 | Multicultural Approaches to Health Care ¯ Kirk Hughes, PhD 1.5 10:00am–12:00pm | Grapevine 1/2 561 | Creative Strategies for Patient Compliance Donna Morton de Souza, MPH, RD 2.0 | Grapevine 3/4 562 | Tainting of the Golden Years: CKD in the Julie Barboza, APRN-BC, MSN, RD 2.0 Geriatric Population 12:00pm–2:00pm | Grapevine C 804 | Dietary Phosphorus and Outcomes in · Chair: Stuart Sprague, DO 1.5 Patients with CKD Supported by an educational grant from Joint with Councils ¯ Shire Pharmaceuticals | DEBATE: Should Phosphorus be Controlled by Dietary Restrictions in CKD? Dietary Phosphorus Control Increases Death Risk! Kamyar Kalantar-Zadeh, MD Dietary Phosphorus Control Improves Survival! Daniel Coyne, MD 12:30pm–2:00pm | Grapevine D 563 | CRN Networking Luncheon Joint with Physicians with Joint · 2:00 am–3:00pm | Texas A/B 264 | NKF Presidential Address – allan J. Collins, MD, FACP 1.0 The National Kidney Foundation: Advancing Public Health in the U.S. and Around the World | Shaul G. Massry Distinguished Lecture – Tom Greene, PhD Randomized and Observational Studies in Nephrology: How Strong is the Evidence? · 3:00pm–3:30pm | Grapevine 1/2 564 | Joel D. Kopple Award Presentation – recipient: Alison Steiber, 0.5 Dietitian: Powerhouse Behind the Patients RD, PhD, LD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.86 National Kidney Foundation Thursday, April 3 Continued time/location session # session notes faculty credits 3:30pm–4:30pm | Grapevine 3/4 565 | Promoting Patient Participation in the Dialysis Setting Mandy Trolinger, MS, RD 1.0 | Grapevine 1/2 566 | What’s Up at Night? Nutritional Management of the Mary Ellen Brabec, RD, CSR. 1.0 Nocturnal Hemodialysis Patient LDN, MHS 4:30pm–5:30pm | Grapevine 3/4 588 | Breaking News Bits: Latest Research 1.0 | Sevelamer HCL Use and Circulating Endotoxin Phyllis Sun, MS, RD, LDN and Inflammatory Biomarkers in HD Patients: a Preliminary Report | Plasma B6 Vitamins in HD Subjects Taking louise Clement, MS, RD, CSR, LD Prescription or Over the Counter Renal MVI Supplements 4:30pm–5:30pm | Grapevine 5/6 567 | Defining, Recognizing, and Achieving Adequate Faith Tootell, MS, RD, CSR, FADA 1.0 HD and PD Dialysis Dosages 6:00pm–7:30pm ˘ | | Exhibit Hall Opening Ceremonies – Visit Posters/Exhibits Separate Registration and/or Fee Required 7:30pm–9:30pm | Grapevine C 815 | An Evidence-Based Review of the · Chair: Vincent Dennis, MD 1.5 Management of Hyperphosphatemia and Its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008 Supported by an educational grant from Fresenius Medical Care – North America | A Review of Recent Clinical Studies of Patients lynda Szczech, MD with Stage 5 CKD: Impact on Clinical Practice | A Pharmacoeconomic Analysis of Phosphate Wolfgang Winkelmayer, MD Binders in the Treatment of Patients with Stage 5 · Joint with Physicians CKD: Impact on the Health Care System 6:00am–8:00am | Grapevine D 809 | Assessing the Role of Proteinuria in the · 1.5 Progression of Chronic Kidney Disease Supported by an educational grant from Genzyme | Proteinuria and Progression: Primary and Barry Brenner, MD ¯ Secondary Prevention Joint with Councils | Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD Targets for Therapy | Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD in Progression of CKD Spring Clinical Meetings ’08 p.87 RENAL AND CLINCAL DIETITIAN PROGRAM Friday, April 4 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 810 | New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen | Improving Delivery of Pre-ESRD Care, Case Discussion ronald Pisoni, PhD, MS | Has Catheter Use Increased Due to Fistula First? lawrence Spergel, MD, FACS No! Case Discussion | Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC Case Discussion | 7:00am–8:00am | Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits 8:00am–10:00am | Grapevine 1/2 568 | MNT and CKD: Making a Difference Kathy Schiro Harvey, MS, RD, CSR 2.0 Carolyn Cochran, RD, LD, MS, CDE | Grapevine 3/4 569 | CRRT: Dosing the Nutrition and Beyond Ann Beemer Cotton, MS, RD 2.0 Kim Hodge, RN 10:15am–12:00pm | Grapevine 1/2 570 | Monitoring Growth in Children with CKD: Meredith Miller, RD, LD 1.5 Putting Dietary Recommendations to Practice | Texas D 268 | End-of-Life Issues in CKD · Chair: Beth Piraino, MD 1.5 | Incorporating Palliative Care into the Dialysis Unit alvin Moss, MD Joint with Councils ¯ | CPR vs. DNR in the Dialysis Unit Jean L. Holley, MD | Withholding and Withdrawing Dialysis Mi-Kyung Song, PhD, RN | 12:00pm–1:15pm | Lunch in the Exhibit Hall – Visit Posters/Exhibits 1:15pm–3:15pm | Grapevine 1/2 572 | An Introduction to the Spirit and Skills Dana Sturtevant, MS, RD 2.0 of Motivational Interviewing | Grapevine 5/6 580 | Extreme Makeover: Plant-Based Diets and CKD Joni Pagekemper, MS, MA, RD, LMNT 2.0 Joint with Physicians with Joint · Duane Sunwold 3:30pm–4:30pm | Grapevine 3/4 573 | IgA Nephropathy and Fish Oils Ronald Hogg, MD 1.0 | Grapevine 1/2 574 | Resistance Training – Good for the Body and Stephanie McIntyre, RD 1.0 Good for People With Kidney Disease 3:30pm–5:30pm | Texas D 271 | Fluid and Electrolytes · Chair: Miguel Vazquez, MD 2.0 | Update on Management of Hyperkalemia Daniel Batlle, MD | Update of Hypophosphatemia Zalman S. Agus, MD | Update on Hyponatremia Therapy Tomas Berl, MD | Update on Metabolic Alkalosis l. Lee Hamm, MD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.88 National Kidney Foundation Friday, April 4 Continued time/location session # session notes faculty credits 3:30pm–5:30pm | Texas B 285 | International and National Guideline Activities: 2008 · Co-Chairs: Garabed Eknoyan, MD 2.0 and Michael Rocco, MD, MSCE | KDIGO: Opening Remarks and Guideline Update: garabed Eknoyan, MD Hepatitis C in CKD; Care of the Transplant Patient | An Overview of the KDIGO CKD-MBD Guidelines Sharon Moe, MD, and Tilman Drüeke, MD | KDOQI 2008 and Beyond Michael Rocco, MD, MSCE | KDOQI Clinical Practice Guidelines for Nutrition in Bradley Warady, MD, and | Children with CKD: 2008 Update Donna Secker, PhD 4:30pm–5:30pm | Grapevine 1/2 575 | Enteral Nutrition Challenges in the CKD Patient Marcia Kalista Richards, 1.0 MPH, RD, CNSD, LDN | Grapevine 3/4 589 | Breaking News: Latest Research 1.0 | Nutrition Practices of Renal Dietitians in Joyce Vergili, MS, RD, LDN, CDE Hemodialysis Centers ˘ | Complementary Intradialytic Nutrition Mary B. Sundell, RD, LDN, CCRP Separate Registration and/or Fee Required Supplementation in Dialysis Patients | Does Nutrition Specific Quality of Life Questionnaire Haewook Han, PhD, RD, CSR, LDN Measure the Impact of Nutrition on the Health Related Quality of Life in HD Patients? 5:30pm–7:00pm | | Networking Reception in the Exhibit Hall – Visit Posters/Exhibits 7:00pm–9:00pm | Grapevine D 811 | Cardiovascular Disease in CKD Patients · Chair: Mark J. Sarnak, MD 1.5 Pre-Dialysis and On Dialysis Supported by an educational grant from Genzyme | Sudden Cardiac Death in Pre-Dialysis CKD Charles Herzog, MD Patients and in Patients Undergoing Dialysis · Joint with Physicians | Calcium and Phosphorus as Cardiovascular David Bushinsky, MD risk Factors | Coronary Artery Disease: Screening and Therapy Mark J. Sarnak, MD ¯ Joint with Councils Spring Clinical Meetings ’08 p.89 RENAL AND CLINCAL DIETITIAN PROGRAM friday, April 4 Continued time/location session # session notes faculty credits 7:00pm–9:00pm | Grapevine C 812 | Optimal Patient Outcomes: Identification and Treatment · Chair: Anatole Besarab, MD 1.5 of Iron Deficiency Anemia in Early CKD Supported by an educational grant from AMAG Pharmaceuticals, Inc. | Prevalence and Diagnosis of Anemia in Patients with CKD allen R. Nissenson, MD | State of the Art in Treatment of Iron Deficiency Anemia: ajay K. Singh, MB, MRCP Current and Future Directions | Case Review and Panel Discussion anatole Besarab, MD Saturday, April 5 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 814 | Exploring the Link Between Chronic Kidney Chair: Tammy Ho, MD 1.5 Disease and Cardiovascular Disease: Reducing Mortality Supported by an educational grant from Abbott | Welcome and Introductions Tammy Ho, MD Joint with Councils ¯ | Exploring the Association Between Cardiovascular Tammy Ho, MD Disease and Chronic Kidney Disease | Mechanisms that Contribute to Altered ravi Thadhani, MD Cardiovascular Regulation in Chronic Kidney Disease | Management Strategies for Reducing Kamyar Kalantar-Zadeh, MD Cardiovascular Risk Factors in Chronic Joint with Physicians with Joint · Kidney Disease | Questions and Answers all Faculty | Grapevine C 813 | Chronic Kidney Disease Interventions: Chair: Peter McCullough, MD 1.5 Improving CKD and CVD Outcomes A Breakfast Symposium | KEEP Overview and Social Conceptions of allan J. Collins, MD Kidney Disease: Myths vs. Realities | Glycemic Control in Kidney Disease Samy McFarlane, MD | Interventions and CVD Interactions in Diabetics Peter McCullough, MD with Proteinuria | Impact of Blood Pressure Control in CKD george Bakris, MD Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.90 National Kidney Foundation Saturday, April 5 Continued time/location session # session notes faculty credits 8:00am–10:00am | Texas B 274 | Nutrition and Inflammation in CKD · Co-Chairs: Srinivasan Beddhu, MD 2.0 and Kamyar Kalantar-Zadeh, MD | Inflammation and Wasting Syndromes Ravi Thadhani, MD | Is Malnutrition a Misnomer in Dialysis Patients Srinivasan Beddhu, MD | Insulin Resistance and Muscle Wasting in CKD edward Siew, MD 8:00am–9:00am | Grapevine 1/2 576 | Oral Health and CKD Cheryl Thomas, RDH 1.0 9:00am–10:00am | Grapevine 3/4 577 | Gut Health: Prebiotics and Probiotics Jeanette Hasse, PhD, RD, 1.0 FADA, CNSD | 10:00am–12:00pm | Brunch Served in the Exhibit Hall – Visit Posters/Exhibits 10:15am–12:00pm | Grapevine 1/2 578 | Sensations of Tasting and Smelling Sarah Washburn, MS, RD, CD 1.5 Barbara Fromm, MS, RD 12:15pm–1:15pm ˘ | Grapevine A 487 | Clinical Conversations Luncheon ˘¯ See page 100 for topics and Separate Registration and/or Fee Required faculty information 1:15pm–3:15pm | Texas B 488 | The CMS Transition to New ESRD Regulations ¯ Judith Kari 2.0 3:30pm–4:30pm | Grapevine 3/4 582 | Staying Ahead to Keep Ahead: What You Need Mary Hastings Hagar, PhD, RD, FADA 1.0 to Know About Public Policy Dolph Chianchiano, JD, MPA | Grapevine 1/2 583 | Using the New Standardized Language Maureen McCarthy, 1.0 in Your Chart Notes MPH, RD, CSR, LD 4:30pm–5:30pm | Grapevine 1/2 584 | It’s Not All in Your Head: Beth McQuiston, MD, MS, RD, LDN 1.0 Neurological Issues in Renal Patients · | Texas 5/6 581 | Transplantation Jeanette Hasse, 1.0 Joint with Physicians PhD, RD, FADA, CNSD 6:00pm–7:00pm | Grapevine B 100 | Allied Health Networking Reception ¯ ¯ Joint with Councils Spring Clinical Meetings ’08 p.91 RENAL AND CLINCAL DIETITIAN PROGRAM Sunday, April 6 time/location session # session notes faculty credits 8:00am–8:50am | Grapevine B 585 | Stage Management of CKD and Diabetes: Janelle E. Gonyea, RD, LD 1.0 A Nutritional Model 8:55am–9:45am | Grapevine B 586 | Cutting-Edge Therapies for Diabetes Management Priscilla Hollander, MD 1.0 10:00am–10:50am | Grapevine B 587 | An Odyssey for 2008: Renal Pharmacology Mary Schira, PhD, APRN, BC, ACNP 1.0 10:55am–11:45am | Grapevine B 590 | CKD and Diabetes Management: Debbie Hinnen, APRN, CDE, 1.0 Clinical Pearls and Patient Teaching Strategies BC-ADM, FAAN 11:45am–12:15pm | Grapevine B 591 | Diabetes Panel Question and Answer All Sunday Morning Faculty 12:15pm | Meeting Adjourns Joint with Councils ¯ Joint with Physicians with Joint · Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.92 National Kidney Foundation NEPHROLOGY SOCIAL WORKER PROGRAM Program Committee Kati Malarcher, LMSW n Florida Board of Clinical Social Work, Mar- Stephanie Stewart, LICSW Fresenius Medical Center – North America riage and Family Therapy and Mental Health Program Chair Plano, TX Counseling, Provider Number BAP 614, Mayo Clinic, Rochester, MN expires March 31, 2009. Christina Denman, LMSW n The National Kidney Foundation Council of Fresenius Medical Center – North America Andrea DeKam, LMSW Nephrology Social Workers, approval num- Plano, TX Program Co-Chair ber PCE 2410, is approved as a Continuing University of Michigan Dialysis, Livonia, MI Jodi Patterson, LMSW Education Provider by the California Board of Behavioral Sciences. This course meets Sandra Coorough, ACSW, LCSW McKinney Dialysis Center the qualifications for continuing education Continuing Education Coordinator McKinney, TX credit for LCSWs as required by the California Phoenix Children’s Hospital Kids Kidney Maggie Marek, LMSW Board of Behavioral Sciences. Center, Phoenix, AZ Baylor All Saints Fort Worth n Massachusetts social workers may receive Jessica Farrell, MSW, LCSW-P Fort Worth, TX Category II continuing education credit Duke University Medical Center, Durham, NC hours upon their own submission. Lisa Pratka, LMSW John Q. Gowan, LMSW Medical City Transplant It is the conference registrants responsibility ESRD Network #14, Dallas, TX Dallas, TX to make sure their home state (if not noted above) accepts the ASWB ACE provider as suf- Rebecca Hays, MSW Debra Jordan, LMSW ficient for CEUs, or if they need to do anything University of Wisconsin Hospital and Clinics, DaVita North Dallas Dialysis Center additional to independently receive state CEUs. Madison, WI Dallas, TX Cindy Miller, MSW, LCSW Advanced Renal Care, Tampa, FL 2008 Program Goals Continuing Education Information n Participants will gain the knowledge and Kristin Stockard, LICSW A minimum of 38.0 continuing education skills for outcome-oriented clinical nephrol- Children’s Hospital and Region Medical credit hours for social workers (for the entire ogy social work practice. Center, Seattle, WA program) have been applied for through the n Participants will gain knowledge of biopsy- following agencies: Lara Tushla, LCSW, MSW chosocial variables affecting chronic kidney n The National Kidney Foundation Council disease patients and their families. Rush Presbyterian Hospital, Chicago, IL of Nephrology Social Workers, provider n Participants will learn skills to ameliorate #1014, is approved as a provider for social and address biopsychosocial variables work continuing education by the Associa- affecting kidney disease patients and Host Committee tion of Social Work Boards (ASWB) their families. Marybeth Callahan, ACSW, LCSW, ACP www.aswb.org, phone: 1.800.225.6880, n Participants will gain knowledge and Dallas Transplant Institute through the Approved Continuing Educa- skills to address issues of diversity among Dallas, TX tion (ACE) program. The National Kidney chronic kidney disease patients and health Foundation Council of Nephrology Social Josefina Houchins, LMSW care professionals. Workers maintains responsibility for DaVita Oak Cliff Dialysis Center the program. Dallas, TX Marianne Moncrief, LMSW Dallas Transplant Institute Dallas, TX Spring Clinical Meetings ’08 p.93 Nephrology Social Worker Program Pre-Conference Course time topic Nephrology Social Work: 8:45am–9:00am Welcome and Introductions An Outcomes-Driven Practice Model 9:00am–9:30am Introduction to Outcomes-Driven Wednesday, April 2, 2008 Nephrology Social Work 8:00am–5:00pm Course Directors: Mary Beth Callahan, ACP, ACSW, LCSW, 9:30am–10:30am Phases of Adjustment to CKD: Stephanie Johnstone, LCSW, MSW, and Megan Prescott, MSW Designing Interventions to Session 420 Enhance Outcomes Course Description: This full-day training will focus on a contemporary model of Nephrology Social Work practice that targets specific variables 10:30am–10:45am Break such as adherence behavior, depression, social support, satisfaction with care, conflict resolution, team training, quality-of-life measurement 10:45am–11:30am Phases of Adjustment to CKD and modality selection to enhance overall outcome goals. The training (continued) will also focus on restructuring social work services within your organization and applying case management and time-saving strategies 11:30am–12:00pm Improving Adherence Behavior to make the delivery of those services possible. 12:00pm–12:30pm Lunch Target Audience: Nephrology Social Workers 12:30pm–1:30pm Improving Transplant Outcomes This course requires a separate registration fee of $100. Light break- fast, box lunch and course syllabus included. Participation is limited. 1:30pm–1:40pm Stretch Break 1:40pm–2:25pm Prevention and Management of Depression 2:25pm–2:45pm Improving Rehabilitation Outcomes 2:45pm–3:00pm Break 3:00pm–3:15pm Patient, Staff and Team Satisfaction 3:15pm–4:15pm Understanding and Managing the Challenging Patient 4:15pm–4:45pm Evolving into an Outcomes-Driven Model of Practice 4:45pm–5:00pm Questions and Evaluations 5:00pm Adjourn p.94 National Kidney Foundation NEPHROLOGY SOCIAL WORKER PROGRAM Wednesday, April 2 time/location session # session notes Course Director(s) credits 8:00am–5:00pm | Grapevine 3/4 420 | Nephrology Social Work: ˘ Stephanie Johnstone, LCSW, BCD 8.0 An Outcomes-Driven Practice Model Mary Beth Callahan, ACP, ACSW, LCSW Megan Prescott, MSW, LCSW Thursday, April 3 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine D 803 | Trends and Challenges in CKD Progression · Chair: Ann O’Hare, MD 1.5 and Management in Older Adults Supported by an educational grant from Ortho Biotech, L.P. | Epidemiology of Chronic Kidney Disease in lesley Stevens, MD, MS, FRCPC ˘ Older Adults Separate Registration and/or Fee Required | Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD in the Elderly | Reasons Why Evidence for the Management ann O’Hare, MD of CKD in Younger Individuals May Not Be generalizable to Older Adults with CKD 8:00am–9:00am | Texas 3 460 | Trans 101: “Miss”understood and “Miss”represented lois Bates 1.0 9:00am–10:00am | Texas 3 483 | Ethical Controversies in Public Solicitations for Organs linda Wright, MHSC, MSW, RSW 1.0 | Texas 4 462 | Nephrology 101 Bruce Morgenstern, MD 1.0 10:15am–12:15pm · | Texas 3 463 | Diagnosing Personality Disorders Sheila Jowsey, MD 2.0 Joint with Physicians 10:15am–12:15pm | Texas 4 464 | The Dangers of Chronic Stress, edward G. Silverhardt, 2.0 Compassion Fatigue and Burnout MSW, LCSW, LSCSW, BCD ¯ Joint with Councils Spring Clinical Meetings ’08 p.95 NEPHROLOGY SOCIAL WORKER PROGRAM Thursday, April 3 Continued time/location session # session notes faculty credits 12:30pm–2:00pm | Grapevine A 466 | CNSW Networking Luncheon Patricia M. McKevitt, 0.5 MSW, ACSW, LCSW 2:00pm–3:00pm | Texas A/B 264 | NKF Presidential Address – · allan J. Collins, MD, FACP 1.0 The National Kidney Foundation: Advancing Public Health in the U.S. and Around the World | Shaul G. Massry Distinguished Lecture – Tom Greene, PhD Randomized and Observational Studies in Nephrology: How Strong is the Evidence? 3:30pm–5:30pm | Texas 3 467 | Depression in the CKD Setting: The Time to Mark Meier, LICSW, MSW 2.0 Act is Now | San Antonio 4/5/6 468 | Spirituality and Chronic Illness: Claire J. Casselman, MSW, 2.0 On Being Some Body and Soul LICSW, LMSW 6:00pm–7:30pm | | Exhibit Hall Opening Ceremonies – Visit Posters/Exhibits Frip day, A ril 4 Joint with Councils ¯ time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 810 | New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen Joint with Physicians with Joint · | Improving Delivery of Pre-ESRD Care, Case Discussion ronald Pisoni, PhD, MS | Has Catheter Use Increased Due to Fistula First? lawrence Spergel, MD, FACS No! Case Discussion | Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC Case Discussion 7:00am–8:00am | | Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits 8:00am–10:00am | Texas 4 469 | Brief Introduction to the Clinical Assessment Ramiro Valdez, PhD 2.0 of Competence Rita-An Kiely, ACSW, LCSW 8:00am–9:00am | San Antonio 4/5/6 470 | Research: Doing What You Love – Showing What Works Jessica Cabness, PhD, MSW 1.0 Separate Registration and/or Fee Required Fee and/or Registration Separate Cindy Miller, MSW, LCSW ˘ p.96 National Kidney Foundation Friday, April 4 Continued time/location session # session notes faculty credits 9:00am–10:00am | San Antonio 4/5/6 471 | Research: Literature Review and Measurement Teri Browne, MSW, LSW 2.0 Selection in Renal Social Work Research Tiffany Washington, MSW 10:15am–12:15pm | San Antonio 4/5/6 472 | Research Design and Data Analysis for Renal Joseph Merighi, MSW, PhD 2.0 Social Workers: A User-Friendly Approach 10:15am–12:15pm | Texas 4 489 | Pediatrics and Transplant ¯ Bruce Morgenstern, MD 2.0 Sandra Coorough, ACSW, LCSW Janelle E. Gonyea, RD, LD Mary Murphy, RN, CCTC | 12:15pm–1:15pm | Lunch in the Exhibit Hall – Visit Posters/Exhibits 1:15pm–2:15pm | Texas 4 473 | Negotiating Goals of Care ronald J. Crossno, MD 1.0 | San Antonio 4/5/6 476 | Research: Effective Strategies for Publishing Joseph Merighi, MSW, PhD 1.0 Renal Social Work Research ˘ 2:15pm–3:15pm Separate Registration and/or Fee Required | Texas 4 474 | Respecting Choices in End-of-Life Care anne Moore, LMSW 1.0 | San Antonio 4/5/6 477 | Research: JNSW/CNSW Grant Process Joseph Merighi, MSW, PhD 1.0 Norma J. Knowles, MSW, LCSW Jeff Harder, MSW, LICSW 3:30pm–5:30pm | Texas 4 478 | Immigration Panel Discussion ramiro Valdez, PhD 2.0 Charlie Thomas, CISW, ACSW, L lCSW, MSW E elena Lucio, MSW Sandra Coorough, ACSW, LCSW Theodor Vogels, MSW · 3:30pm–4:30pm Joint with Physicians | San Antonio 4/5/6 479 | Research: CNSW Research Grant Winner Robert Whitlock, MSSW, LCSW, MHA 1.0 Norma J. Knowles, MSW, LCSW 4:30pm–5:30pm | San Antonio 4/5/6 480 | Research Panel Discussion Joseph Merighi, MSW, PhD 1.0 Teri Browne, MSW, LSW Jeff Harder, MSW, LICSW ¯ Norma J. Knowles, MSW, LCSW Joint with Councils | 5:30pm–7:00pm | Networking Reception in the Exhibit Hall – Visit Posters/Exhibits Spring Clinical Meetings ’08 p.97 NEPHROLOGY SOCIAL WORKER PROGRAM Saturday, April 5 time/location session # session notes faculty credits 6:00am–8:00am | Grapevine C 813 | Chronic Kidney Disease Interventions: · Chair: Peter McCullough, MD 1.5 Improving CKD and CVD Outcomes A Breakfast Symposium | KEEP Overview and Social Conceptions of allan J. Collins, MD Kidney Disease: Myths vs. Realities | Glycemic Control in Kidney Disease Samy McFarlane, MD | Interventions and CVD Interactions in Diabetics Peter McCullough, MD with Proteinuria | Impact of Blood Pressure Control in CKD george Bakris, MD 8:00am–10:00am | Texas 4 481 | Ethical Dilemmas in Pediatric Practice Cassandra Aspinall, LICSW, MSW 2.0 Kathryn Thurber-Smith, LICSW 8:00am–9:00am | San Antonio 4/5/6 461 | Dare to Self-Care Kristie Lewis, LLMSW 1.0 Tracey A. Tyus-Bailey, MSW, L lMSW, ACSW 9:00am–10:00am | San Antonio 4/5/6 482 | Dial a Donor: The Living Donor Andrea Kostick, MSW, LICSW 1.0 | Telephone Screening Process | 10:00am–12:00pm | Brunch Served in the Exhibit Hall – Visit Posters/Exhibits Joint with Councils 10:15am–12:15pm ¯ | San Antonio 4/5/6 484 | Pediatric Practice: Clinical Studies and Skills Building Mikhaelle Heald, LMSW 2.0 Karen Egolso, MSW, BSW, L lSW, LNSW Kristin Stockard, LICSW 10:15am–11:15am | Texas 4 485 | Transplant Tourism Michael Talamantes, LCSW, MSSW 1.0 Joint with Physicians with Joint · 11:15am–12:15pm | Texas 3 491 | Update on the Proposed Kidney Trent Tipple, MD, FAAP 1.0 Organ Allocation System Separate Registration and/or Fee Required Fee and/or Registration Separate ˘ p.98 National Kidney Foundation Saturday, April 5 Continued time/location session # session notes faculty credits 12:15pm–1:15pm | Grapevine A 487 | Clinical Conversations Luncheon ˘¯ See page 100 for topics and faculty 1:15pm–3:15pm | Texas B 488 | The CMS Transition to New ESRD Regulations ¯ Judith Kari 2.0 3:30pm–5:30pm | Texas D 490 | “Decrease the Increase” Regarding CKD ¯ glen H. Stanbaugh, MD 2.0 A anton C. Schoolwerth, MD, FAHA E eduardo Sanchez, MD, MPH R robert Duncan 3:30pm–4:30pm | San Antonio 4/5/6 486 | Getting Patients Through Transplant Fast amy Waterman, PhD 1.0 and Without Dropping Out: What Really Makes the Difference 4:30pm–5:30pm | San Antonio 4/5/6 492 | Life with a Kidney Transplant James R. Rodrigue, PhD 1.0 ˘ 6:00pm–7:00pm Separate Registration and/or Fee Required | Grapevine A 100 | Allied Health Networking Reception ¯ Sunday, April 6 time/location session # session notes faculty credits 8:00am–10:00am | Grapevine1/2 493 | Ethics and the Many Shades of Gray ellen Case, BSW, MSW, LICSW 2.0 Stephanie Stewart, LICSW 10:15am–12:15pm | Grapevine1/2 494 | CNSW Town Hall Meeting CNSW Executive Committee · This session is a must for all nephrology social work Joint with Physicians attendees! Join us to learn all about the new nephrology social work certification, in-depth information about CNSW projects and opportunities, and to ask questions and make suggestions to the CNSW Executive Committee. 12:15pm Meeting Adjourns ¯ Joint with Councils Spring Clinical Meetings ’08 p.99 CLINICAL CONVERSATIONS LUNCHES Saturday, April 5, 12:15pm–1:15pm Indulge in stimulating moderated discussions with your colleagues: These roundtable discussions present various topics that are clinically relevant to the care and treatment of your patients. Topics and presenters: Renal and Clinical Dietitian Program: 1 CKD and MNT: Making a Difference // Carolyn Cochran, RD, LD, MS, CDE and Kathy Shiro Harvey, MS, RD, CSR 2 Resistance Training: Good for the Body and Good for People with Kidney Disease // Stephanie McIntyre, RD 3 Oral Health and CKD // Cheryl Thomas, RDH 4 Enteral Nutrition Challenges in the CKD Patient // Marcia Kalista Richards, MPH, RD, CNSD, LDN 5 a. Nutrition Practices of Renal Dietitians in Hemodialysis Centers // Joyce Vergili, MS, RD, LDN, CDE b. Does Nutrition Specific Quality of Life Questionnaire Measure the Impact of Nutrition on the Health Related Quality of Life in HD Patients? // Haewook Han, PhD, RD, CSR 6 a. Complementary Intradialytic Nutrition Supplementation in Dialysis Patients // Mary Sundell, RD, LD b. Sevelamer HCL Use and Circulating Endotoxin and Inflammatory Biomarkers in HD Patients: A Preliminary Report // Phyllis Sun, RD Nephrology Social Worker Program: 7 Trans 101 // Lois Bates 8 The Living Donor Telephone Screening Process // Andrea Kostick, MSW, LICSW 9 Immigration // Ramiro Valdez, PhD, Charlie Thomas, CISW, ACSW, LCSW and Theodor Vogels, MSW 10 Pediatrics and Transplant // Bruce Morgenstern, MD, Sandra Coorough, ACSW, LCSW, Janelle E. Gonyea, RD, LD, and Mary Murphy, RN, CTRN One topic per table. Tickets, which include lunch, are $25.00 and are available at the ticket sales booth in the NKF Registration area. Tickets are available on a first come, first served basis. Register early—tables fill up quickly! Save 20% on job postings on the National Kidney Foundation’s Kidney Career Center NOW THROUGH APRIL 9, 2008 Looking for that perfect fit? Visit NKF’s online Kidney Career Center, a leading quality kidney health care professionals, as well as quick and resource for making employment connections in the easy job posting and online job activity reports. fast-growing fi eld of kidney health care. Job-seeking professionals enjoy free and confi dential resume The one-size-fi ts-all approach of the mega job boards posting, automated e-mail notifi cation of new job listings and may not be the best way to fi nd the physicians, the ability to save jobs for later review. pharmacists, nurses, technicians, dietitians and social workers you’re looking for. Kidney Career Center The Kidney Career Center, is the only job site that offers employers targeted access to www.careers.kidney.org ©2008 National Kidney Foundation, Inc. All Rights Reserved. 02-75-483A p.100 National Kidney Foundation EXIT EXIT SHOW NOTES LEGEND & = MEN'S REST ROOM =WOMEN'S RESTROOM =FREIGHT ELEVATOR =PASSENGER ELEVATOR = 2'8" x 5'6" COLUMN = 2'8" x 2'8" COLUMN ELECTRICAL & TELEPHONE120/280V, WITH / DATA = FLOOR DRAIN 100AMP, 3 0,5 WIRE HEAVYRECEPTACLE DUTY MOUNTED ON ALL COLUMNSNEAREST EXCEPTROW SOUTH WALL,& FLOORS DESIGNATED. WHERE FA FA = FIREALARM FX EXTINGUISHER = FIRE LONGHORNEXHIBIT24' - HALL REGISTRATION12' & - LOBBY AREAS FHV =VALVE FIRE HOSE LEGEND: CEILING HEIGHTS: ELEC GUEST PARCEL OPERABLE WALL STOR REGISTRATION OFFICE EXIT IDF ROLL-UP DOOR IDF 20' 1033 1031 1029 1001 1039 1023 1021 1019 1015 1007 1005 EXIT EXIT STAFF OFFICE 30' 1028 1004 1040 1041 10361034 1037 1032 1035 10121010 1013 1011 1000 20' 20' 20' 20' 20' 20' 20' 933 911 901 937 919 915 907 905 929 ROLL-UP DOOR EXIT 20' 40' 916 914 912 910 940938 941 939 944 20' 30' 40' ELEC 30' 839 821 813 811 OFFICE 801 OPERABLE WALL 846 40' 30' 840 841 STOR 844 845 REGISTRATION 30' 729 OFFICE 40' EXIT EXIT 715 713 812 711 810 719 APRIL2-6, 2008 IDF 20' 740738 741 736 739 734 744 GRAPEVINE,TEXAS 20' 40' 30' 30' 629 639 635 20' 20' Main 601 619 611 Entrance 646 IDF 30' 640 641 636 637 644 645 20' 40' 523 ROLL-UP DOOR 30' 30' STAFF OFFICE 40' 30' 540538 541 536 539 537 GAYLORDC-F TEXAN HALL LONGHORN EXHIBIT 30' 30' 544 20' 401 411 423 419 441 439 437 EXIT EXIT NATIONALKIDNEYMEETING FOUNDATION CLINICAL SPRING 20' 30' 420 418 404 428 20' 20' 20' 20' 20' 20' ELEC 30' 329 323 321 319 311 OFFICE 334 20' 322 320 318 314 312 310 306 304302 305 300 STORAGE OPERABLE WALL 20' REGISTRATION 229 OFFICE ROLL-UP DOOR IDF IDF EXIT EXIT Spring Clinical Meetings ’08 p.101 CM08 Exhibitors company // booth Abbott // 601 Foundation Medical Staffing // 1029 Nephrology News and Issues // 812 Abbott Nutrition // 711 Fresenius Medical Care // 423 Nephrology Nursing Certification Commission // 320 Alaven Pharmaceutical, LLC. // 1000 Fresenius Medical Care // 523 Nephro-Path // 420 Alcavis HDC // 939 Genzyme Corporation // 729 Nephro-Tech // 1023 AMAG Pharmaceuticals, Inc. // 919 The Gideons International // 1032 Nipro Medical Corporation // 715 American Academy of Nurse Hawthorn Pharaceuticals // 536 Practitioners // 537 Nova Biomedical // 318 Health Informatics, Inc. // 306 American Academy of Physician Novartis // 321 HemoCue, Inc., A Quest Diagnostics Assistants // 538 Company // 1007 Novo Nordisk Inc. // 929 American Association of Kidney Innovation 4 Dialysis // 839 Nutrepletion Resources // 811 Patients // 302 Keryx Biopharmaceuticals, Inc. // 901 Omron Healthcare // 322 American Regent, Inc. // 404 Kidney Community Early Response Ortho Biotech Products, LP // 801 American Society of Nephrology // 1005 Coalition // 437 Pentec Health // 933 Amgen // 229 Llorens Pharmaceutical Int'l Division // 914 Pfizer // 629 Amgen // 401 Meals for LIFE // 312 Physician’s Capital Investment // 713 AngioDynamics // 319 MedComp // 903 PKD Foundation // 539 Arrow International // 1015 Medical Nutrition USA, Inc. // 907 Quality Dialysis // 636 Astellas Pharma US, Inc. // 619 Merck & Co., Inc. // 1001 Renal and Urology News // 1021 Baxter Healthcare // 611 National Association of Nephrology Renal Business Today/ The Binding Site, Inc. // 1004 Technicians/Technologists (NANT) // 1033 Virgo Publishing Medical Group // 304 Boehringer Ingelheim // 419 National Kidney and Urologic Renal Physicians Association // 734 Disease Information Clearinghouse Breckenridge Pharmaceutical, Inc. // 418 (NKUDIC) // 736 Satellite Healthcare, Inc. // 1028 Courier Med // 738 National Kidney Foundation // 719 Satellite Laboratory Services // 311 Covidien // 1012 AJKD Scantibodies Clinical Laboratory // 310 KDIGO DaVita // 314 KDOQI Shire // 411 DCA—Dialysis Corporation of America // 916 KEEP Sigma-Tau Pharmaceuticals, Inc. // 305 KLS Dialysis and Transplantation // 910 Solinmed Billing & Transcription // 739 NKF cyberNephrology Experience // 334 Dialysis at Sea // 639 Specta Laboratories // 428 NKF “People Like Us” Constituent Council Dialysis Recruiting Specialists/ "Hope Street” // 821 TEVA Pharmaceuticals // 1019 The Fortus Group // 912 NKF Professional Councils // 813 University of Minnesota Medical Diazyme Laboratories // 637 Center, Fairview // 441 National Kidney Foundation of DVA Laboratory Services, Inc. // 937 North Texas // 1013 U.S. Renal Care, Inc. // 635 Elsevier, Inc. // 1011 National Renal Alliance // 329 U.S. Renal Data System (USRDS) // 300 Evercare // 1036 Natural Balance Bodywork // 938 Watson Nephrology // 911 FMQAI // 439 Nature Publishing Group // 1010 Wyeth Pharmaceuticals // 915 Nephrocor // 810 p.102 National Kidney Foundation 2008 Exhibitors EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS ABBOTT AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS Booths 601 Booth 538 Abbott is a global, broad-based health care company devoted to discov- The American Academy of Physician Assistants is the only national ering new medicines, new technologies and new ways to manage health. organization to represent all physician assistants (PAs) in all medi- cal specialties. For more information about the Academy and the PA ABBOTT Nutrition profession, visit our Web site at www.aapa.org. Booth 711 is THE world leader in adult nutrition. Nepro with Carb Steady is thera- AMERICAN ASSOCIATION OF KIDNEY PATIENTS peutic nutrition for people on dialysis clinically shown to help manage Booth 302 blood glucose response and Suplena with Carb Steady is therapeutic The American Association of Kidney Patients (AAKP) is the national, nutrition for people with CKD. patient organization which, for over 35 years, has been dedicated to improving the lives of kidney patients and their families by helping them ALAVEN PHARMACEUTICAL, LLC cope with the emotional, physical and social impact of kidney disease, Booth 1000 thereby enabling them to resume productive and satisfying lives. UniFiber® (powdered cellulose) is an insoluble fiber supplement clinically proven to restore and maintain bowel regularity. UniFiber is AMERICAN REGENT, INC. sodium, potassium, phosphorus and gluten free and contains less than Booth 404 one net carb per serving. UniFiber has no minimum liquid requirement. American Regent, “Your IV Iron Company,” is the manufacturer and www.unifiber.com distributor of Venofer®, (iron sucrose injection, USP), the #1 prescribed IV Iron in the U.S.1 Venofer® is available in 100mg/5mL single dose vi- ALCAVIS HDC als (preservative free). Venofer® is covered nationally by CMS/Medicare Booth 939 and has been assigned a permanent national HCPCS Code “J1756” for Alcavis HDC is dedicated to supporting the renal community through services provided on or after January 1, 2003.1 Based on IMS Health, education and aid with innovative and progressive antiseptics, disin- National Sales Perspectives™ - 3rd Quarter 2007 Results (October fectants and medical devices. Our core products are electolytically 2007) - Total Sales Volume ($) and units (100 mg equivalents). produced sodium hypochlorite based solutions available in several concentrations for applications that include skin and wound care and AMERICAN SOCIETY OF NEPHROLOGY connectivity. Alcavis HDC also distributes peracidic acid for dialyzer Booth 1005 reprocessing and the MAKY and ARM II reuse machines. The American Society of Nephrology (ASN) was founded in 1967 as a nonprofit corporation to enhance and assist the study and practice of AMAG PHARMACEUTICALS, INC. nephrology, to provide a forum for the promulgation of research, and to Booth 919 meet the professional and continuing education needs of its members. AMAG Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary nanoparticle superparamagnetic iron oxide technol- AMGEN ogy for the development and commercialization of therapeutic iron Booths 229 & 401 compounds to treat anemia and novel imaging agents to aid in the Amgen (NASDAQ:AMGN), a biotechnology pioneer, discovers, devel- diagnosis of cancer and cardiovascular disease. Visit us at http://www. ops and delivers innovative human therapeutics. Our medicines have amagpharma.com helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and AMERICAN ACADEMY OF NURSE PRACTITIONERS broad pipeline of potential new medicines, we continue to advance Booth 537 science to serve patients. The American Academy of Nurse Practitioners (AANP), formed in 1985 to provide NPs with a unified way to network and to advocate for NP issues at the local, state and federal levels, was the first national organization created for nurse practitioners of all specialties. With ap- proximately 23,000 individual members and more than 140 group mem- bers, AANP represents the interests of approximately 100,000 NPs as providers of high-quality, cost-effective and personalized healthcare. Spring Clinical Meetings ’08 p.103 2008 Exhibitors EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS ANGIODYNAMICS Boehringer Ingelheim Booth 319 Booth 419 (www.angiodynamics.com) is a leading provider of innovative medical de- Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of vices used by interventional radiologists, surgeons, and other physicians Boehringer Ingelheim, headquartered in Germany, operates globally in for the minimally invasive treatment of cancer and peripheral vascular 47 countries with approximately 38,400 employees. The company is com- disease. AngioDynamics’ diverse product line includes radiofrequency mitted to researching, developing, manufacturing and marketing novel ablation systems, vascular access products, angiographic products and products of high therapeutic value for human and veterinary medicine. accessories, dialysis products, angioplasty products, drainage products, BRECKENRIDGE PHARMACEUTICAL, INC. thrombolytic products, embolization products and venous products. Booth 418 ARROW INTERNATIONAL Breckenridge Pharmaceutical, Inc. is a privately held pharmaceutical Booth 1015 marketing, research and development company which has a broad Arrow International, a leader in central venous devices, presents a range of branded and generic prescription products in many broad range of products for the dialysis access community. These therapeutic categories. products include acute and chronic hemodialysis catheters and clot COURIER MED management devices for dialysis grafts and fistula. Our featured prod- Booth 738 ucts will include the Arrow Cannon Plus chronic hemodialysis catheter A Durable Medical Equipment and Supply Company that specializes along with the Arrow-Trerotola PTD. in reimbursement and delivery of Dialysis related medical supplies to ASTELLAS PHARMA US, INC. patients at their home anywhere in the USA. Among many products, Booth 619 Courier Med carries: CD-1000 Catheter Access Protector Dressing Astellas Pharma, Inc. manufactures and markets proprietary phar- that allows patients living with Catheters to safely resume high risk maceutical products in specialty therapeutic areas where there is an activities such as showering (covered by Medicare and most Private unmet medical need. Astellas Pharma's global mission to explore the Insurances), Diabetic Supplies, Free Monitors, Less-N-Pain, an afford- frontiers of human health underscores the company's commitment to able Topical Anesthetic, and SureSeal Pressure Bandages that reduce the field of immunology, where aggressive research and development clotting time, allowing the patient to leave dialysis sooner. initiatives have helped to put Astellas at the forefront of transplantation. COVIDIEN BAXTER HEALTHCARE Booth 1012 Booth 611 Covidien, formerly Tyco Healthcare, is a global $10 billion manufac- Baxter Healthcare is a leading provider of a complete and comple- turer of leading medical devices and supplies, imaging products and mentary portfolio of dialysis products to support people with kidney pharmaceuticals. The Company employs more than 43,000 people disease around the world, including Peritoneal Dialysis, Hemo Dialysis, worldwide and is dedicated to working with medical professionals to education tools, and Continuous Renal Replacement Therapy (CRRT) improve patient outcomes. for acute renal failure. DAVITA THE BINDING SITE, INC. Booth 314 Booth 1004 DaVita is one of the largest providers of kidney services in the United Freelite serum free light chain assays are more sensitive than current States. We care for nearly 100,000 patients through our nationwide methodologies for detecting multiple myeloma and AL Amyloidosis network with over 1,200 outpatient centers located in 42 states and the patients, many of whom first present with renal failure. They replace District of Columbia. the need for urine assays. DCA - DIALYSIS CORPORATION OF AMERICA Booth 916 Dialysis Corporation of America is a physician-focused organization. At the core of our company is a philosophy of developing a true alliance with our physicians. We seek to partner with Nephrologists who want to expand their dialysis presence, be afforded the opportunity to share in ownership of dialysis units, seek out management expertise, and gain control over the clinical quality their patients are currently receiving. p.104 National Kidney Foundation DIALYSIS AND TRANSPLANTATION ELSEVIER, INC. Booth 910 Booth 1011 Available from John Wiley & Sons, Dialysis & Transplantation (D&T) pub- ELSEVIER is proud to publish the American Journal of Kidney Diseases, lishes original research pertaining to all aspects of renal replacement the official journal of the National Kidney Foundation. Please stop by therapy and renal transplant, with a focus on clinical application. D&T our booth to view the latest issue of the journal and browse our other has the largest multidisciplinary audience among nephrology journals books and journals in the field of Nephrology. in the United States and is read in more than 120 foreign countries. Visit EVERCARE www.Eneph.com for submission guidelines/free access to online issues. Booth 1036 DIALYSIS AT SEA Evercare End Stage Renal Disease Program – Uses well-established Booth 639 Evercare Clinical Model to promote member’s disease self-management Dialysis at Sea Cruises is the largest provider of dialysis treatment and care. The program bridges dialysis and the community by providing aboard cruise ships. We provide nephrologists, nurses and suppliers management assistance in the unit, home, and during hospitalization. onboard select sailings ensuring a stress-free environment for dialysis FMQAI patients to enjoy the enchantment of cruising. Booth 439 DIALYSIS RECRUITING SPECIALISTS/ The Centers for Medicare and Medicaid Service (CMS) welcome you to THE FORTUS GROUP preview the next generation of renal information collection – CROWN- Booth 912 Web. CROWNWeb provides a secure web interface that enables dialysis The First full service executive search firm specializing in Dialysis and facilities to submit and monitor patients’ clinical data in real time, thus Transplantation, providing recruitment and permanent placement of helping facilities improve patient care and consequently their overall dialysis professionals worldwide, including permanent physicians, quality of life. Travel nursing and Locum Tenens. Place your future in the hands of FOUNDATION MEDICAL STAFFING the “Dialysis Recruiting Specialist.” We set the standard in advancing Booth 1029 careers and responding to employers professional needs. Foundation Medical Staffing is the nation's leading provider of staffing DIAZYME LABORATORIES services for nephrologists and dialysis nurses. Our expert agents focus Booth 637 on your specialty exclusively to find premier travel opportunities and Diazyme Laboratories is developing a capillary whole blood point of permanent positions. care device for the rapid determination of Cystatin C based GFR for use FRESENIUS MEDICAL CARE in the physician office or clinic. Diazyme's products include diagnostic Booths 423 & 523 blood markers for diabetes, renal, cancer, liver and cardiac. Diazyme is Fresenius Medical Care, the dialysis equipment and products market a life science division of General Atomics. leader, offers a comprehensive portfolio of clinically valid, cost-effective DVA LABORATORY SERVICES, INC. treatment enhancement tools that positively impact dialysis therapy. Booth 937 Success@home, our comprehensive home therapies program, provides DVA Laboratory Services offers state-of-the-art ESRD laboratory testing. nephrologists and clinicians with the therapy choices, treatment flex- We recognize the need for precise patient data, and address it with a ibility, support, and education programs that achieve better outcomes. comprehensive range of laboratory services including: dialysis specific GENZYME CORPORATION testing, client support staff, rapid turn-around times, peritoneal dialysis Booth 729 testing, water analysis and a leading-edge order entry and reporting sys- Genzyme, a global health care company, delivers innovative biotechnol- tem – LabScope Online®. Now you can access LabScope from anywhere, ogy products and services in therapeutics, surgery and diagnostic ar- anytime using LSO On The Go from any computer with Internet access. eas. Genzyme is the manufacturer of Renvela® (sevelamer carbonate), Renagel® (sevelamer hydrochloride), and Hectorol® (doxercalciferol). Genzyme is a leader in health care awareness and education for renal care specialists and patients worldwide. For more information visit www.genzyme.com or call 1.800.847.0069 Spring Clinical Meetings ’08 p.105 2008 Exhibitors EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS THE GIDEONS INTERNATIONAL KERYX BIOPHARMACEUTICALS, INC Booth 1032 Booth 901 White New Testaments bound in gold with Psalms and Proverbs. Keryx is developing ferric citrate, an oral, iron-based compound Available to all in the medical field free of charge. that has the capacity to bind to phosphate and form non-absorbable complexes. Ferric citrate is currently in Phase 2 clinical development HAWTHORN PHARMACEUTICALS for the treatment of hyperphosphatemia (elevated phosphate levels) in Booth 536 patients with end-stage renal disease, or ESRD. Hawthorn Pharmaceuticals, Inc., is a specialty pharmaceutical com- pany focused on the sales, marketing and development of niche prod- KIDNEY COMMUNITY EARLY RESPONSE COALITION ucts in areas such as Nephrology. Hawthorn's professional sales force Booth 437 is committed to meeting the needs of patients and physicians in these The Kidney Community Emergency Response (KCER) Coalition col- target markets. Hawthorn endeavors to be a distinguished leader and laboratively develops, disseminates, implements and maintains a partner in the Nephrology marketplace while bringing innovative prod- coordinated preparedness and response framework for the kidney ucts and technologies to market. community in the event of any type of emergency or disaster. HEALTH INFORMATICS, INC. LLORENS PHARMACEUTICAL INT’L DIVISION, INC. Booth 306 Booth 914 Health Informatics, Inc. (HII) is the renal industry leader in electronic During the past 22 years, Llorens Pharmaceutical has experienced medical records and billing software. The TIMETM System has been significant growth, introducing a diversity of new products in the United employed in dialysis units for over 20 years and over 42 states. States and Puerto Rico. Llorens Pharmaceutical is continually working HII's TIMETM System is the backbone of its outsourced billing solutions to improve the health and well-being of patients, with products such as for both dialysis facilities and multi-specialty practices. To learn Proteinex, Proteinex-18 and Nephronex. more about our company and services, please visit us on the web MEALS FOR LIFE at www.hiiweb.com. Booth 312 HEMOCUE, INC., A QUEST DIAGNOSTICS COMPANY Introducing Meals for LIFE, a brand new company specializing in Booth 1007 delicious microwaveable frozen entrees that are low in Potassium, HemoCue is a World Leader in Point-Of-Care Testing. The name Phosphorous, and Sodium. Specifically formulated for diabetics and HemoCue has long been synonymous with precision, accuracy and dialysis patients, Meals for LIFE is a convenient and healthy alternative reliability. HemoCue’s leading point-of-care analyzers allow any and is readily available in the frozen foods section of your local healthcare professional the ability to obtain lab quality results anytime, grocery stores. anywhere. www.hemocue.com MEDCOMP INNOVATIONS 4 DIALYSIS Booth 903 Booth 839 Medcomp is the market leader for dialysis access catheters. The Clear Band: ClearBand provides reliable hemostasis and eliminates Tesio Catheter and Split Cath long-term products have set the stan- manual pressure following needle or sheath removal. ClearBand dard for patient care. Medcomp offers a full line of CVCs and acces- is a soft plastic that comfortably fits the arm without cutting into it. sories, designed to save peripheral veins and future access sites. Locking ridges face away from the skin to prevent binding or pinching. MEDICAL NUTRITION USA, INC. Hemo: Hemo is a topical hemostasis pad with calcium ions to speed Booth 907 up the clotting process for reliable hemostasis. Medical Nutrition USA, Inc. develops and distributes products for nutritionally at-risk individuals under medical supervision. Our low- volume Pro-Stat® products are ideal for ESRD patients, as they provide 15 grams of protein and up to 101 calories per ounce. Fiber-Stat, our liquid fiber supplement, delivers 11 grams of soluble fiber per ounce. p.106 National Kidney Foundation MERCK & CO., INC. KDOQI – Kidney Disease Outcomes Quality Initiative Booth 1001 Stop by the NKF booth to learn about the newest KDOQI activity; Merck & Co., Inc. is a global research-driven pharmaceutical company Pediatric Nutrition Guideline Update: 2008 and learn why KDOQI is dedicated to putting patients first.E stablished in 1891, Merck discovers, recognized throughout the world for significantly improving patient develops, manufactures and markets vaccines and medicines to address outcomes. There are 12 current sets of KDOQI Guidelines. Visit the unmet medical needs. For more information, visit: www.merck.com. booth or the website for more information on KDOQI's new guideline implementation programs: http://www.kidney.org/Professionals/kdoqi/ National Association of Nephrology Technicians/Technologists (NANT) KEEP – Kidney Early Evaluation Program Booth 1033 Over 110,000 people across the country have participated in the NKF’s NANT promotes education and advances the professional role of the Kidney Early Evaluation Program (KEEP). To learn more about this multidisciplinary team in delivering the highest quality of care to the free, community-based health screening for people at increased risk CKD patient. It provides educational opportunities, encourages the for chronic kidney disease (CKD) and all the recent KEEP program development of nephrology professionals in leadership roles and updates, stop by booth #719. You can also pick up a free copy of achieves recognition of technology practitioners in the total care of the the KEEP Annual Data Report which will be published in AJKD's April CKD patient. 2008 supplement. NATIONAL KIDNEY AND UROLOGIC DISEASE KLS™ – Kidney Learning System INFORMATION CLEARINGHOUSE (NKUDIC) The National Kidney Foundation's KIDNEY LEARNING SYSTEM™ (KLS) Booth 736 provides educational programs and practical tools for physicians and National Kidney and Urologic Disease Information Clearinghouse health care professionals, CKD patients and their families and those (NKUDIC) is an information and referral service of the National Insti- at increased risk for CKD. KLS incorporates new science into all its tute of Diabetes & Digestive & Kidney Diseases (NIDDK), one of the educational resources, drawing from the ongoing guideline develop- National Institutes of Health. The clearinghouse responds to inquiries, ment process and regularly published KDOQI Guidelines updates develops and distributes publications, and provides referrals to kidney which are used by government health agencies, professional societ- and urologic organizations. ies, physicians, nurses, dieticians, social workers, pharmacists and patient groups. KLS programs are researched, tested, peer-reviewed, NATIONAL KIDNEY FOUNDATION produced and fully supported by the professional KLS staff of the Booth 719 National Kidney Foundation. KLS offers a full line of CME/CE programs AJKD – American Journal of Kidney Diseases as well as clinical tools and online clinician support resources, such American Journal of Kidney Diseases (AJKD), the official journal of the as a GFR calculator and interactive clinical action plans. Visit our Web National Kidney Foundation, is the world's leading journal in clinical site at www.kidney.org/KLS for a comprehensive presentation of CKD nephrology. Please visit the NKF booth to browse AJKD and the two educational resources. other journals from the National Kidney Foundation and Elsevier: Advances in Chronic Kidney Diseases and Journal of Renal Nutrition. NKF CYBERNEPHROLOGY EXPERIENCE Booth 334 KDIGO – Kidney Disease: Improving Global Outcomes Come relax and enjoy a special area in the expo hall devoted to cy- Kidney Disease Improving Global Outcomes (KDIGO) berNephrology to gain hands-on experience with some of the many Visit the booth to learn about KDIGO Guidelines, including the first resources available. This booth area is sponsored in part by Amgen. global guideline for the Prevention, Diagnosis, Evaluation and Treat- ment of Hepatitis C in CKD, and for a demonstration of KDIGO's online tool for accessing and comparing the latest nephrology guideline rec- ommendations from around the world. KDIGO was established in 2003 as an independently incorporated non-profit foundation governed by an international Board with the stated mission "to improve care and out- comes of kidney patients worldwide through coordination of initiatives to develop and implement clinical practice guidelines." www.kdigo.org Spring Clinical Meetings ’08 p.107 2008 Exhibitors EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS NKF “PEOPLE LIKE US” CONSTITUENT COUNCIL/ THE NATIONAL KIDNEY FOUNDATION OF "HOPE STREET” NORTH TEXAS Booth 821 Booth 1013 The NKF’s “People Like Us” initiative empowers, educates and encour- North Texas affiliate of the National Kidney Foundation which serves ages people affected by CKD, transplantation and donation to become Dallas, Fort Worth and 64 surrounding counties. advocates on public policy and other issues related to their health. NATIONAL RENAL ALLIANCE "People Like Us" is comprised of advocates from the NKF's constituent Booth 329 groups: Patient and Family Council (PFC), transAction Council and the National Renal is a dialysis provider where physicians are partners. If National Donor Family Council (NDFC), and living donors. This booth you are a physician who would like to receive the benefits of ownership includes a wide variety of patient educational materials and empower- and be in control of your dialysis unit, please call Kim at (866) 312-9400 ment tools to help them and their loved ones become their own best ext. 4424. advocate. One such tool featured in the booth is "Hope Street," the NKF's comic strip "reality series" of, by and for the dialysis community. NATURAL BALANCE BODYWORK NKF PROFESSIONAL COUNCILS Booth 938 Deep tissue Corrective Massage, Chair Massage, stress reduction Booth 813 education, food/mood connection education, 30 day cleansing program The National Kidney Foundation Council of Nephrology Nurses and for wellness and weight loss, video demonstration. Technicians (CNNT), a 500-strong volunteer professional membership organization, participates in public services directed toward preven- NATURE PUBLISHING GROUP tion, detection and the care of persons with kidney and/or related Booth 1010 diseases. The Council advocates and contributes to the professional Nature Publishing Group brings leading scientific and medical development of members through education, networking and the dis- research to your desk top. The NPG portfolio combines the continued semination of information related to professional practice and qual- excellence of Nature and its associated research and review journals, ity of patient care. CNNT invites all meeting attendees to stop by the over 42 leading academic and society journals, including Kidney Booth to learn more about the council and its activities. International and Eight Nature Clinical Practice journals. Visit Booth 1010 for free sample copies. The National Kidney Foundation Council of Nephrology Social Workers (CNSW) upholds and supports the profession of nephrology social NEPHROCOR work through advocacy and the creation of patient and professional Booth 810 education materials. With over 800 social work members the council Nephrocor™ offers renal biopsy and chemistry profiles for the diagno- provides assistance, education and support to patients and their fami- sis, treatment and management of kidney diseases. A full service ana- lies in dealing with the psycho social stresses and lifestyle readjust- tomic and clinical pathology laboratory, Nephrocor™ serves nephrolo- ments encountered by patients in all stages of CKD. Visit Booth 813 to gists throughout the U.S. learn about new publications and professional resources and how to get involved. NEPHROLOGY NEWS AND ISSUES Booth 812 The National Kidney Foundation Council on Renal Nutrition (CRN), Nephrology News & Issues® (www.nephronline.com), is a national, is a 1,700-member volunteer professional organization dedicated to peer-reviewed news journal covering the political, social, and eco- promoting quality nutritional care and education to kidney patients. nomic issues surrounding the delivery of dialysis and transplantation. Members impact regulatory and legislative issues and actively promote Stop by the booth for the latest issue, along with the 2008 Renal Care the professional education of the renal dietitian. The Council stimulates, Calendar and Meetings Guide, and Renal Resource and Buyer’s Guide. supports and disseminates nutrition-related research, and develops patient and professional public education materials encouraging quality nutrition care for CKD patients. Come see us at Booth 813 and view our display of professional resources for renal dietitians. p.108 National Kidney Foundation NEPHROLOGY NURSING CERTIFICATION NOVA BIOMEDICAL COMMISSION Booth 318 Booth 320 Nova’s new StatSensor™ Creatinine Meter is a handheld point-of-care The Nephrology Nursing Certification Commission (NNCC) was es- analyzer for accurate, 30-second measurement of creatinine and es- tablished in 1987 to develop and implement certification examinations timated Glomerular Filtration Rate (eGFR) on capillary blood. Stat- for nephrology nursing. The NNCC offers the following examinations: Sensor's small, 1.2 microliter whole blood samples can be obtained Certified Nephrology Nurse-Nurse Practitioner (CNN-NP), Certified virtually painlessly by fingerstick. Nephrology Nurse (CNN), Certified Dialysis Nurse (CDN), Certified NOVARTIS Clinical Hemodialysis Technician (CCHT). For more information, stop Booth 321 by our booth or visit our website at www.nncc-exam.org For over 20 years, Novartis Pharmaceuticals Corporation has been NEPHRO-PATH a leading contributor to the advancement of transplant science and Booth 420 medicine. Our focus remains on developing meaningful therapeutic Under the direction of Patrick D. Walker, MD, NephroPath offers more advances that improve the quality of life of transplant recipients and than 30 years of experience interpreting renal biopsies. Because enhancing the long-term success of transplantation. Please visit our we understand the critical effect time to diagnosis can have on the exhibit where Specialists from Novartis will be available to discuss our outcome of many renal diseases, we offer complete results (Light, products, answer questions and supply scientific information. Immunofluorescence, and Electron Microscopy) on the same day we NOVO NORDISK INC. receive a biopsy. Booth 929 NEPHRO-TECH Novo Nordisk Inc., Princeton, N.J., is the United States headquarters Booth 1023 of Novo Nordisk A/S, a global healthcare company leader in diabetes Nephro-Tech, Inc. provides high quality pharmaceuticals at affordable care. It manufactures and markets a comprehensive line of diabetes prices. Introducing Vital-D Rx™; treat vitamin D (25-OH D3) deficiency care products, growth hormone therapy, and treatment for specific daily. Nephron FA® is an iron, vitamin, stool softener combination. types of hemophilia. Novo Nordisk is committed to research to address Great for PD patients! NephPlex® Rx is one of the most cost-effective, unmet medical needs. renal multivitamins on the market that contains zinc. The MagneBind® NUTREPLETION RESOURCES products are magnesium/calcium combination phosphate binders– Booth 811 reduce calcium intake without compromising binding ability. Calphron NutrePletion Resources is “Your First Choice for Nutritional Solutions.” is 667 mg calcium acetate and costs $15.00/200 through Nephro-Tech, This specialty pharmacy provides nationwide coverage for the par- Inc. RenaPlex® is a direct sell multivitamin costing $9.00/100 plus enteral nutrition needs of the end stage renal disease patient. Our $4.95 shipping. Call 800-879-4755 for more information. pharmacists, reimbursement specialists, and field based registered NIPRO MEDICAL CORPORATION dietitians work closely with dialysis facility staff to provide high quality Booth 715 IDPN and IPN services. Nipro Medical Corporation is a worldwide manufacturer of disposable OMRON HEALTHCARE medical products specializing in the renal and med-surg markets. Booth 322 Includes bloodlines, safety fistula needles, dull needles, dose-saver The most important feature of Omron blood pressure monitors is that syringes, safety and non-safety syringes and needles. Expert staff they consistently provide accurate results. This is why every Omron specializes in product inservice and technical support in which CEU blood pressure model has been tested, evaluated and proven to meet credits are earned. Quality and prices ensures you receive the lowest the rigorous safety and accuracy standards set by independent cost care for your facility. organizations. Spring Clinical Meetings ’08 p.109 2008 Exhibitors EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS ORTHO BIOTECH PRODUCTS, L.P. RENAL AND UROLOGY NEWS Booth 801 Booth 1021 Ortho Biotech Products, L.P. markets PROCRIT® (Epoetin alfa) used to Renal & Urology News is a monthly tabloid with a circulation of 16,000 treat anemia associated with serious medical conditions. The company Nephrologists, dialysis nurses and urologists. The publication’s pri- also markets other biotechnology products. It is based in Bridgewater, mary editorial mission is to report on new scientific developments of New Jersey. interest to these three specialist groups. News coverage focuses on medical conferences but also includes reporting on recently published PENTEC HEALTH papers in peer-reviewed journals. Various features and departments Booth 933 complement the news coverage. Pentec Health - a niche specialty pharmacy company that is a provider of IDPN/IPN therapies to the ESRD population tracking outcomes data. RENAL BUSINESS TODAY/VIRGO PUBLISHING website at www.pentechealth.com MEDIA GROUP Booth 304 PFIZER Renal Business Today delivers top-notch editorial content for practice- Booth 629 management professionals. http://www.renalbusiness.com/. Please visit the Pfizer Inc, U.S. Pharmaceuticals exhibit featuring: www.renalbusiness.com offers daily news, an editorial library, a blog by LIPITOR® (atorvastatin calcium) editor Keith Chartier, Pharma Corner, a free E-newsletter and more. PHYSICIANS’ CAPITAL INVESTMENT, LLC RENAL PHYSICIANS ASSOCIATION Booth 713 Booth 734 Physicians’ Capital Investment, LLC is the innovator of the seamless ap- The Renal Physicians Association is a national organization with the proach to patient care facilities. From design, to construction, to finance, expertise and successful track record of pro-actively defending the to operations; PCI’s staff has over 85 years of combined healthcare discipline of the nephrology practice. Membership is comprised of experience in providing state of the art healthcare facilities, allowing our healthcare providers in the subspecialty of internal medicine known as physician partners to focus on their number one priority… their patients. nephrology. Stop by to check out RPA’s latest programs and publica- PKD FOUNDATION tions or visit us at www.renalmd.org. Booth 539 SATELLITE HEALTHCARE INC. /WELLBOUND Stop by our booth to learn about our new KidneyWise Nutrition Booth 1028 Program, featuring a cookbook and website tailored to each stage of Satellite Healthcare is an established leader in driving clinical excel- kidney disease! The PKD Foundation fights polycystic kidney disease lence through joint ventures with nephrologists. Through its partners (PKD) through research funding and patient education. Learn WellBound and Satellite Dialysis, Satellite Healthcare provides early more today! patient wellness education, superior clinical support services and a QUALITY DIALYSIS complete range of dialysis therapy choices. This comprehensive of- Booth 636 fering allows Satellite Healthcare to advance the standard of chronic Dialysis services are performed at home in an environment, which is kidney disease care while optimizing patient wellness. safe, secure, and closely monitored to insure that patient care is not SATELLITE LABORATORY SERVICES compromised. With increasing demand for quality medical care and the Booth 311 reduced funds available to the health care system, medical providers Satellite Laboratory Services, an independent, full service ESRD labo- are seeking alternatives that are cost effective without compromising ratory provides a complete renal testing menu, simplified management quality care. tools and easy access to laboratory services backed by dedicated service personnel. We provide a single source for all your laboratory needs. p.110 National Kidney Foundation SCANTIBODIES CLINICAL LABORATORY U.S. RENAL CARE, INC. Booth 310 Booth 635 Scantibodies Clinical Laboratory (SCL) will showcase a new study Founded in 2000, US Renal Care works in partnership with nephrolo- demonstrating a dramatic decrease in adynamic bone disease in renal gists to develop and operate outpatient dialysis centers. We support patients resulting from use the PTH Accuratio™ Third generation test- our physician partners and clinical staff with strong financial resources, ing. SCL invites clinical labs worldwide to join the 10-year initiative to experienced operations management, state of the art technology, and compare accuracy/stability of PTH assays. patient and family education. SHIRE U.S. RENAL DATA SYSTEM (USRDS) Booth 411 Booth 300 Shire is a leading global specialty pharmaceutical company focusing The USRDS Coordinating Center, funded by NIDDK, is the national reg- on specialist physicians and their patients in the areas of attention istry that collects, analyzes, and distributes information on trends and deficit and hyperactivity disorder (ADHD), human genetic therapies patient outcomes in the ESRD population. Annual Data Report CDs, (HGT), gastrointestinal (GI) and renal diseases. handouts, and website demonstrations will be available. SIGMA-TAU PHARMACEUTICALS, INC. University of Minnesota Medical Center, Booth 305 Fairview Sigma-Tau Pharmaceuticals is the manufacturer and distributor of Booth 441 Carnitor® (levocarnitine) Injection. Carnitor Injection is covered nation- We lead the nation in living donor kidney transplantation. We celebrate ally by CMS/Medicare. The Carnitor Injection Reimbursement Assistance 45 years of pioneering research in living donor transplantation. We Program provides in-depth support services regarding reimbursement have performed over 10,000 adult and pediatric transplants in kidney, policy, documentation requirements and claims troubleshooting. kidney/pancreas, pancreas, liver, heart, heart/lung, lung, intestinal and Contact the Reimbursement Hotline at 800-490-3262 for assistance. islet cells. Please visit www.carnitor.com for more information. WATSON NEPHROLOGY SOLINMED BILLING & TRANSCRIPTION Booth 911 Booth 739 Watson Nephrology, marketers of Ferrlecit® (sodium ferric gluco- 1.) Ensuring your Financial Health with Medical Billing & Transcription nate complex in sucrose injection), offers specialty products includ- Services. 2.) Medical Billing: 60% cost-reduction to you, patentable ing injectable iron therapy, oral iron supplements, and renal vitamin technology for ERROR-free billing, superfast payment cycle, lowest formulations. Watson Nephrology, a Division of Watson Pharma, Inc. cost. 3.) Transcription: 99.6-100% accuracy, 12-24 hour turnaround, demonstrates their commitment to the nephrology community through 6-7 cents/line! 4.) Leading with Low Cost solutions & ERROR-free anemia education programs and support of national organizations service. 972-347-9026. www.solinmed.com such as the National Kidney Foundation. SPECTRA LABORATORIES WYETH PHARMACEUTICALS Booth 428 Booth 915 Spectra is the leading provider of renal-specific laboratory services. Wyeth Pharmaceuticals, a division of Wyeth, has leading products in Our advanced equipment, specimen packaging, and reporting applica- the areas of women’s health care, cardiovascular disease, central tions help provide rapid and reliable test results. Our on-site training nervous system, inflammation, transplantation, hemophilia, oncology, by a team of renal clinicians and coordination of STAT testing services vaccines and nutritional products. help customers deliver optimal patient care. TEVA PHARMACEUTICALS Booth 1019 Teva Pharmaceuticals, the nation's leading generic manufacturer, markets over 320 products and 1100 SKU's in all major therapeutic areas, including immunosuppressive agents to prevent the rejection of kidney, liver and heart allograft. Spring Clinical Meetings ’08 p.111 Keep Learning & Growing Join the National Kidney Foundation Today! Thousands of renal health care professionals rely on membership in the National Kidney Foundation to help them keep abreast of the latest developments in kidney prevention and treatment through industry-leading journals, news- letters, authoritative guidelines, brochures, online information, clinical meeting and CME courses. The NKF relies on the support of its members to carry out its mission to s Support kidney patients and families s Encourage organ donation s Offer early detection programs s Provide comprehensive public and professional education s Sponsor scientifi c research s Spearhead advocacy programs to ensure the rights and welfare of kidney patients, their families and kidney professionals. If you are a member, renew now at 2007 prices.* If you’re not a member, join now and start receiving NKF I]Z?djgcVad[ CZe]gdad\nHdX^VaLdg` KdajbZ',L^ciZg'%%, membership benefi ts. 8djcX^ad[CZe]gdad\n HdX^VaLdg`Zgh KdajbZ',L^ciZg'%%, Go to the membership desk or www.kidney.org for a Ê Ê =ZbdY^Vanh^hGZ\^bZc/ZgVijgZ I]Z?djgcVad[CZe]gdad\nHdX^VaL 6GZk^Zld[i]ZA^i =ZbdY^Vanh^h/B^hhZYVcY H]dgiZcZYIgZVibZcih KdajciZZg^c\VcY8@9 complete list of member benefi ts and to register online. :beadnbZci;daadl^c\GZcVa IgVcheaVciVi^dc bZg\ZcXn @^YcZn8dbbjc^in: GZhedchZ8dVa^i^dc dg` * Current members can save $25 off their NKF Membership Fee when they recruit a new member. *Offer good through 5/30/08. The renewal and new member forms must be mailed together in order to receive the discount. The new member will pay the full price for their membership. Both renewing and new members will lose the option to complete their transactions online and must mail in their forms together for processing. New members can download the PDF of the member application from www.kidney.org. U www.kidney.org © 2008 National Kidney Foundation, Inc. All rights reserved. 0280-366A p.112 National Kidney Foundation NATIONAL KIDNEY FOUNDATION’S PROFESSIONAL COUNCILS RESEARCH GRANT RECIPIENTS 2007–2008 Council of Nephrology Council on Renal Nutrition Grants Council of Nephrology Nurses and Social Workers Grants Jackie Carder, MS, RD, CDE, and Technicians Grant Mary Beth Callahan, ACSW, LCSW Kay Taylor, RD, CDE Robert W. MacKinnon, RN, CNN Dallas Transplant Institute Dialysis Center of Lincoln Caritas St. Elizabeth’s Medical Center Dallas, Texas Lincoln, Nebraska Brighton, Massachusetts Title of Project: Kidney Transplant Patient Title of Project: Comparison of Predicted Resting Title of Project: The Impact of Continuous Employment Potential: Re-valuation of an Metabolic Rate to Measured Resting Metabolic Renal Replacement Therapy (CRRT) Staffing Important Outcome Measure by Use of New Rate in Maintenance Dialysis Patients and Technique on Nursing Resource Utilization, Methodologies Quality of Care and Patient Safety Joyce Vergili, MS, RD Caroline Jennette, MSW Columbia University Teachers College University of North Carolina New York, New York Chapel Hill, North Carolina Title of Project: Nutritional Practices of Renal Title of Project: Renal Replacement Therapy Dietitians in Hemodialysis Centers Throughout and Barriers to Choice: The Patient’s Perspective the United States Joseph Merighi, PhD Boston University School of Social Work Boston, Massachusetts Title of Project: A Nationwide Survey of Kidney Transplant Social Workers’ Job Roles, Respon- sibilities, and Occupational Well-Being Spring Clinical Meetings ’08 p.113 GAYLORD TEXAN FLOOR PLAN p.114 National Kidney Foundation FACULTY Kara Abbas, MS, RD, CSR Arif Asif, MD Gerald Beck, PhD Abbott University of Miami School of Medicine Cleveland Clinic Foundation Gilbert, AZ Miami, FL Cleveland, OH Martin J. Abrahamson, MD Cassy Aspinall, MSW, LICSW Srinivasan Beddhu, MD Joslin Diabetes Center Children’s Hospital and Regional Medical University of Utah Health Sciences Center Harvard Medical School Center Salt Lake City, UT Boston, MA Seattle, WA Ann Beemer Cotton, MS, RD, CNSD Kenneth Abreo, MD John R. Asplin, MD Methodist Hospital Louisiana State University Health Sciences Litholink Corporation Westfield, IN Center Chicago, IL Filitsa H. Bender, MD Shreveport, LA Carolyn Atkins, RN, BS, CCTC University of Pittsburgh Medical Center Beth Adams, PA Children’s Medical Center Dallas Pittsburgh, PA Henry Ford Hospital Dallas, TX Laurie E. Benton, RN, PA-C, BS, MPAS Detroit, MI Mary Ann Baily, PhD Scott and White Hospital, Texas A&M Sharon Adler, MD The Hastings Center Health Science Center College of Medicine UCLA Medical Center Garrison, NY Temple, TX Torrance, CA George Bakris, MD, FAHA, FASN Suzanne M. Bergman, MD Anil K. Agarwal, MD University of Chicago University of Alabama at Birmingham Ohio State University Chicago, IL Birmingham, AL Dublin, OH Lynda K. Ball, RN, BSN, CNN Tomas Berl, MD Zalman S. Agus, MD Northwest Renal Network University of Colorado Health Sciences University of Pennsylvania Seattle, WA Center School of Medicine Denver, CO Julie Barboza, MSN, RD, APRN-BC Philadelphia, PA Evercare Renal Disease (RD) Program Jeffrey S. Berns, MD Michael Allon, MD Berkley, MA University of Pennsylvania University of Alabama at Birmingham School of Medicine Joanne M. Bargman, MD, FRCPC Birmingham, AL Philadelphia, PA Toronto General Hospital Gerald Appel, MD Toronto, Ontario, Canada Anatole Besarab, MD Columbia University College of Physicians Henry Ford Hospital Lois Bates and Surgeons Detroit, MI Howard Brown Health Center New York, NY Chicago, IL Judith Beto, PhD, RD George Aronoff, MD Loyola University Medical Center Daniel C. Batlle, MD University of Louisville Maywood, IL Northwestern University Louisville, KY Chicago, IL Peter Blake, MD, FRCPC, FRCPI Stephen R. Ash, MD, FACP Victoria Hospital Gerald A. Beathard, PhD Clarian Arnett Health London, Ontario, Canada RMS Lifeline Lafayette, IN Paige, TX Mary Ellen Brabec, MHS, RD, CSR, LDN Diversified Specialty Institutes Hazel Crest, IL Spring Clinical Meetings ’08 p.115 FACULTY Kathleen Brady, MS, BC-ANP Claire Casselman, MSW, LMSW, LICSW Danny Concepcion, CCHT, CHT University of Colorado Health Sciences University of Michigan Health Systems St. Joseph Hospital Renal Center Center Ann Arbor, MI Orange, CA Denver, CO Lee Cauble, MPH, RD, CSR, LD Bonnie Conrad, RN, CDN Emmanuel Bravo, MD DCI/ Desert Dialysis Center Albany Regional Kidney Center Cleveland Clinic Foundation Tucson, AZ Albany, NY Cleveland, OH Donna Calvin, APRN, BC-FNP, CNN Gabriel Contreras, MD, MPH Barry Brenner, MD University of Illinois at Chicago University of Miami School of Medicine Harvard Medical School Chicago, IL Miami, FL Boston, MA Sheldon C. Chaffer, MD Sandra Coorough, ACSW, LCSW Valerie Brinkman-Kaplan, MS, RD, LD Scott and White Clinic, Texas A&M Phoenix Children’s Hospital Kid’s Kidney US Renal Care/Tarrant Dialysis Centers University HSC Center Central Fort Werth Temple, TX Phoenix, AZ Fort Worth, TX Christopher Chan, MD Daniel Coyne, MD Bridget K. Brosnihan, PhD University of Toronto Chromalloy American Kidney Center Wake Forest University School of Medicine Toronto, Ontario, Canada St. Louis, MO Winston–Salem, NC Alfred Cheung, MD Ronald J. Crossno, MD Teri Browne, MSW, LSW University of Utah Vista Care Hospice University of Chicago Salt Lake City, UT Rockdale, TX Glenview, IL Dolph Chianchiano, JD Jackie Crouch John M. Burkart, MD National Kidney Foundation Scott and White Memorial Hospital Wake Forest University Medical Center New York, NY Temple, TX Winston–Salem, NC Michael J. Choi, MD Jim R. Curtis, CHT, CCHT David Bushinsky, MD Johns Hopkins University School of Medicine Jim Curtis & Associates University of Rochester Baltimore, MD Portland, OR Rochester, NY Louise Clement, MS, RD, CSR, LD Kirsten de Groot, MD Jessica Cabness, MSW, PhD South Plains Kidney Disease Center Klinikum Offenbach University of South Florida Lubbock, TX Offenbach, Germany St. Petersburg, FL Carolyn Cochran, RD, LD, MS, CDE Jan Deane, RN, CNN Mary Beth Callahan, ACSW, LCSW Dallas Nephrology Associates Renal Network of the Upper Midwest Dallas Transplant Institute Dallas, TX Saint Paul, MN Dallas, TX Jean Colaneri, ACNP, MS Andrea DeKam, LMSW Donna Calvin, APRN, BC-FNP, CNN Albany Medical Center Hospital University of Michigan Dialysis University of Illinois at Chicago Albany, NY Livonia, MI Olympia Fields, IL Allan J. Collins, MD, FACP Francis Delmonico, MD Ellen Case, MSW, LGSW National Kidney Foundation Massachusetts General Hospital Mayo Clinic Minneapolis, MN Boston, MA Rochester, MN p.116 National Kidney Foundation Laura Dember, MD Paul W. Eggers, PhD Allon Friedman, MD Boston University School of Medicine National Institute of Health Indiana University School of Medicine Boston, MA Bethesda, MD Carmel, IN Christina Denman, LMSW Karen Egloso, BSW, MSW, LSW, CNSW Barbara Fromm, MS, RD Collin County Sunrise Children’s Hospital Harborview Medical Center, University Plano, TX Las Vegas, NV of Washington North Bend, WA Vincent W. Dennis, MD Garabed Eknoyan, MD Cleveland Clinic Baylor College of Medicine Mary Ann Fuller, RD, LD Cleveland, OH Houston, TX DaVita Arlington Dialysis Lake Dallas, TX Peter B. DeOreo, MD, FACP Kimberly English, MSN, RN, FNP Centers For Dialysis Care Scott & White Sleep Disorders Clinic Anthony Furlan, MD Shaker Heights, OH Temple, TX Cleveland Clinic Cerebrovascular Center Cleveland, OH Thomas Depner, MD Jessica Farrell, MSW, LCSW-P University of California, Davis Duke University Medical Center Mindy Gentile, MS, RD, LD Sacramento, CA Durham, NC McKinney, TX David DeWalch, MSPA, PA-C, MS, MA Daniel I. Feig, MD, PhD Joel Glickman, MD, FACP American Association of Surgical Physician Texas Children’s Hospital University of Pennsylvania Assistants, Tyler Radiology Associates Houston, TX Philadelphia, PA Tyler, TX Harvey A. Feldman, MD, FACP Deborah Glidden, ARNP, BC, CNN Lesley Dinwiddie, MSN, RN, FNP, CNN Nova Southeastern University Nephrology Associates of Central Florida, PA Institute for Clinical Excellence, Ft. Lauderdale, FL Orlando, FL Education and Research Harold I. Feldman, MD, MSCE David S. Goldfarb, MD Cary, NC University of Pennsylvania New York Harbor VA Medical Center/NYU Bradley Dixon, MD Philadelphia, PA School of Medicine Veterans Affairs Medical Center and New York, NY Fredric O. Finkelstein, MD University of Iowa Hospital of St. Raphael, Yale University Cheri Goldstein, PA-C Iowa City, IA New Haven, CT Dallas Nephrology Associates Bart Dolmatch, MD Dallas, TX Michael Flessner, MD, PhD UT Southwestern Medical Center University of Mississippi Medical Center Thomas Golper, MD, FASN, FACP Dallas, TX Jackson, MS Vanderbilt University Medical Center Mary Anne Dooley, MD, MPH Nashville, TN Charles J. Foulks, MD University of North Carolina Scott and White Hospital, Texas A&M Thomas A. Gonwa, MD, FASN, FACP Chapel Hill, NC University HSC Mayo Clinic Tilman Drüeke, MD Temple, TX Jacksonville, FL Hôpital Necker Stanley S. Franklin, MD, FACP, FACC Janelle E. Gonyea, RD, LD Paris, France UCI Heart Disease Prevention Program Mayo Clinic Dialysis Services Senator Robert Duncan Los Angeles, CA Rochester, MN Crenshaw, Dupree and Milam Austin, TX Spring Clinical Meetings ’08 p.117 FACULTY John Q. Gowan, LMSW Rebecca Hays, MSW Priscilla Hollander, MD ESRD Network # 14 University of Wisconsin Hospital and Clinics Baylor Endocrine Center Dallas, TX Madison, WI Dallas, TX Michael Grasso, MD Mikhaelle Heald, LMSW Norman K. Hollenberg, MD, PhD Saint Vincents Medical Center The Children’s Mercy Hospitals and Clinics Brigham & Women’s Hospital Rye, NY Kansas City, KS Boston, MA Tom Greene, PhD David J. Hellmann, MD Jean L. Holley, MD University of Utah Health Sciences Center Johns Hopkins University School of Medicine University of Illinois Salt Lake City, UT Baltimore, MD Urbana, IL Loic Guillevin, MD Brenda R. Hemmelgarn, MD Josefina Houchins, LMSW Hopitaln Avicenne University of Calgary DaVita Oak Cliff Dialysis Center Bobigny Cedex, France Calgary, Alberta, Canada Dallas, TX Kay Hall, BSN, RN, CNN Johann Herberth, MD, FASN Tricia Howard, MHS, PA–C DaVita, Inc. University of Kentucky Medical Associates of Savannah Brentwood, TN Lexington, KY Savannah, GA Lisa Hall, MSSW, LCSW Charles Herzog, MD Kirk Hughes, MD The Florida ESRD Network Hennepin County Medical Center University of Iowa Hospitals & Clinics Tampa, FL Minneapolis, MN Iowa City, IA L. Lee Hamm, MD Jonathan Himmelfarb, MD Marianne Hutton, RD, CDE Tulane Medical School Maine Medical Center Research Institute Fresenius Medical Services-North America New Orleans, LA Portland, ME Santa Rosa, CA Haewook Han, PhD, RD, CSR, LDN Debbie Hinnen, ARNP, CDE, BC-ADM, FAAN Tami Hyziewicz Case, PA–C Tufts-New England Medical Center Mid-America Diabetes Associates Scott & White Hospital North Quincy, MA Wichita, KS Temple, TX Jeff Harder, MSW, LICSW Sandra Hinton, RN, BSN Ajay Israni, MD, MS University of Washington Medical Center Medical City Transplant Hennepin Faculty Associates Seattle, WA Dallas, TX Minneapolis, MN John W. Hartman, MD Tammy Ho, MD Bertrand L. Jaber, MD, MS Visonex, LLC Evanston Hospital Caritas Medical Group Green Bay, WI Evanston, IL Boston, MA Jeanette Hasse, PhD, RD, FADA, CNSD R. Michael Hofmann, MD Aimee Jaremowicz, RD, LD Baylor Regional Transplant Institute University of Wisconsin Diversified Specialty Institute (DSI) Baylor University Madison, WI Chicago, IL Dallas, TX Ronald Hogg, MD Arfrances Johnson, LD, RD, MS Mary Hastings Hagar, PhD, RD, FADA Scott and White Hospital Liberty Dialysis American Dietetic Association Temple, TX Fort Worth, TX Washington, DC Jeffery Hoggard, MD Stephanie Johnstone, LCSW, MSW Eastern Nephrology Associates Fresenius Medical Care-North America Greenville, NC San Diego, CA p.118 National Kidney Foundation Debra Jordan Stephen M. Korbet, MD, FASN Anne Liles, PharmD DaVita North Dallas Dialysis Center Rush University Medical Center Auburn University Dallas, TX Chicago, IL Auburn, AL Sheila Jowsey, MD Andrea Kostick, MSW, LISW Robert M. Lindsay, MD Mayo Clinic Mayo Clinic The University of Western Ontario and Rochester, MN Rochester, MN London Health Sciences Centre London, Ontario, Canada Peter Juergensen, PA-C Csaba Kovesdy, MD, FASN Metabolism Assoicates Salem VA Medical Center Robert S. Lockridge, MD Cheshire, CT Salem, VA Lynchburg Nephrology Physicians, PLLC Lynchburg, VA Kamyar Kalantar–Zadeh, MD Sumit Kumar, MD Harbor-UCLA Dallas Nephrology Associates Charmaine Lok, MD Torrance, CA Dallas, TX Toronto General Hospital Toronto, Ontario, Canada Marcia Kalista Richards, MPH, RD, CNSD, Dana Kumjian, MD LDN Medical Associates of Savannah Cynthia Lord, MHS, PA-C Pennsylvania State University Savannah, GA Quinnipiac University Slatington, PA Cheshire, CT Warren Kupin, MD Judith Kari University of Miami Elena Lucio, LMSW Centers for Medicare & Medicaid Services Miami, FL Christus Santa Rosa Children’s Hospital Baltimore, MD San Antonio, TX Nadiya Lakhani, RD, LD Pamela S. Kent, MS, RD, CSR, LD Fresenius Medical Center Kati Malarcher, LMSW Genzyme Renal Dallas, TX Collin County Dialysis Center Vermilion, OH Plano, TX Kristin Larson, RN, ANP, GNP, CNN, MSN Rita-An Kiley, MSW Nephrology Associates Maggie Marek Elm Grove, WI Salt Lake City, UT Baylor All Saints Fort Worth Forth Worth, TX Paul Kimmel, MD Thu H. Le, MD George Washington University Durham VA Medical Centers Cathi Martin, RD, CSR Washington, DC Durham, NC NutrePletion Resources Nashville, TN Lisa Kindy, JD Nathan Levin, MD Medical University of South Carolina Renal Research Institute Arthur J. Matas, MD Charleston, SC New York, NY University of Minnesota Minneapolis, MN Alan S. Kliger, MD Kristie Lewis, LLMSW, MSW Hospital of St. Raphael Henry Ford Health System, Greenfield Health Ivan D. Maya, MD New Haven, CT Systems – Taylor Dialysis University of Alabama at Birmingham Westland, MI Birmingham, AL Bobbie Knotek, RN, BSN, CNN, CPHQ ESRD Network of Texas, Inc. Edmund J. Lewis, MD Maureen McCarthy, MPH, RD, CSR, LD Dallas, TX Rush University Medical Center Oregon Health & Science University Chicago, IL Portland, OR Norma Knowles, MSW, LCSW Dialysis Clinic, Inc. Julia B. Lewis, MD William McClellan, MD Columbia, MO Vanderbilt University Medical Center Emory University Nashville, TN Atlanta, GA Spring Clinical Meetings ’08 p.119 FACULTY Peter McCullough, MD, MPH Jeffery C. Metzger, MD Donna Morton de Souza, MPH, RD William Beaumont Hospital, University of Texas Southwestern Professional Nutrition Services, Inc. Beaumont Health Center Medical Center Sacramento, CA Northville, MI Dallas, TX Alvin Moss, MD Samy McFarlane, MD Mariam Michaels, MD West Virginia University SUNY Downstate Kings Howard University Morgantown, WV County Hospital Center Washington, DC Salim Mujais, MD Brooklyn, NY Ronald Miller, MD, FACP Astellas Pharma US Jennifer McGuoirk, MS, RD, LDN University of California, Irvine McGaw Park, IL Abbott Renal Care Irvine, CA Mary Murphy, RN, CCTC Aston, PA Cindy Miller, MSW, LCSW Phoenix Childrens Hospital Stephanie McIntyre, RD Advanced Renal Care, Inc. Phoenix, AZ Avondale, AZ Tampa, FL Patrick Murray, MD Dianne McKay, MD Meredith Miller, RD, LD University of Chicago The Scripps Research Institute Cleveland Clinic Foundation Chicago, IL La Jolla, CA Cleveland, OH Mohanram Narayanan, MD, FASN Patricia M. McKevitt, MSW, ACSW, LCSW Richard Mishler, MD Scott and White Hospital Washington University School of Medicine Arizona Kidney Disease & Temple, TX St. Louis, MO Hypertension Center Nancy Nardelli, RN, CCRC Phoenix, AZ Beth McQuiston, MD, MS, RD, LDN Medical City Dallas Hospital Rush University Medical Center Orson W. Moe, MD Dallas, TX Park Ridge, IL University of Texas Southwestern Andrew S. Narva, MD, FACP Medical Center Rajnish Mehrotra, MD, FACP, FASN National Institutes of Health Dallas, TX UCLA Medical Center Bethesda, MD Torrance, CA Sharon Moe, MD Ira Nemeth, MD Indiana University Ravindra Mehta, MD Dallas County Health and Human Services Indianapolis, IN University of California – San Diego Dallas, TX La Jolla, CA Michele H. Mokrzycki, MD, MS Marianne Neumann, RN, CNN Montefiore Medical Center, Albert Einstein Mark Meier, LICSW, MSW Albany Dialysis Center College of Medicine Creative Workplace Solutions Albany, NY Bronx, NY Minneapolis, MN Allen Nissenson, MD Marianne Moncrief, David Mendelssohn, MD, FRCPC David Geffen School of Medicine at UCLA Dallas Transplant University of Toronto Los Angeles, CA Dallas, TX Toronto, Ontario, Canada Ann O’Hare, MD Anne Moore, LMSW Joe Merighi, MSW, PhD University of Washington Texas Partnership for End of Life Care Boston University School of Social Work Seattle, WA Sugarland, TX Boston, MA Bruce Z. Morgenstern, MD Phoenix Children’s Hospital Phoenix, AZ p.120 National Kidney Foundation Edmund O’Riordan, MB, BCH, BAO, MRCPI Lisa Pratka, LMSW Carol Roe, RN, JD Salford Royal Foundation Trust Medical City Transplant Centers for Dialysis Care Salford, Manchester Dallas, TX Shaker Heights, OH Emil Paganini, MD Megan Prescott, MSW, LCSW Arturo R. Rolla, MD The Cleveland Clinic Foundation University of Colorado Hospital Joslin Diabetes Center Cleveland, OH Aurora, CO Boston, MA Robert L. Page, PharmD, FCCP, FAHA, Pat Preston, MS Jamie Ross, MD FASCP, FSGC, CGP, BCPS Pat Preston Medical Enterprises, Inc UC Davis University of Colorado Health Sciences Astoria, OR Sacramento, CA Center Wajeh Qunibi, MD, FACP Prabir Roy-Chaudhury, MD Aurora, CO University of Texas Health Science Center University of Cincinnati Joni J. Pagenkemper, MS, MA, RD, LMNT San Antonio, TX Cincinnati, OH Creighton University Medical Center Jai Radhakrishnan, MD, MR, MRCP Bharat Sachdeva, MD Omaha, NE Columbia University Louisiana State University Health Paul M. Palevsky, MD New York, NY Science Center University of Pittsburgh Shreveport, LA Panduranga S. Rao, MD, DNB, MS Pittsburgh, PA University of Michigan Antoine Samaha, MD Jodi Patterson, LMSW Ann Arbor, MI Kidney and Hypertension Center McKinney Dialysis Center Cincinnati, OH Robert Reilly, MD McKinney, TX University of Texas Southwestern Milagros D. Samaniego, MD Jessie Pavlinac, MS, RD, CSR, LD Irving, TX University of Wisconsin Oregon Health & Science University Madison, WI Cleo Richard, RN, PhD Portland, OR Consultant Eduardo Sanchez, MD, MPH Marc Penn, MD, PhD Missouri City, TX University of Texas Health Center The Cleveland Clinic Foundation Austin, TX Mark S. Roberts, MD, MPP Cleveland, OH University of Pittsburg School of Medicine Paul W. Sanders, MD Mark A. Perazella, MD Pittsburgh, PA Birmingham VA Medical Center Yale University School of Medicine Birmingham, AL Bruce Robinson, MD Cheshire, CT Arbor Research Collaborative Gail Sansivero, MS, ANP Beth Piraino, MD Ann Arbor, MI Community Care Physicians University of Pittsburgh Albany, NY Michael Rocco, MD, MSCE Pittsburgh, PA Wake Forest University School of Medicine Mark J. Sarnak, MD Ronald Pisoni, PhD, MS Winston Salem, NC Tufts-New England Medical Center Arbor Research Collaborative Boston, MA Roger Rodby, MD Ann Arbor, MI Rush University Medical Center Mary Schira, PhD, APRN, BC, ACNP Marc Pohl, MD Chicago, IL University of Texas at Arlington School The Cleveland Clinic Foundation of Nursing James R. Rodrigue, PhD Cleveland, OH Arlington, TX Harvard Medical School Boston, MA Spring Clinical Meetings ’08 p.121 FACULTY Kathy Schiro Harvey, MS, RD, CSR Lesley Stevens, MD, MS, FRCPC Michael Talamantes, MSSW, LCSW Puget Sound Kidney Centers Tufts – New England Medical Center University of Colorado Hospital Mountlake Terrace, WA Boston, MA Aurora, CO Donald Schon, MD Stephanie Stewart, LICSW Maria Taylor, PharmD Arizona Kidney Disease & Hypertension Mayo Clinic University of Alabama at Birmingham Phoenix, AZ Rochester, MN Birmingham, AL Anton Schoolwerth, MD, FAHA John C. Stivelman, MD Stephen C. Textor, MD Dartmouth-Hitchcock Medical Center University of Washington, Mayo Clinic Foundation Spofford, NH Northwest Kidney Centers Rochester, MN Seattle, WA Donna Secker, PhD Ravi Thadhani, MD The Hospital for Sick Children Kristin Stockard, LICSW Massachusetts General Hospital Toronto, Ontario, Canada Children’s Hospital and Regional Boston, MA Medical Center Mary Ann Sevick, ScD, RN Charlie Thomas, LCSW, ACSW, MSW, CISW Seattle, WA University of Pittsburgh Banner Good Samaritan Medical Center Pittsburgh, PA Dana Sturtevant, MS, RD Phoenix, AZ Be Nourished Edward Siew, MD Cheryl Thomas, RDH Portland, OR Vanderbilt University Medical Center Founder Dental Inspirations, Inc. Nashville, TN Wadi N. Suki, MD, FACP Galveston, TX The Kidney Institute Edward G. Silverhardt, LCSW, LSCSW, Kathryn Thurber-Smith, LICSW Houston, TX BCD, MSW Children’s Hospital and Regional Sparks Dialysis Center Phyllis Sun, RD Medical Center Sparks, NV St. Elizabeth’s Medical Center Seattle, WA Brighton, MA Ajay Singh, MBBS, FRCP Trent Tipple, MD, FAAP Brigham and Woman’s Hospital Mary Sundell, RD, LDN, CCRP The Research Institute at Nationwide Boston, MA Vanderbilt University Medical Center Children’s Hospital Nashville, TN Columbus, OH Mi-Kyung Song, PhD, RN University of Pittsburgh Duane Sunwold Ashita Tolwani, MD, MSc Pittsburgh, PA Spokane Community College University of Alabama at Birmingham Spokane, WA Birmingham, AL Stuart M. Sprague, DO Northwestern University Lynda Szczech, MD, MCSE, FASN Faith Tootell, MS, RD, CSR, FADA Evanston, IL Duke University School of Medicine Satellite Healthcare Inc. Durham, NC Fremont, CA Glen Stanbaugh, MD Texas Renal Coalition Paul Szczybor, PA–C Jose Torrealba, MD Lubbock, TX The Franklin Square Hospital Center University of Wisconsin – Madison Catonsville, MD Madison, WI Alison Steiber, PhD, RD, LD Case Western Reserve University Harold M. Szerlip, MD, FACP, FCCP Robert D. Toto, MD Cleveland, OH Medical College of Georgia UT Southwestern Medical Center at Dallas Augusta, GA Dallas, TX p.122 National Kidney Foundation Michelle Trahan, MS, RD, LD Thomas Vesely, MD, FSIR Barbara Weis Malone, BSN, RN, MSN, CFNP Genzyme Renal Self-Employed University of Colorado Health Richardson, TX Saint Louis, MO Sciences Center Aurora, CO Mandy Trolinger, MS, RD Ronald Victor, MD DaVita Littleton Dialysis University of Texas Southwestern Steven D. Weisbord, MD, MSc, FASN Highlands Ranch, CO Dallas, TX University of Pittsburgh School of Medicine Pittsburgh, PA Lara Tushla, LCSW, MSW Theodôr Vogels, MSW Rush Presbyterian Máxima Medical Centre John Jason White, MD Chicago, IL The Netherlands Medical College of Georgia Augusta, GA Tracey A. Tyus–Bailey, MSW, LMSW, ACSW Bradley Warady, MD Greenfield Health Systems Children’s Mercy Hospitals and Clinics Robert Whitlock, MSSW, LCSW, MHA Southfield, MI Kansas City, MO Missouri Kidney Program Columbia, MO Mark Unruh, MD, MSc Richard A. Ward, PhD University of Pittsburgh University of Louisville Karen Wiesen, CHT, LPN, RD, LD Pittsburgh, PA Louisville, KY Washington University School of Medicine – Barnes Jewish Dialysis Center Aris Q. Urbanis, MD Kurt A. Wargo, PharmD, BCPS St Louis, MO RMS Lifeline, Inc. University of Alabama – Birmingham Grosse Pointe Park, MI Huntsville, AL Alan Wilkinson, MD UCLA Medical Center Tushar Vachharajani, MD, FASN, FACP David G. Warnock, MD Los Angeles, CA Wake Forest University School of Medicine University of Alabama – Birmingham Winston Salem, NC Birmingham, AL Wolfgang Winkelmayer, MD Harvard Meical School Ramiro Valdez, PhD Sarah Washburn, MS, RD, CD Cambridge, MA Valdez Seminars Seattle Cancer Center Alliance Denton, TX Seattle, WA Alexander Wiseman, MD University of Colorado Health Joseph P. Vande Griend, PharmD Tiffany Washington, MSW Sciences Center University of Colorado Denver UNC Chapel Hill School of Social Work Denver, CO School of Pharmacy Chapel Hill, NC Aurora, CO Jay B. Wish, MD Amy Waterman, PhD Case Western Reserve University Joseph Vassalotti, MD Washington University in St. Louis Cleveland, OH National Kidney Foundation St. Louis, MO New York, NY Myles Wolf, MD, MMSc Pat Weber, MS, RD, CDE, CSR, LDN Massachusetts General Hospital Miguel Vazquez, MD Genzyme Corporation Harvard Meical School UT–Southwestern in Dallas Springville, AL Brookline, MA Dallas, TX Matthew R. Weir, MD Jack Work, MD Joyce Vergili, MS, RD, CDN, CDE University of Maryland School of Medicine Emory University, Dialysis Access Center Columbia-Greene Dialysis Centers Baltimore, MD Atlanta, GA Catskill, NY Spring Clinical Meetings ’08 p.123 FACULTY Linda Wright, MHSC, MSW, RSW University Health Network Toronto, Ontario, Canada Qingyu Wu, MD, PhD The Cleveland Clinic Foundation Cleveland, OH Steven Wu, MD Massachusetts General Hospital Boston, MA Judy Yang, RD, LD USRC/TDC–PD Clinic Fort Worth, TX Alexander S. Yevzlin, MD University of Wisconsin Madison, IL Kim Zuber, PA-C, MSPS Metropolitan Nephrology Alexandria, VA www.nkfclinicalmeetings.org Patrice Zyry, RN, BSN, CNN Nephros, Inc. Manalapan, NJ 30 East 33rd Street New York NY 10016 www.kidney.org www.nkfclinicalmeetings.org Spring Clinical Meetings ’08 p.125 Innovation Delivering Biotechnology Innovation to Nephrology © 2008 Amgen. All rights reserved. MC40657-A 40657-A_NKF_ProgramAd_1.indd 1 2/13/08 11:01:07 AM